Age-related impact of proteobacteria colonization on mucosal homeostasis and the microbial community in gastrointestinal health and disease by Wymore Brand, Meghan Joyce
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2017
Age-related impact of proteobacteria colonization
on mucosal homeostasis and the microbial
community in gastrointestinal health and disease
Meghan Joyce Wymore Brand
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
and the Medical Immunology Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Wymore Brand, Meghan Joyce, "Age-related impact of proteobacteria colonization on mucosal homeostasis and the microbial
community in gastrointestinal health and disease" (2017). Graduate Theses and Dissertations. 16112.
https://lib.dr.iastate.edu/etd/16112
 
Age-related impact of proteobacteria colonization on mucosal homeostasis and the 
microbial community in gastrointestinal health and disease 
 
 
by 
 
 
Meghan Joyce Wymore Brand 
 
 
 
 
 
 
A dissertation submitted to the graduate faculty 
 
in partial fulfillment for the requirements of the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
Major: Immunobiology 
 
 
Program of Study Committee: 
Michael J. Wannemuehler, Co-major Professor 
Albert E. Jergens, Co-major Professor 
Amanda E. Ramer-Tait 
Jesse Hostetter 
Qijing Zhang 
 
 
 
 
 
 
 
Iowa State University 
 
Ames, Iowa  
 
2017 
 
 
Copyright © Meghan Joyce Wymore Brand, 2017. All rights reserved. 
	 ii 
DEDICATION 
 
 
This dissertation is dedicated to:  
 
 
My son, Henry Lester Brand, the joy of my life, born December 14, 2015 in the midst of my 
PhD. Finishing graduate school and writing a dissertation with a one year old is a challenge. 
That is an understatement. 
 
My husband, Jonathan Andrew Brand, with whom I celebrated 10 years of marriage on June 
9, 2017. I have been a student for 10 of those years.  
 
My father, Lee Allen Wymore, my first science teacher who instilled a love of science in me. 
Sorry I didn’t study plants Dad. 
  
	 iii 
TABLE OF CONTENTS 
 
                   Page 
 
DEDICATION                       ii 
 
ACKNOWLEDGEMENTS           v 
 
ABSTRACT            ix 
 
CHAPTER 1  GENERAL INTRODUCTION        1 
 Introduction            1 
 Dissertation Organization          2 
 Review of the Literature          3 
Gastrointestinal Microbiota Overview       3 
  Gastrointestinal Physiology and Immunology                 5 
  Inflammatory Bowel Disease         9 
  Dual-Hit Colitis Model                   11 
  Campylobacter jejuni         12 
  Neonatal Microbiota         14 
  Multigenerational Evaluation of the Microbiota     19 
  Probiotics          20 
  References                     22 
 
CHAPTER 2  THE ALTERED SCHAEDLER FLORA: CONTINUED  
APPLICATIONS OF A DEFINED MURINE MICROBIAL COMMUNITY  42 
 Abstract          42 
 The Gut Microbiota         43 
 Mice as Models for the Gut Microbiota      44 
 Development of the ASF        47 
 Phylogeny of the ASF        49 
 In Vivo Evaluation of the ASF       50 
 ASF as a Microbial Model Community      53 
 ASF Microbial Functions In Vivo       55 
 ASF and Gut Immunology Research       56 
 ASF and Colitis Research        59 
 Limitations of the ASF Model       60 
 Conclusions          61 
 Acknowledgements         62 
 References          62 
 
CHAPTER 3  INFLUENCE OF MATERNAL GASTOINTESTINAL  
INFLAMMATION ON VERTICAL TRANSMISSION OF MICROBIOTA  
OVER MULTIPLE GENERATIONS       68 
 Abstract          68 
Introduction          69 
	 iv 
Materials and Methods        72 
Results                     79 
Discussion          87 
Acknowledgements         94 
References          94 
 
CHAPTER 4  LASTING IMPACT OF NEONATAL COLONIZATION BY  
AN AIEC PATHOBIONT ON INTESTINAL HOMEOSTASIS   100 
Abstract         100 
Introduction         102 
Materials and Methods       105 
Results                    116 
Discussion         141 
Acknowledgements        160 
References         160 
 
CHAPTER 5  IMPACT OF A PROBIOTIC ESCHERICHIA COLI ON  
DSS-INDUCED COLITIS        175 
Abstract         175 
Introduction         175 
Materials and Methods       178 
Results              185 
Discussion         190 
Acknowledgements        195 
References         196 
 
CHAPTER 6  CAMPYLOBACTER JEJUNI CHRONICALLY COLONIZES  
A GNOTOBIOTIC MOUSE MODEL AND INDUCES MILD COLITIS  202 
 Abstract         202 
Introduction         202 
Materials and Methods       204 
Results                    206 
Discussion         208 
Acknowledgements        211 
References         212 
 
CHAPTER 7  GENERAL CONCLUSIONS AND FUTURE DIRECTIONS         214 
 
APPENDIX OTHER PUBLICATIONS      219 
  
	 v 
ACKNOWLEDGEMENTS 
 
 Science is a collaborative effort, and this work would not be possible without 
tremendous help and support – there are so many individuals to acknowledge and thank. 
Thank you to my co-major professors and committee members: Dr. Mike Wannemuehler, 
Dr. Al Jergens, Dr. Amanda Ramer-Tait, Dr. Jesse Hostetter, and Dr. Qijing Zhang. First, to 
my co-major professor Dr. Wannemuehler, who has been a genuine mentor in shaping the 
work contained in this dissertation, motivating and guiding through my graduate career. 
Additionally I’m so appreciative for the travel to numerous conferences, and for the 
incredible support as I adjusted to the dual roles of graduate student and mommy. Thank you 
to my co-major professor Dr. Jergens, who hired me on as a summer undergraduate student 
in 2006, little knowing I would spend the next 11 years off and on in the lab. You opened my 
eyes to veterinary research as a career, and gave me the nudge to go to veterinary school… 
and then graduate school. Thank you to Dr. Ramer-Tait, who was first a tremendous mentor 
at Iowa State and prepared me to manage a gnotobiotic mouse colony, and then became my 
committee member from afar. Thank you to Dr. Hostetter, for allowing me to rotate in your 
laboratory, learn immunohistochemistry under the supervision of Elise Huffman, for reading 
my histopathology slides, and support as a former Immunobiology DOGE. Thank you to Dr. 
Zhang for allowing me to do a mini rotation - though this dissertation didn’t continue in the 
Campylobacter direction we initially considered, I appreciated the opportunity with you and 
Dr. Orhan Sahin, and we’ll get this paper out soon! I am also grateful to Dr. Zhang as 
Associate Dean for Research and Graduate Studies, for supporting Dr. Matt Brewer and I on 
a One Health course at the University of Pretoria in South Africa in 2015 – that was truly an 
amazing experience! 
	 vi 
Thanks also to Randy Sacco as current Imbio DOGE, for writing letters of 
recommendation for my USDA-NIFA fellowship, and influencing the next stage in my 
scientific career following my PhD. Also thanks to Katie Blair for your work as Imbio 
program coordinator, and to Liz, Tammy, and Vern in the VMPM office, for all your time 
spent doing travel reimbursements and helping compile my USDA grant, and even for acting 
as occasional baby sitters. 
 Thank you to all the others who directly helped with this work and are coauthors on 
these chapters. Thanks to Dr. Greg Phillips, who was the first person associated with my 
graduate career that I met, as a high school student who needed a lab E. coli strain for a 
science fair project, and for these studies supported the microbial analyses. Thanks to Dr. 
James Fox for inviting us to co-author a review of the ASF, and Roger Orcutt for sharing 
your tremendous experience and expertise. Thank you to Dr. Damarius Fleming, for agreeing 
to perform the RNAseq pathway analyses after a brief, chance meeting at the USDA. Thanks 
to Rachel Phillips who performed all the RNAscope and Halo analysis, Dr Jessica Elbert for 
performing the FISH analysis and imaging as a summer vet student researcher, and Katarina 
Kohn for running some of the QIIME and statistics of the microbial data. Additionally thanks 
to Naihui (Ashley) Zhou, for running some complicated statistics on a tight timeline with 
support from Dr. Iddo Friedberg. Finally thank you to Allie Proctor, for not only being a 
great friend, but also performing more than your fair share of DNA extractions, all the Qubit 
analyses, patiently teaching me QIIME and R analyses, answering numerous email and text 
messages, and biking across the Golden Gate Bridge with a pregnant lady. 
 Thank you to my Wannemuehler lab mates for all your teaching and support and help 
through the last 11 years – there have been a lot of you overlapping with my time in the lab. 
	 vii 
First Jenny Wilson-Welder, Abby Henderson, and Zhiping Liu – Jenny taught me the basics 
of microbiology including growing anaerobes, Zhiping taught me real-time PCR, and Abby 
was my first immunology teacher, teaching me about IL-17 way before I knew much beyond 
the difference between a lymphocyte and a macrophage, and then years later we collaborated 
again. Next Kelley Haarberg initiated the botanical projects with Prunella and Hypericum 
that I worked on during my rotation, and eventually assisted in getting published. Lucas 
Huntimer, Yashdeep Phanse, Anne-Marie Overstreet, Susie Knetter, and Amy Schoofs were 
the current students as I started graduate school. Thanks to Luke and Yash for teaching me 
procedures such as western blots and flow cytometry, and Anne-Marie for teaching me 
everything about the multiple hit colitis model and how to run a gnotobiotic mouse 
experiment. Thanks AMCO, Susie, and Amy for being great friends – and thanks to all for 
helping with the first necropsies in my graduate career. And finally Ross Darling, Danielle 
Wagner Muniz, and Jorrell Fredericks, my lab mates for most of my graduate career – thanks 
guys for all your help with necropsies and cell and tissue processing. Especially thanks to 
Ross for your guidance in flow cytometry analysis, as well as Paola Boggiato – thanks also 
Paola for your motivating and inspiring discussions. 
 I owe gratitude to numerous rotation students that have helped with necropsies, and 
especially Julian Trachsel who performed the C. jejuni study with SPF mice. Also the 
numerous undergrads, vet students and summer students, who have worked both in the lab 
and in the mouse colony: Ryan, Maria, Lisa, Tim, Anna, Reid, Kyle, Jaimie, Justine, 
Kristina, Keanon, Josh, Lizzy, Nicole, Katelyn, Cara, Tom, and Gabby. Especially thanks to 
Tim for all your help in managing the gnotobiotic mouse colony, and Maria, Nicole and Cara 
prepping for necropsies and labeling and filling tubes, and Karrie Wright also for assistance 
	 viii 
the mouse colony. And many, many other who have helped with various things throughout 
my graduate career: Andy Peterson, Jenny Groeltz-Thrush, Nathan Peroutka-Bigus, Paul 
Leuth, Claire Mitzelfeldt, Genitta George, Shivani Ghiasis, Sarah Wiechert, and everyone 
else I’m forgetting. I also owe a big thank you to the LAR crew in building 40, especially 
Stevan Wilson, for supporting complicated animal experiments in the gnotobiotic isolators. 
I’m also grateful to Todd Atherly, Curtis Mosher, and Angela Bryan for assistance with FISH 
and FISH imaging. 
My biggest lab thank you of all is to Mary Jane Long. THANK YOU for being 
everything… my research support in the lab, later taking over management of the gnotobiotic 
mouse colony, and my listening ear for all my problems, from research problems to the woes 
of being pregnant and then a new mom trying to finish a PhD. MJ you are amazing and I will 
miss your support so much in my future research career away from Iowa State University. 
Thanks to my friends from Imbio, especially Kirsten, Kristin, Zahra, Katie, Shivani 
for being great friends and colleagues. Thanks to my friend Amanda Heeren, especially for 
assistance as I adjusted to life in the new role as “mom.” Thanks to my family, especially my 
Mom for helping with childcare duties in the early stages of adjustment, and backup for 
daycare, and all your support and encouragement through all of my education. 
Finally thank you to Jonathan, for being an amazing husband, father, and support 
through all the craziness of both veterinary and graduate school. Thank you for supporting 
this crazy educational journey of mine, your patience and tolerance in the roller coaster that 
is parenthood compounded by graduate school, and for doing more than your fair share of 
toddler time in the last few months.  Thank you. Thank you. Thank you. 
  
	 ix 
ABSTRACT 
 
Inflammatory bowel disease is a group of chronic intestinal inflammatory disorders 
with a complex etiology, and has been associated with a microbial dysbiosis and presence of 
GI pathogens including adherent and invasive Escherichia coli (AIEC) and Campylobacter. 
A gnotobiotic murine model (altered Schaedler flora, ASF) devoid of proteobacteria was 
utilized to evaluate microbial and host responses after colonization with AIEC LF82, E. coli 
Nissle 1917, and C. jejuni alone or treated with dextran sodium sulfate (DSS). The ultimate 
goal of this research was to understand the effects on mucosal homeostasis after disturbance 
of the resident microbiota by proteobacterial pathobionts. As few studies have evaluated the 
stability of the microbiota over multiple generations, Chapter 3 evaluates the impact of AIEC 
LF82 colonization on the heritability/transmissibility of the ASF over multiple generations. 
Results indicated minimal changes in ASF abundance within a generation, but there was a 
significant shift in the microbial population when comparing early and later generations. As 
early-life microbial exposures have been demonstrated to influence mucosal homeostasis 
later in life, Chapter 4 describes changes in the sensitivity to colitis following E. coli LF82 
colonization of ASF mice as an adult or neonate. We demonstrate neonatal colonization with 
LF82 increases the susceptibility to colitis, with increased inflammatory responses and 
minimal microbial changes, with neonatal colonization inducing subclinical, chronic 
inflammation that may predispose to more severe inflammation. In Chapter 5 of this 
dissertation, the benefits associated with probiotic Escherichia coli Nissle 1917 (EcN) 
colonization of neonatal mice to prevent or attenuate colitis as described in Chapter 4 were 
evaluated. Results indicated that co-colonization of neonatal mice with EcN did not impact 
	 x 
the severity of colitis, but did reduce the host’s proinflammatory cytokine response. Finally, 
in Chapter 6, both conventional and gnotobiotic mice were used to demonstrate that the 
pathogenesis of C. jejuni is differentially influenced by the complexity of the microbiota. By 
investigating host-microbial relationships and their effects on intestinal homeostasis, this 
work provided insights into the underlying mechanisms contributing to the onset of 
inflammatory bowel disease, as well as what constitutes a ‘healthy’ state in the relationship 
with our gut microbiota. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
 
Introduction 
 
The mammalian gastrointestinal microbiota has a mutualistic relationship with the 
host, is integral in maintaining homeostasis, and is implicated in contributing to multiple 
diseases. Inflammatory bowel disease describes a group of chronic intestinal inflammatory 
disorders with a multifactorial etiology, consisting of complex interactions between the 
gastrointestinal microbiota, genetics, environment, and the immune system. While IBD 
usually presents in young adults, pediatric IBD cases are on the rise in the United States. A 
dysbiotic microbiota is associated with IBD, as well as GI pathogens including multiple 
pathobionts such as adherent and invasive Escherichia coli (AIEC) and Campylobacter 
species.  
With a large diversity between individuals, the microbiota can be difficult to study. 
Utilization of a simplified microbial model, such as gnotobiotic mice harboring the well-
characterized murine altered Schaedler flora, simplifies this complexity and diversity 
between individuals. Together, the research in this dissertation evaluates microbial and host 
responses after colonization of these pathobionts in healthy and diseased animals. The 
ultimate goal of this research was to understand the effects on mucosal homeostasis after 
disturbance of the resident microbiota by these proteobacteria. By investigating basic 
mechanisms associated with the host-microbial relationship and effects on mucosal 
homeostasis in the gut, we can achieve a greater understanding of the mechanisms of 
inflammatory bowel disease, as well as what constitutes a ‘healthy’ state in the relationship 
with our microbiota. 
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Dissertation Organization 
 
  This dissertation is composed of seven chapters, five of which are written in the 
journal submission format. Chapter 1 is a review of the literature relevant to this dissertation. 
Chapter 2 is a published review article on the murine model used throughout most of this 
dissertation written primarily by Wymore Brand. Chapters 3 – 6 are full or partial 
manuscripts to be submitted to the Journal of Bacteriology, Gut, and Microbes and Infection 
and/or utilized as pilot data for future grant proposals. The final chapter, Chapter 7 contains 
general conclusions and future directions for research. The following is a list of author 
contributions for each of the research chapters. Chapter 3: All authors designed the 
experiments; Wymore Brand and Proctor conducted the experiments and analyzed the data; 
Wymore Brand wrote this portion of the manuscript that will be compiled with more of 
Proctor’s analyses for submission to the Journal of Bacteriology. Chapter 4: Wymore Brand, 
Jergens, G. Phillips, and Wannemuehler designed the experiments; Wymore Brand 
conducted the in vivo experiments; Wymore Brand, Proctor, Elbert, R. Phillips, and Hostetter 
performed ex vivo analyses; Wymore Brand, Proctor, Fleming, Zhou, and Kohn analyzed the 
data; Wymore Brand wrote the manuscript to be submitted to Gut. Chapter 5: Wymore Brand 
and Wannemuehler designed the experiments; Wymore Brand conducted the experiments, 
analyzed the data, and wrote this dissertation chapter that will be used as pilot data for future 
grant proposals. Chapter 6: Wymore Brand, Sahin, Zhang, and Wannemuehler designed the 
experiments; Wymore Brand and Traschel conducted the in vivo experiments; Hostetter 
performed histopathological analyses; Wymore Brand analyzed the data and wrote the 
manuscript to be submitted to Microbes and Infection as a short communication. 
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Review of the Literature 
 
Gastrointestinal Microbiota Overview 
Autochthonous microbiota 
The human body is colonized with a large population of microorganisms, with 
distinct microbial communities colonizing the skin, vagina, mucosal surfaces, and the 
intestine [1]. These microbes have co-evolved with humans, and are integral in maintaining 
homeostasis [2, 3]. The human intestine is home to a diverse population of bacteria that 
reaches 1011 cells/gram contents in the colon, along with populations of archaea, fungi, and 
viruses [2, 4-7]. Old estimates placed the host to microbial cell ratio at 10:1, but revised 
estimates place it closer to 1:1, with a 70kg man having approximately 3.8 x 1013 microbial 
cells [6]. Humans and other mammals have a complex microbiota dominated by Firmicutes, 
Bacteroidetes, Proteobacteria, and Actinobacteria, with hundreds of individual bacterial 
species [4, 8, 9]. The microbiota is not evenly distributed throughout the gastrointestinal 
tract, but has many niches for concentration of specific organisms, both longitudinally 
through the tract, and radially from lumen to mucosa [4, 10-12].  
The word “commensal” is often used to describe these organisms, but the relationship 
between the host and the microbiota is really one of mutualism, with both the host and the 
microbiota experiencing benefit. The microbiota thrives in a largely stable environment with 
continuous nutrient delivery, and the host benefiting from microbial roles in metabolism, 
vitamin production, immune system development, and competitive exclusion of pathogens 
[2, 13]. Thus the word “autochthonous” will be used in this dissertation to describe the 
resident microbiota, rather than the term “commensal”. The microbiota is initially acquired 
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from the dam/mother, as well as the environment, and is shaped through diet, genetics, and 
environmental influences, discussed more below. 
In an attempt to further understand the diverse organisms that compromise the 
microbiota, microbes have been classified as “good” or “bad.” When “bad” bacteria or 
pathogens colonize and cause disease, sick patients are treated with antibiotics in an attempt 
to eliminate and/or control the pathogen. Yet antibiotics usually have broad ranging effects, 
affecting other microorganisms beyond the intended target, and may lead to a collapse of the 
entire community if a few key species are altered [14, 15]. Another example of “bad” 
bacteria are pathobionts, organisms that may be normal members of the resident microbiota 
but can cause disease in certain circumstances. Conversely, in order to promote “good” 
bacteria and their metabolites, prebiotics and probiotics may be taken to enhance beneficial 
bacteria and promote their favorable metabolic effects on the host. Prebiotics are compounds 
that support the growth of “good” bacteria, and probiotics are live microorganisms that 
promote gut health, and will be discussed more below. 
With the hundreds of species and large diversity between individuals, the microbiota 
can be difficult to study [16]. Today methods to assess microbial community dynamics 
include 16s rRNA and whole genome sequencing, RNA sequencing, and metabolomics. 
Before the advances in technology allowing DNA-based microbiome analysis, the organisms 
of the microbiota were studied by culture, but many gut bacteria are extremely oxygen 
sensitive and difficult to impossible to culture even with modern techniques. Restriction 
enzyme and electrophoresis-based techniques to evaluate differences in communities without 
evaluating specific organisms, as well as southern blots and in situ hybridization, were 
utilized before 16S rRNA sequencing became cheap and efficient. Today, cheap DNA-based 
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PCR amplification and sequencing technologies that allow assessment of taxonomic profiling 
dominate microbial community structure analyses [17, 18]. Additionally as more microbial 
genomes are sequenced, gene expression can be evaluated, as well as functional changes and 
metabolomics with mass spectrometry (MS) and nuclear magnetic resonance (NMR) [17, 
18]. Additionally, improvements in culture techniques allow ex vivo microbial community 
analysis, such as with high throughput culturing, bioreactors, stem cell-derived organoid 
systems, and other complex microbial culture techniques [17, 18].  
 
Dysbiosis 
When the microbiota is in imbalance with an altered compositional and/or functional 
state, it is termed to as dysbiosis, although there is not a precise definition of what qualifies 
as a dysbiotic state or a healthy microbiota [19, 20]. A complicating factor is the huge 
diversity between individuals, and that the microbiota is impacted by perturbations, such as 
infection, antibiotics, and diet change, reshaping community structure and function to adapt 
to changing conditions [16, 21-23]. Alterations in the microbiota have been linked to 
gastrointestinal conditions such as inflammatory bowel disease, but also a wide a range of 
extraintestinal developmental processes and diseases not directly associated with the gut, 
including obesity, diabetes, heart disease, and brain development [19, 24-28]. The role of 
dysbiosis in inflammatory bowel disease will be discussed further below.  
 
Gastrointestinal Physiology and Immunology 
In normal homeostatic conditions, a physical and immunological barrier separates the 
immune system from the microbiota, including the epithelium, mucus, secretory IgA, 
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antibacterial peptides, and the presence of regulatory T cells (Tregs) that help maintain 
tolerance and hyporesponsiveness to the microbiota [29, 30]. The gastrointestinal (GI) tract is 
a highly specialized system that extends from the mouth to the rectum. The individual 
structures in between are the esophagus, stomach, small intestine (composed of the 
duodenum, jejunum, and ileum), cecum, and colon. Each structure is specialized for a 
specific function, such as digestion in the stomach, absorption of nutrients in the small 
intestine, and absorption of water and elimination of waste in the colon [30]. The interior 
lumen of the entire GI tract is colonized with varying levels of bacteria dependent on the 
oxygen gradient, with a smaller number of aerotolerant organisms colonizing at the “top” and 
a larger number of anaerobic organisms colonizing at the “bottom” [30].  
A mucous layer provides physical separation of the huge mass of microbial antigen 
from a single layer of epithelial cells, connected by tight junctions that maintain barrier 
function [30-32]. The epithelium is continually regenerated by stem cells in the crypts, and 
diversifies to absorptive enterocytes, mucous producing goblet cells, antimicrobial peptide-
producing Paneth cells, and neuroendocrine cells. Epithelial cells also express various pattern 
recognition receptors, such as toll-like receptors (TLRs), within and on the cell surface that 
recognize microbial-associated molecular patterns (MAMPs) to help survey the environment. 
Underneath the epithelial layer is a basement membrane, followed by the loose connective 
tissue of the lamina propria, that together with the muscularis mucosa comprise the mucosa 
of the GI tract. Below the mucosa is the submucosa containing the extensive parasympathetic 
nervous system of the gut, another layer of muscle called the muscularis, and the serosa, the 
outermost layer of the GI tract. 
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The GI tract contains an intricately organized lymphatic system, collectively termed 
the gut-associated lymphoid tissue (GALT), that contains the largest population of immune 
cells in the body that serve a dual purpose to survey for infection and maintain tolerance to 
microbiota, as well moving absorbed nutrients to the rest of the body [29, 30, 33]. In the 
small intestinal Peyer’s patches, microfold cells (M cells) constantly sample luminal 
antigens, passing them to the dendritic cells below in the subepithelial zone, which then 
stimulate antigen-specific lymphocytes below, and similar isolated structures exist in the 
large intestine [34]. Additionally the mucosa contains macrophages and dendritic cells that 
constantly sample luminal antigens and clean up antigen entering the mucosa through breaks 
in barrier function [35]. These phagocytes are important for bridging innate and adaptive 
immunity, and drain to the mesenteric lymph node to initiate priming of naïve lymphocytes, 
which then return to the effector site of the mucosa. Neutrophils are rare during homeostasis, 
but rapidly accumulate with inflammation to kill invading bacteria [36]. The intricate, 
coordinated cellular migration that occurs with cellular trafficking to and from these initiator 
and effector sites is due to physical mechanisms such as lymphatic and blood flow, as well as 
a network of cytokines and chemokines that are specific for various cellular structures that 
allow cells to migrate by following gradients of cellular signals [37]. 
The lamina propria contains a wide range of innate and adaptive immune cells, while 
the epithelial layer mainly has T cells. The majority of intraepithelial lymphocytes (IELs) are 
CD8+ in mice and humans, but is still a diverse population of cells with a higher population 
of cells with the CD8αα homodimer and δγTCR than other locations of the body [30, 38]. 
These IELs are important for defense against pathogens, as well as promoting healing, and to 
maintain barrier function [30, 38].  Of the lamina propria T cells, CD4+ predominate, with 
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lower numbers of CD8αβ+ cells, are dominated by IFNγ-producing T-bet+ Th1 cells, IL-17-
producing RORγt+ Th17 cells, and IL-10-producing FoxP3+ Tregs maintained by dietary, 
microbial, and immune signals [33, 38, 39]. However these T cell fates are plastic and some 
cells represent interrelated phenotypes, with a delicate balance dependent on environmental 
factors such as the microbiota and diet [33].Various microbial species and components such 
as the metabolite polysaccharide A (PSA) from Bacteroides fragilis, segmented filamentous 
bacteria (SFB), and cluster IV and XIVa Clostridial species have been associated with 
development and expansion of specific T cell subsets such as Th1, Th17, and Tregs, though 
the complex signals that drive development of specific T cell populations is likely far more 
complicated than a single bacterial species or metabolite [40-43]. The lamina propria also 
contains a large population of plasma cells, especially in the colon, that secrete IgA that is 
transported into the lumen to bind microbial antigen [30]. 
The gut also contains populations of more recently described innate lymphoid cells 
and invariant T cells, that lack a rearranged antigen-specific cell receptor and are CD4/CD8 
negative [44, 45]. Innate counterpoints for each of the classical subsets of effector 
lymphocytes exist, relying on the same transcription factors and producing the same 
cytokines. In general, ILC1s represent Th1 cells, ILC2s represent Th2, ILC3s represent 
Th17, and NK cells represent CD8+ T cells [44]. Additionally like effector lymphocytes in 
the gut, these innate lymphoid cells represent a diverse array of phenotypes and functions 
[44]. 
It has long been recognized that the microbiota is necessary for proper development 
of the GI structure and immune function. Early studies in germfree mice revealed the 
development of enlarged ceca, reduced motility, altered epithelial cell morphology, and 
	 9 
defects in development of lymphoid tissue in the gut and throughout the body [46-49]. 
Additionally microbes are necessary for proper immune system maturation, including the 
development of lymphocytes [48, 50-52]. Some but not all of these effects are reversible with 
a later introduction of a microbiota [53-57]. 
 
Inflammatory Bowel Disease 
Overview 
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative 
colitis (UC), are a group of chronic intestinal disorders with a multifactorial etiology 
consisting of complex interactions between the gastrointestinal (GI) microbiota, genetics, 
environment, and the immune system [58]. IBD costs the American economy over $6 billion 
annually with a prevalence of over 400 cases per 100,000 in American adults, and pediatric 
IBD in particular is increasing [59-62]. The etiology of IBD is complex, with contribution 
from genetics, the microbiota, the immune system, and the environment. To date, over 200 
genes have been identified as IBD susceptibility loci, with more being identified all the time 
[63]. A higher proportion of pediatric cases are familial, and there is similar susceptibility 
genes between pediatric and adult-onset cases [64, 65].  
Additionally implicated are both a dysbiosis and an enhanced immune reactivity to 
the autochthonous microbiota [66-68]. The dysbiosis associated with IBD is generally 
described as a decrease in microbial and functional diversity, though whether this dysbiosis is 
a cause or effect of gastrointestinal inflammation is still unclear [7, 67]. Canine IBD and 
murine models of colitis have also demonstrated an association between disease and a 
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dysbiotic microbiota [69-71]. Pediatric IBD patients have altered microbiota, and an increase 
in mucosa-associated bacteria has also been observed in IBD patients [66, 72-76]. 
An aberrant T cell response to the host microbiota and anti-microbial serum antibody 
have been demonstrated in IBD patients, suggesting a break in tolerance to the autochthonous 
microbiota [68, 77, 78]. IL-10 producing regulatory T cells function to keep the immune 
response from targeting normal microbial antigens, but with overwhelming inflammation this 
system may break down [68, 79]. Indeed, IL-10-/- develop spontaneous colitis, and transfer of 
CD4+ T cells without Tregs to immunodeficient mice results in intestinal inflammation [80, 
81]. Both of these colitis models depend on a microbiota, as germ-free mice do not develop 
inflammation [82, 83]. 
 
Adherent Invasive Escherichia coli 
GI pathogens have been suggested to contribute to the etiology of IBD, notably the 
pathobiont adherent and invasive E. coli (AIEC) in Crohn’s disease [84-88]. Darfeuille-
Michaud found AIEC up to 36.4% of CD patients and 6.2% of control samples from the 
ileum [85]. LF82 is an AIEC strain isolated from damaged ileal mucosa of a CD patient, in 
phylogenetic group B2 and closest related to avian pathogenic strain APEC_01, meningitis-
associated strain S88, and urinary-isolated strain UT189 [86, 89, 90]. 
AIEC doesn’t contain virulence genes associated with other E. coli pathogens, and it 
is still debated if AIEC is causative or simply a provocateur that triggers disease [85, 91]. 
However, AIEC has been isolated from boxer dogs with granulomatous colitis and remission 
can be achieved with antibiotic therapy [92-94]. Adhesion of AIEC is via type 1 pili to the 
human cell surface marker carcinoembryonic antigen-related cell adhesion molecule 6 
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(CEACAM6), and Crohn’s patients have higher expression of this molecule [89, 95]. Mice 
do not naturally express this receptor, but CEACAM6 transgenic mice can be persistently 
colonized with AIEC and exhibit inflammation [96]. Additionally pointing to a potential 
pathogenic mechanism for E. coli, patients with some types of CD have a higher prevalence 
of antibodies directed against E. coli OmpC and flagellin [97, 98].  
Other studies with AIEC have demonstrated its survival within macrophages, 
disruption of the polar epithelium, and ability to form biofilms [99-101]. It has also been 
demonstrated to interact with Peyers patches via long polar fimbriae, and has been 
demonstrated within granulomas in tissue [102, 103]. In immunosufficient, conventional 
microbiota mice, LF82 does not readily colonize, though antibiotic treatment allows 
colonization in some models [104, 105]. Even in a NOD2 knock out mouse model pretreated 
with antibiotics, AIEC was not able to persistently colonize mice [105]. In another study with 
multiple strains of streptomycin-treated mice, AIEC infection with isolate NRG857c induced 
Th17 response, increased proinflammatory cytokines, and led to transmural inflammation 
and fibrosis [104]. TLR5-/- mice exhibit inflammation after colonization with LF82, and 
LF82 increases severity of DSS-induced colitis dependent on flagellin signaling [106-108].  
 
Dual-Hit Colitis Model 
Michael Wannemuehler’s laboratory has developed a “dual hit” colitis model where 
Helicobacter bilis, or a murine-isolated E. coli, act as a provocateur in gnotobiotic C3H/HeJ 
mice colonized with the Altered Schaedler Flora (ASF). Past results in the Wannemuehler 
laboratory indicate H. bilis colonization results in changes in the ASF community, altered 
mucosal gene expression, and increased susceptibility to colitis following low dose dextran 
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sulfate sodium treatment [109-113]. The ASF mouse model and the laboratory’s previous 
studies are reviewed in depth in Chapter 2 of this dissertation, as published in the ILAR 
Journal in 2015. Recent studies have utilized the ASF model as a reduced ammonia 
production microbiota to evaluate liver disease, to evaluate compositional and spatial 
changes in microbiota following colonization with Helicobacter bilis, and with Oxalobacter 
formigenes to evaluate host and microbial interactions [113-116]. The ASF model has also 
recently been utilized to determine the effect of serum-derived bovine 
immunoglobulin/protein isolate in colitis, to evaluate the host response to antimicrobial 
growth promoters, and to examine the impact of quorum sensing E. coli regulators B and C 
within the context of a microbial community [117-119]. Recently a real-time qPCR assay for 
quantification was published, as well as systems-level analysis of metabolism in the 8 ASF 
[120, 121]. Additionally, an in-depth functional evaluation of ASF 457, Mucispirillum 
schaedleri, has been performed [122]. With the increasing amount of publications since the 
review in Chapter 2 was published, interest in the ASF mouse model is growing. 
 
Campylobacter jejuni 
Campylobacter jejuni is a major cause of human bacterial gastroenteritis worldwide, 
with increasing case prevalence in developed countries [123, 124]. Campylobacter 
gastroenteritis is usually self-limiting, but some patients progress to the autoimmune disease 
Guillain-Barre syndrome [123]. C. jejuni is naturally maintained in the poultry 
gastrointestinal tract, and poultry meat serves as a primary vector for human transmission, 
along with contaminated milk, water, and other animal meat [123, 124]. In addition to its 
food-borne disease significance, C. jejuni has a veterinary impact as it causes abortion in  
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small ruminants, and human transmission may occur through contact with infected animals 
[123, 124].  
 IBD, functional gastrointestinal disorders such as irritable bowel syndrome, 
periodontitis, and other gastrointestinal conditions have been associated with different 
species of Campylobacter infection [123]. Camylobacter jejuni has been associated with IBD 
as an inciter or in exacerbating symptoms, potentially by impacting barrier function allowing 
for increased translocation, or by increasing transcytosis of mucosal bacteria [125-129]. 
Additionally, Campylobacter concisus is another adherent invasive proteobacterium 
associated with IBD, and serum immunoreactive proteins to C. concisus have been observed 
in CD patients [130-134].  
Despite the high public health significance of C. jejuni, human disease research 
models are limited. C. jejuni generally irregularly colonizes immunocompetent, conventional 
microbiota mice without intestinal disease, suggesting the murine microbiota exhibits 
colonization resistance to C. jejuni [135, 136]. Murine models such as humanized microbiota 
or limited microbiota mice, serial C. jejuni in vivo murine passage, antibiotic pre-treatment, 
and dietary fat manipulation may result in successful C. jejuni colonization, though usually 
without gastrointestinal disease [135-140]. Some immunodeficient mouse models, including 
IL-10-/-, TLR and NF-κB deficient signaling, and SCID mice can be colonized with variable 
levels of resulting gastrointestinal inflammation [135-139, 141]. Because of the unreliability 
of rodent models, non-human primates, neonatal swine, and ferrets are the most widely used 
disease models for Campylobacter disease [124, 138].  
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Neonatal Microbiota 
Development 
The mammalian microbiota begins developing in the neonatal period and continues to 
be shaped with early environmental factors and microbial exposures through adolescence 
[38, 142, 143]. Healthy babies have a variation of composition and colonization patterns that 
eventually converge to a more standard adult composition [143]. We are only beginning to 
appreciate how these early-life exposures and the progression of bacterial colonization with 
specific microbes shape health and mucosal homeostasis later in life.  
In 1900 Tissier described the sterile womb paradigm, where babies are sterile in the 
uterus and birth provides the first exposure to microbes [144, 145]. Recently this dogma has 
been challenged, as DNA-based analyses have detected bacterial DNA in fetal and placental 
samples as well as the meconium, and in some studies even cultured bacteria, though these 
analyses and their results are controversial [146-153]. The meconium of premature infants 
has even had bacterial DNA detected, with different organisms detected in premature versus 
term infants [154-156]. One study demonstrated detection by PCR and culture of a 
genetically-labeled Enteroccous fecium strain in the meconium of fetal pups after inoculation 
to pregnant mice [146]. Yet in most cases whether the detection of microbial DNA in fetal 
samples is indicative of live organisms remains to be determined. If in utero microbial 
transmission is a normal process in mammals that is simply yet to be fully explored, humans 
and other mammals would not be unique as this has been observed in a variety of species 
from marine invertebrates to insects to some vertebrate species such as fish and turtles [145]. 
However as Perez-Munoz and colleagues discuss in a recent review, a major hurdle to  
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accepting in utero microbial transmission as a normal physiologic process is the ability to 
derive mice and other organisms (including humans) germ-free by cesarean sections [153]. 
Regardless if in utero microbial transmission is occurring, it is possible that the fetus 
is at least exposed to microbial components prior to parturition. It has been documented that 
during pregnancy bacterial diversity increases, with an expansion in Proteobacteria and 
Actinobacteria [157-159]. In mice in late pregnancy, bacterial translocation to MLN and 
mammary gland has been observed and suggested to be contributing to fetal or neonatal 
microbial exposure [160]. One murine study describes how the maternal microbiota drives 
development of intestinal ILC3s  and F4/80+CD11c+ mononuclear cells in offspring, by using 
a reversibly colonized germfree model, via maternal antibodies binding microbial molecules 
and transferring to the pup in utero and during lactation [161].  
Neonates certainly get a diverse microbial exposure during birth regardless if there is 
in utero colonization or microbial component exposure. Vaginal delivery exposes neonates to 
microbes from the vagina, skin, and fecal matter, while the first ex utero microbial exposure 
in cesarean section delivery is the skin [16, 162-165]. It has been debated how much delivery 
mode impacts the microbiota, with multiple studies indicating differing microbiota in infants 
born vaginally versus by caesarean section [164-169]. However a recent large study 
demonstrated there was no long-term effect of delivery mode on the microbial community 
structure beyond the immediate neonatal period, and the authors suggest the previous 
observation of impact of delivery mode on infant microbial composition may be due to the 
underlying medical reason for performing cesarean [170]. Also still debated is the extent 
delivery mode has long-term impacts of the infant, with some studies suggesting caesarean  
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delivery increases association with certain disease such as diabetes, asthma, atopy, celiac 
disease, and obesity [168, 169, 171-174].  
The early microbiota is variable and unstable but becomes more uniform and adult-
like with time, as specific successions of organisms colonize [16, 143, 175]. The early diet, 
formula feeding versus breastfeeding, has been demonstrated to impact the developing early 
microbiota [166, 169, 176, 177]. Additionally, breastfeeding also works to influence the early 
immune system with transfer of maternal antibody, cells, immunomodulatory compounds, 
and cytokines, as well as transfer of microbes, though some formulas now contain 
immunomodulatory components including prebiotics, probiotics, and bovine lactoferrin [160, 
163, 178-181]. Beyond the gastrointestinal tract the developing microbiota is also impacted 
by the environment, with recent data indicating the early microbiota is homogenous across 
most body sites immediately after birth, but by six weeks of age it has expanded and 
diversified to be specific for all body sites, indicating site-specific microbial communities 
develop very quickly [170]. 
 
Microbial colonization lasting impact on health 
In 1966, the concept of Biological Freudianism was introduced to demonstrate that 
early environmental contributions from the microbiota had a lifelong impact on “production 
traits” in the first colony of specific pathogen free mice [182]. Dubos, Savage, and Schaedler 
performed a serious of experiments with New Colony Swiss (NCS) mice, essentially the first 
specific pathogen free mice derived from Standard Swiss (SS) mice. These mice had more 
offspring and grew faster and larger more efficiently, especially on nutrient-deficient diets, 
and survived bacterial endotoxin exposure [183]. The NCS mice lacked E. coli and had other 
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differences in their microbial communities, and these differences were transferrable with co-
housing [184]. This concept of Biological Freudianism is consistent with the hygiene 
hypothesis (a decrease in early childhood exposure to microbes is responsible for the 
increased allergic and autoimmune diseases as adults in the developed world), in that early 
life exposures have a lasting impact on health [185]. Other terms such as “programming,” 
“metabolic imprinting,” and the “Barker Hypothesis” have been used for the concept of fetal 
or neonatal origins of adult disease [186-188]. This concept has received increased interest 
recently, with multiple studies and reviews focused on this topic.  
As previously discussed, it has long been recognized the microbiota impacts the 
development of the immune system [189]. A study evaluating host tissue transcriptional 
profiling identified differences between mice colonized with a microbiota as adults or 
neonates, identifying age as an important factor in shaping host homeostasis [190]. Another 
microarray study demonstrated microbial exposure during the neonatal period altered 
expression of immune-related genes [191]. This impact of age of colonization has been 
termed a “critical window,” a period of time where the microbiota can be perturbed or 
modified, and by effect increase association with specific diseases or conditions, such as 
asthma and eczema [190, 192, 193]. The field of allergy has been particularly well studied in 
relation to the gut microbiota, and multiple studies have identified differences in the 
microbiota in early life correlating with the development of allergic conditions later in life 
[192-198]. Other studies have demonstrated altering the microbiota during early life with 
antibiotics has a lasting metabolic impact, and may influence the development of chronic 
inflammatory conditions like IBD and asthma [199-201].  
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Maternal microbial modulation impact on neonate 
It has also been demonstrated how modulation of the mother’s microbiota can impact 
the neonate. In mice, antibiotic administration to pregnant mice results in decreased fecal 
microbial richness and altered microbial composition and function in offspring, and in 
humans has been linked to increased risk of childhood obesity and asthma [202-204]. 
Additionally, probiotics given to pregnant women have demonstrated alterations in the 
offspring microbiota, as well as expression alterations of TLRs in placental and fetal gut 
[150]. The maternal diet also impacts the neonatal microbiota, demonstrated in a macaque 
model where a maternal high fat diet resulted in a microbial dysbiosis in offspring that was 
only partially corrected by a post-weaning low fat diet [205]. Exposure to a farm 
environment has been associated with altered microbiota in general, and farm exposure 
during pregnancy has been demonstrated to alter immune parameters of cord blood cells, 
increasing Treg activity, lower Th2 cytokine secretion, and changes of innate immunity 
receptors, again linking back to the hygiene hypothesis [185, 206-208].  
 
Epigenetics 
A potential mechanism for neonatal imprinting/programming is epigenetic 
modification of the genome. Epigenetics describes heritable modifications to chromatin that 
regulate gene transcription, and include histone modifications and DNA methylation, though 
the mechanism for heritability is not well understood [209-212]. Epigenetics have been 
linked to a variety of complex diseases, and have been suggested to be a factor in IBD, 
especially DNA-methylation [213, 214]. 
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A well-studied example of long-lasting epigenetic changes due to developmental 
origins in human medicine is the study of individuals conceived during the Dutch Hunger 
Winter in 1944-1945 during World War II [215-217]. Due to a German food embargo, there 
was a sudden, discrete period of famine in The Netherlands, and researchers have been 
studying the children conceived during the famine for decades. These studies have revealed 
life-long effects on health in these individuals, including metabolic, cardiovascular, and 
psychiatric disorders that are thought to be at least in part mediated through epigenetic 
mechanisms [215-217]. A mouse model of intergenerational developmental programming 
has demonstrated that in utero nutritional manipulation impacts germline gene methylation 
and can be associated with metabolic alterations in the offspring [218]. 
Exposure to farm environments in pregnancy and early childhood have demonstrated 
epigenetic changes in genes related to asthma and allergy [206, 219]. In a murine model of 
asthma, pregnant mice exposure to farm-derived Acintobacter lwoffii F78 resulted in 
epigenetic changes in the Ifng and Il4 promoters that associated with IFN-γ and IL-4 
expression in offspring [220]. A recent study in a murine DSS-induced colitis model revealed 
altered DNA-methylation and associated gene expression changes in offspring of males with 
colitis, and increased susceptibility to colitis in offspring [221]. 
 
Multigenerational Evaluation of the Microbiota  
Minimal studies have been performed on the stability of the microbiota over multiple 
generations, and the impact of dysbiosis in being passed to further generations. One study in 
mice demonstrated selective inbreeding over four generations did not result in a more 
uniform microbiota between individuals, though a similar studies depicted generational 
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differences in multiple generations in microbial structure and function after introduction to a 
new barrier facility [222-224]. Other studies have evaluated the stability of reduced microbial 
communities through generations, including the ASF [22, 225, 226]. A study evaluating the 
impact of microbiota-accessible carbohydrate (MAC) component of dietary fiber reported 
that successive generations of a low-MAC diet resulted in permanent loss of taxa that were 
not recoverable with reintroduction of MAC to the diet in later generations [227]. Faith and 
colleagues have developed a transmission algorithm to describe the probability of 
colonization with a particular microbe, and suggest that studying microbial inheritance of 
specific organisms could be beneficial in determining the microbial contribution to complex 
diseases, and a recent review discusses how little we know about transmission of the 
autochthonous microbiota between individuals [228, 229]. 
 
Probiotics 
The FAO/WHO defines a probiotic as “live bacteria which when administered in 
adequate amounts confer a health benefit to the host” [230].  Probiotics have become a more 
attractive option in therapeutics for a wide range of conditions that provide an effect by 
competitive exclusion of microbial organisms and/or modulation of the immune system [231, 
232]. Probiotics have been administered to neonates with the intent to decrease colonization 
of pathogenic bacteria and decrease the impact of chronic disease, and pre-and probiotics are 
often a component of infant formula [233, 234]. Probiotic supplementation has been 
demonstrated to reduce allergic diseases in young children [197]. 
Alfred Nissle in the early 1900s in Freiburg Germany, was evaluating growth 
inhibiting properties of human intestinal E. coli to pathogens like Salmonella and Shigella 
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and discovered some inhibitory effects when grown together in vitro [235]. The Nissle strain 
of E. coli was isolated in 1917 from a solider serving in WWI in the Balkan peninsula who 
was not suffering from enteropathogens, while many of his fellow servicemen were suffering 
[235]. Nissle studied and self-experimented with this strain, and eventually introduced it into 
medicine where it became the product Mutaflor® [235].  
E. coli strain Nissle 1917 (EcN) is still marketed as Mutaflor® in Europe, and is a 
non-pathogenic, O6:K5:H1 E. coli with no pathogenic adhesion factors, enterotoxins, or 
cytotoxins, is non-invasive, and rapidly killed by innate immune components of normal 
serum [235, 236]. One of the only gram-negative probiotics available, Mutaflor® is used for 
the treatment of chronic constipation, infectious diarrhea, and chronic colitis and related 
conditions [237, 238]. EcN’s exact mechanism of action is unknown, though is likely 
multifactorial as it has been demonstrated to have a wide variety of effects, well reviewed in 
multiple publications [235]. Generally, EcN has been demonstrated to produce 
immunomodulatory molecules and decrease inflammatory immune responses in the gut, 
especially TNFα via TLR2 signaling [239-243]. Additionally it promotes barrier function, 
including inducing defensin production and up-regulating tight junction proteins [244-246]. 
EcN produces an altered LPS that evidently reduces its toxicity and allows for 
immunomodulatory properties [247]. Additionally, EcN has multiple mechanisms to 
competitively exclude pathogens, including production of microcins/siderophores/iron 
competition molecules, competition for other nutrients, and directly preventing pathogen 
adhesion [248-254].	EcN has been used as therapy in IBD patients, mostly in UC, and 
multiple studies have demonstrated beneficial effects in preventing relapses in UC patients 
equivalent to mesalazine therapy [255-258]. In cell culture, EcN has been shown to inhibit 
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adhesion to and invasion into intestinal epithelial cells of multiple AIEC isolates including 
LF82, as well as suppress proinflammatory cytokines, though it did not prevent invasion to 
ileal mucosa biopsies [259-261]. Additionally EcN use in infants has been demonstrated to 
have a lasting impact on the immune system, by reducing the risk of allergies in children up 
to 10 years after therapy [262].  
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Abstract 
The gastrointestinal (GI) microbiota forms a mutualistic relationship with the host 
through complex and dynamic interactions. Because of the complexity and inter-individual 
variation of the GI microbiota, investigating how members of the microbiota interact with 
each other as well as with the host is daunting. The altered Schaedler flora (ASF) is a model 
community of eight microorganisms that was developed by R. P. Orcutt and has been in use 
since the late 1970s. The eight microorganisms composing the ASF were all derived from 
mice, can be cultured in vitro, and are stably passed through multiple generations (at least 15 
years or more by the authors) in gnotobiotic mice continually bred in isolator facilities. With 
the limitations associated with conventional, mono- or bi-associated, and germfree mice, use 
of mice colonized with a consortium of known bacteria that naturally inhabit the murine gut 
offers a powerful system to investigate mechanisms governing host-microbiota relationships, 
and how members of the GI microbiota interact with one another. The ASF community 
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offers significant advantages to study homeostatic as well as disease-related interactions by 
taking advantage of a well-defined, limited community of microorganisms. For example, 
quantification and spatial distribution of individual members, microbial genetic 
manipulation, genomic-scale analysis, and identification of microorganism-specific host 
immune responses are all achievable using the ASF model. This review compiles highlights 
associated with the 37 year history of the ASF, including descriptions of its continued use in 
biomedical research in elucidating the complexities of host-microbiome interactions in health 
and disease.  
 
The Gut Microbiota 
It is well established that the number of bacteria living in our gastrointestinal (GI) 
tract outnumber our own cells 10 to 1, with values that reach 1011 cells/gram contents in the 
colon [1-4]. The mutualistic relationship with the host has co-evolved to form a dynamic 
interaction between the gut microbiota and the host. In healthy individuals, the microbiota 
thrives in a largely stable environment with continuous nutrient delivery, and where the host 
benefits from microbial contributions to metabolism, vitamin production, immune system 
development, and competitive exclusion of pathogens [5, 6].  
Determining how specific autochthonous microorganisms contribute to the health of 
the mammalian host remains a significant challenge due to the vast diversity of microbial 
species in the gut, which is colonized with several hundred species and subspecies [1, 3]. 
Members of the microbiota are also not evenly distributed throughout the GI tract, but are 
concentrated in many niches throughout the alimentary tract from the lumen to the mucosa 
[1, 7-9]. Understanding how microorganisms have adapted to colonize specific niches is also 
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challenging due to the varying environmental conditions that can be encountered throughout 
the GI tract including pH, nutrient availability, host immunity, and bacterial cell density. 
 
Mice as Models for the Gut Microbiota 
Mice are the most common mammalian model to examine the mutualistic relationship 
between the host and the microbial world living within us. Similar to humans, mice have a 
complex gut microbiota dominated by Firmicutes and Bacteroidetes along with members of 
the Proteobacteria, as well as other phyla that respond to perturbations such as diet and 
antibiotics [5, 10]. The murine microbiota can also be manipulated in ways not possible with 
humans, including generation of gnotobiotic mice encompassing both germfree and defined 
microbiota mice. In addition to their overall complexity, conventionally reared mice have 
been demonstrated to have a variable microbiota between individuals, as well as significant 
cage-to-cage variation [11]. Differences in the GI microbiota within the same strain of mouse 
obtained from different vendors have been shown to influence research results; for example, 
the presence or absence of segmented filamentous bacteria have been shown to influence the 
development of Th17 cells [12]. Additional examples demonstrating the influence of the 
microbiota on host responses has been reported with respect to the phenotypic variation in 
murine inflammatory bowel disease models that are a consequence of the differences in the 
microbiota; these differences have been recently reviewed by Schoeb and Bullard [13]. 
Though this diversity in the GI microbiota makes commercially available mice similar to the 
humans who also have a variable GI microbiota between individuals, microbial diversity 
makes it difficult to draw conclusions between studies regarding how changes in the 
microbiota affect the host when the study subjects do not have a uniform microbiota as a 
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point of reference. Thus, defined microbiota models offer the advantage of a known and 
consistent standard upon which to determine how manipulation of GI microorganisms impact 
physiological processes in the host. 
 
 
Figure 1. Morphological features of the ceca from gnotobiotic and conventional mice. Left panel: 
Representative images of the cecum excised from a germfree (left), a monoassociated (center), or a 
conventional (right) C3H/HeN mouse. Right panel: Representative images of the cecum excised from 
an ASF (left) or conventional (right) C3H/HeN mouse. 
 
Gnotobiotics, and more specifically, the generation of germfree mice has provided the 
basis to allow investigators the ability to study host-microbe as well as microbe-microbe 
interactions following the purposeful introduction of selected microorganisms. Germfree 
animals, however, are not representative of a normal host because they have an 
underdeveloped mucosal and systemic immune systems characterized by reduced serum 
leukocytes and antibody [14-16]. Germfree mice also display anatomical alterations (Figure 
1) (i.e., an enlarged cecum), along with histological, physiological, and metabolic differences 
[16, 17]. Colonization of germfree mice with one or more bacterial species has been used as 
an approach to study host-microbe interactions including bacterial pathogenesis. Again, it 
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should be realized that mono- or biassociated models lack the community dynamics of a 
complex microbiota and the resultant host-microbial interactions would not be representative 
of those interactions that naturally occur in the conventional mammalian gut. 
Germfree mice have also been used to develop defined microbiota models by 
colonizing them with a limited number of bacterial species isolated from humans.  These 
“humanized” mice, however, are utilized mainly for short-term biomedical research studies 
because it is not clear how bacteria adapted to other hosts and their diets (i.e., bacteria from 
human GI tract) in order to maintain genetic and numerical stability, or organizational 
structure during long-term colonization and vertical transmission in murine hosts [18, 19].
 
Given the limitations of conventional, germfree, or highly contrived defined 
community mouse models, use of mice with a consortium of known bacteria that normally 
inhabit the murine GI tract offers a powerful system to understand how expression of specific 
genes within the microbiome impact the host, as well as determine how members of the GI 
microbial community interact with one another. The altered Schaedler flora (ASF) represents 
 
Table 1. Meta data characterizing the eight members of the altered Schaedler flora (ASF) 
 
*members of the original Schaedler flora. 
**mouse strain from which the organism was isolated. 
 
 
 ASF 356* ASF 360* ASF 361* ASF 457 ASF 492 ASF 500 ASF 502 ASF 519* 
Mouse 
strain**  
Nelson Collins Swiss 
(NCS) NCS NCS  NCS  CD-1  CD-1  CD-1  NCS  
Date of 
isolation Early 1960s Early 1960s Early 1960s Early 1960s Early 1970s Early 1970s Early 1970s Early 1960s 
Geographic 
location 
Rockefeller 
University 
Rockefeller 
University 
Rockefeller 
University 
Rockefeller 
University 
Charles River 
Laboratories 
Charles River 
Laboratories 
Charles River  
Laboratories 
Rockefeller 
University 
Scientist Russell Schaedler Russell Schaedler Russell Schaedler Russell Schaedler Roger Orcutt Roger Orcutt Roger Orcutt Russell Schaedler 
Source Intestine/Cecum Stomach Stomach Intestine/Cecum Intestine/cecum Intestine/cecum Intestine/Cecum Intestine/Cecum 
Taxonomy Clostridium species Lactobacillus intestinalis 
Lactobacillus 
murinus 
Mucispirillum 
schaedleri 
Eubacterium 
plexicaudatum 
Pseudoflavonifactor 
species Clostridium species 
Parabacteroides 
goldsteinii 
Genome 
size (Mb) 2.91 2.01 2.17 2.33 6.51 3.70 6.48 6.87 
GenBank 
Accession 
No. 
AQFQ00000000.1 AQFR00000000.1 AQFs00000000.1 AYGZ00000000.1 AQFT00000000.1 AYJP00000000.1 AQFU00000000.1 AQFV00000000.1 
Cellular 
morphology 
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a gnotobiotic mouse model that has been in use for decades (Table 1) that offers significant 
advantages to study microbiome-host interactions. 
 
Development of the ASF 
In 1965, Russell W. Schaedler developed a defined microbiota mouse colony in 
which the mice were colonized with two Lactobacillus spp., an anaerobic Streptococcus sp. 
(Group N), a strain of bacteroides, an Enterococcus sp., and a coliform strain, all of which 
were isolated from Nelson Collins Swiss mice [20]. The microbial population was 
maintained from dam to offspring, and the mice’s GI tissue resembled that of a mouse with 
conventional microbiota, but not that of a germfree mouse (Figure 1) [20]. The bacteria 
comprising this defined microbial community (Schaedler flora) were supplied to animal 
vendors for use as a base microbiota for newly derived germfree rodents as a means to 
provide a competitive niche to limit or prevent colonization of GI opportunistic bacterial 
pathogens [21]. A limitation of the Schaedler flora, however, was the presence of facultative 
aerobes (specifically Escherichia coli and Streptococcus fecalis) that typically outgrew 
isolator contaminants when cultured aerobically [22].  
In 1978, at the behest of the National Cancer Institute, Roger P. Orcutt, whose Ph.D. 
mentor was Russell W. Schaedler, developed a refined microbiota based on the Schaedler 
flora to be used by contract suppliers [21, 23]. He replaced four of the original bacterial 
species from the Schaedler flora with microorganisms isolated from CD-1 mice [21]. The 
new organisms represented major constituents of the authotchotonous microbiota of the 
mouse, as opposed to the original Schaedler facultative anaerobes which only reach 
significant levels in infant mice during their second week of life before the extremely oxygen 
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sensitive (EOS) anaerobes arrive as the mice start to ingest solid food on day 11 after birth. 
Three of the newly introduced bacterial species were EOS anaerobes, selected for 
morphological differences and ease of identification with direct phase microscopy of cecal 
contents or a fecal smear [21]. The final addition was a spiral-shaped microorganism (i.e., 
ASF 457) that was originally isolated by Dr. Schaedler, using differential filtration through a 
0.45 um millipore filter. This species was later named Mucispirillum schaedleri in his honor 
[24]. 
The new microbial community derived by Dr. Orcutt (Table 1) consisted of eight 
anaerobic bacteria of which only the two lactobacilli could grow aerobically, allowing for 
detection of contamination under aerobic growth conditions. This was not possible in the 
original Schaedler flora formulation due to the presence of bacterial species that would 
replicate aerobically. The ASF members do not have cocci or spore-forming blunt ended 
rods, which are the predominant contaminates in gnotobiotic isolators [22]. The ASF 
establish stable GI colonization in the mouse, although ASF 360 (Lactobacillus intestinalis) 
may disappear depending on the mouse’s diet. The impact of the diet on the microbiota was 
noted in the 1960s when Dubos and Schaedler observed that ASF 360 was unable to be 
cultured when mice bearing the Schaedler flora were fed a 15% casein diet [7, 25].  
This new ASF microbiota was utilized by major vendors of commercial mice and rats 
(e.g., Charles River Laboratories, Harlan Laboratories, Simonsen Laboratories, and Taconic 
Biosciences) as all had contracts with the National Cancer Institute. The new set of eight 
microorganisms eliminated the problems of the original Schaedler “cocktails” as voiced by 
these NCI suppliers [21]. Many vendors including Taconic Biosciences and Charles River 
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Laboratories continue to use the ASF in their isolator foundation breeding colonies to 
provide a baseline microbiota prior to conventionalization.  
The ASF community is representative of a normal murine GI microbiota that can be 
stably maintained for generations under gnotobiotic conditions [26-28]. The ASF 
longitudinally distribute through the GI tract, differentially occupy niches similar to a 
complex GI microbiota, and ASF-colonized mice are healthy with a normal immune system 
and GI function [23, 27]. Each microorganism can be individually evaluated, as organism-
specific PCR primers have now been developed and used in research studies [26, 27]. Each 
of the ASF can be individually cultivated in vitro, allowing the production of bacterial 
antigen that can be used to evaluate organism-specific immune responses, and offer the 
opportunity for genetic manipulation of the individual ASF species [29]. Thus, this model is 
relevant to investigate specific members of the bacterial community, as well as its impact on 
the host immune system.  
 
Phylogeny of the ASF 
In 1999, the 16S rRNA genes of the ASF were sequenced providing new 
phylogenetic information about each of the ASF members [30]. From this, ASF 361 was 
found to be identical to the type strains of both L. murinus and L. animalis, while ASF 360 
was determined to be a novel Lactobacillus similar to L. acidophilus and L. lactis [30]. ASF 
519 was most closely related to Porphyromonas and aligned with an unnamed genus, while 
ASF 457 was determined to be in a distinct phylum [30]. ASF 457 is now classified as a 
novel bacterium, Mucispirillum schaedleri, in the phylum, Deferribacteres [24]. The 
remaining four ASF members comprised a group of Gram positive bacteria possessing a low 
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G/C content [30]. ASF 492 was identical to Eubacterium plexicaudatum and ASF 500 was 
not closely related to any other microorganism [30]. With the availability of additional DNA 
sequence-based taxonomic information, ASF 519 was recently identified as Parabacteroides 
goldsteinii, ASF 360 as Lactobacillus intestinalis, and ASF 500 has been more specifically 
identified as a species of Pseudoflavonifractor within the order Clostridiales [31-33]. Whole 
genome sequencing further classified ASF 502 as a Clostridium sp. [34]. 
Near complete genome sequences of each of the ASF members have recently been 
reported (Table 1), revealing the genetic composition of an entire gut microbiome [34]. This 
resource will provide unprecedented opportunities to understand how gene expression and 
metabolic activity respond to changes to the mammalian host. For example, transcriptome 
analysis of the ASF bacteria can be used to interrogate how the GI community responds to 
changes in diet, genetic background, or pathogenic bacterial infection. In addition, ongoing 
work in the author’s laboratories includes resequencing the ASF genomes in an effort to 
identify heritable genetic alterations within the ASF in response to changes (e.g., diet, 
inflammation, additional microbes) to the host’s GI microenvironment. 
 
In Vivo Evaluation of the ASF 
Quantitative, real-time PCR (qPCR) has been developed to monitor the absolute 
abundance of each ASF member [27]. For example, Sarma-Rupavtarm et al. evaluated the 
distribution of the ASF in the GI tract of six week old C.B-17 SCID mice and noted that P. 
goldsteinii (ASF 519) was the dominant microorganism, with Clostridium spp. (ASF 502), 
Mucispirillum sp. (ASF 457), and Lactobacillus sp. (ASF 361) were the next most prevalent 
organisms [27]. An independent study also revealed ASF 519 as the dominant organism and 
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ASF 519 and 502 have previously been reported to be the dominant organisms from fecal 
samples [27, 35]. More recently, use of 16S rRNA gene sequencing on the Illumina platform 
confirms the results of these previous studies (Figure 2). Also, consistent with previous 
studies, ASF 360 is too low in abundance to routinely be detected by 16S sequencing but is 
detectable with organism-specific PCR from stomach contents. This high throughput 
approach facilitates analysis of a larger number of samples than is feasible using qPCR and, 
thus, will be useful to study changes in the microbiota during longitudinal studies in great 
detail.  
 
 
Figure 2. Stability and relative abundance of the altered Schaedler flora (ASF) in gnotobiotic 
C3H/HeN mice bred at Iowa State University between 2005 and 2013. a) Pie chart representing the 
relative abundance of the members of the ASF in feces collected and archived in 2005. b) Piechart 
chart representing the relative abundance of the members of the ASF in feces collected and archived in 
2013. The relative distribution of taxonomic classes were determined by 16s ribosomal gene sequence 
analysis (V4 variable region) on the Illumina MiSeq platform. While the relative abundance of ASF 
360 was below limits of detection by species specific 16s amplicon sequencing, this species was 
detectable by end-point PCR analysis of contents from the upper GI tract.  
 
Fluorescence in situ hybridization (FISH) can be used to monitor changes in bacterial 
mucosal association. Using a colony of gnotobiotic ASF-colonized C3H/HeN mice 
continuously maintained for fourteen years, the Wannemuehler laboratory at Iowa State 
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University has utilized FISH to evaluate spatial distribution of the ASF following the 
colonization of E. coli (Figure 3). Mucispirillum schaedleri (ASF 457) has been 
demonstrated to be a mucous colonizer in the mouse GI tract and also translocates to the liver 
[24]; the fusiform ASF organisms are likely to be differentially associated with the mucous 
layer of the GI tract as previously suggested [36]. 
 
 
Figure 3. Photomicrograph depicting the use of fluorescent in situ hybridization (FISH) to evaluate the 
spatial distribution of the altered Schaedler flora (ASF) relative to the mucosal epithelium (DAPI stain 
- blue) of the proximal colon in a C3H/HeN mouse colonized with the ASF and Escherichia coli. The 
EUB338-FITC probe (green) was used as a nonspecific probe to detect the ASF with a species-specific 
Cy3-labeled probe for E. coli (orange). 
 
Several studies have evaluated the ASF in multiple genetic backgrounds of mice 
revealing that GI colonization dynamics are influenced by host genetic background, sex and 
age of the mice, though the community structure largely remains stable over time [26-28, 
37]. Longitudinal evaluation demonstrates that oxygen availability affects colonization 
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dynamics, with aerotolerant Lactobacillus (ASF 361) dominating in the upper GI tract, 
stomach and esophagus, and obligate anaerobes more heavily colonize the cecum and colon 
[26, 27]. ASF 360 (Lactobacillus) was detected in very low numbers [26, 27] in the proximal 
alimentary tract (i.e., esophagus). Also, fecal samples were not necessarily equivalent to 
samples isolated from within different compartments of the gastrointestinal tract [26, 27]. 
When gnotobiotic ASF mice are conventionalized, the ASF remain stable 
components of the complex microbial community [26, 28]. Conversely, colonization of 
gnotobiotic ASF mice with H. hepaticus has revealed quantitative changes in the community 
structure with the introduction of the new microorganism [37].  
 
ASF as a Microbial Model Community 
The ASF provides a well-defined, limited community of microorganisms available 
for manipulation, quantification, and organism-specific immune responses. This model has 
been used for microbiological, immunological, and metabolic studies. The ASF have mostly 
been used in mice, but also in rats and pigs [38, 39]. However, colonization of gnotobiotic 
pigs was unreliable as one might expect as pigs have their own autochthonous microbiota 
[38]. 
Mice colonized with the ASF can be useful to study the impact of enterobacteria 
colonization on a model microbial community as the ASF is devoid of proteobacteria. The 
ASF was used to colonize germfree mice resulting in mice harboring a low complexity 
microbiota (LCM) (i.e., raised under barrier conditions) in order to study colonization 
resistance of Salmonella enterica [40]. These LCM mice were easily colonized with S. 
enterica and developed pathological changes intermediate between conventional and 
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germfree mice. When the authors co-housed the LCM mice with a mouse harboring a 
conventional microbiota, the LCM mice developed colonization resistance towards S. 
enterica as evidenced by lower CFU of S. enterica in fecal and cecal samples [40]. The most 
abundant ASF members identified in these studies were ASF 519 and ASF 500 [40]. 
 At Iowa State University, we have stably colonized Helicobacter bilis, 
Campylobacter jejuni, and different E. coli strains in gnotobiotic C3H/HeN ASF-colonized 
mice. Microorganisms that typically do not stably colonize mice with a conventional 
microbiota have been shown to chronically colonize mice with an established ASF. Four 
strains of C. jejuni stably colonized for at least seven weeks and LF82, an adherent invasive 
E. coli strain associated with Crohn’s disease, has been stably maintained across six 
successive generations of mice (manuscripts in preparation). Additionally, a study using 
Helicobacter felis demonstrated stable colonization of ASF mice, whereas this 
microorganism was lost from conventional microbiota mice [41].  
The ASF-colonized mice have been used to evaluate the dynamics of the mucosal 
IgA response to the resident microbiota [42]. Recently, ASF has also been used to determine 
that the colonization of the GI tract with bacteria in the postnatal period is necessary for 
development of the enteric nervous system (ENS); in fact, the ENS of ASF colonized mice 
was similar to that found in conventionally-reared, SPF animals [43]. When colonizing 
germfree MyD88-deficient NOD mice with the ASF, a reduced type 1 diabetes (T1D) 
phenotype, similar to conventional SPF mice, was observed compared to the germfree, 
MyD88-deficient NOD mice [44]. This demonstrates that the ASF community is sufficient to 
reduce the tendency to develop T1D mellitus. The ASF have also been used in HLA-B27 
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transgenic rat model of colitis to colonize germfree rats demonstrating that the microbiota, 
especially Bacteroides species, contributed to colitis in this model [39].   
The ASF has been used as a representative subset of the GI microbiota in order to 
evaluate the changes in the distribution of the microbial community following GI 
perturbation. For example, colonization of conventional mice with H. pylori was shown to 
increase the numbers of ASF 356, 361, 457, and 500 detected in the stomach [45].  In 
contrast, co-infection of the mice with Heligmosomoides polygyrus prevented the H. pylori 
induced detection of these same four ASF members in the stomach [45]. Another study with 
H. pylori used a subset of the ASF to augment gastric cancer progression mouse model [46]. 
Collectively, the use of the ASF as representatives of the lower bowel microbiota 
demonstrated that spatial changes in microbial colonization along the GI tract likely 
contributed to ongoing inflammation and development of precancerous dysplasia.  
 
ASF Microbiological Functions In Vivo 
The importance of the microbiota with respect to contributing to the nutritional needs 
of the host is well documented. For example, the GI microbiota produce short chain fatty 
acids (SCFAs) such as butyrate by digestion of dietary fiber and butyrate has been described 
as a major energy source for colonic epithelial cells. In addition, Garrett and co-workers have 
demonstrated that SCFAs are capable of attenuating the severity of colitis [47]. With respect 
to using the ASF to study production of SCFAs, ASF 356 and ASF 492 have been shown to 
produce large amounts of SCFAs in vivo and in vitro [47]. Because the ASF genomes have 
now been sequenced, it is now possible to evaluate the metabolic pathways responsible for 
production of SCFAs and to predict metabolic changes (i.e., metabolites) that would be 
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associated with dietary changes or those associated with disease. The ASF is a stable 
community suggesting that each member of the ASF contributes metabolically to the 
homeostasis of this model microbiota and/or to that of the host (Figure 2). In this regard, 
ASF-colonized animals have been used to evaluate the role of intestinal bacteria in the 
metabolic activation of nitrotoluene into a genotoxin; it was demonstrated that ASF-
colonized animals were less efficient at metabolizing the compound [48]. Members of the 
ASF have been used to evaluate foraging of host metabolites by the microbiota, 
demonstrating that a simplified microbiota was not as efficient as a complex microbiota at 
utilizing these host-derived compounds (e.g., mucins) [49].  
 
ASF and Gut Immunology Research 
ASF colonization has been used in several studies to evaluate components of mucosal 
immunity including CD4+ T cells, IgA, and RegIII-γ. ASF-colonized mice have also been 
used to demonstrate that microbial antigens are necessary for homeostatic development of 
mucosal T cells in the colonic lamina propria; specifically, the ASF was shown to be 
sufficient to induce regulatory T cells (iTREG cells) and to induce both spontaneous and 
homeostatic T cell proliferation that was essential to establish GI immune homeostasis [50]. 
Furthermore, germfree mice reconstituted with the ASF lacked Th17 cells and had increased 
proportions of FoxP3+ TREG cells in the small intestinal lamina propria [12]. Because of the 
complexity of a conventional microbiota, it is difficult to evaluate the role of the GI 
microbiota in the development of mutualistic immune adaptations. To address these 
limitations, Geuking and colleagues used ASF-colonized mice to study the maintenance of 
mutualistic CD4+ T cells response [35]. Following treatment of these ASF-colonized mice 
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with low dose dextran sulfate sodium (DSS), the colonic lamina proprial T cells responses 
were characterized by the presence of iTREG cells and the absence of demonstrable Th1 or 
Th17 cells which resulted in the maintenance of mucosal homeostasis [35].  While ASF 519 
was the dominant organism in the GI microbiota of these mice, colonization with ASF 519 
alone, unlike B. fragilis, was unable to induce an expansion of the iTREG cell population 
demonstrating the necessity for a community of organisms to establish mucosal homeostasis 
[35, 51]. Additionally, a later study demonstrated that ASF colonization was sufficient to 
induce thymic stromal lymphopoietin (TSLP) expression that was critical for the prevention 
of the exaggerated production of IL-17A in the colonic lamina propria [35, 52].  
The colonization of the GI tract with the ASF alone was sufficient to stimulate the 
development of mucosal immunity as demonstrated by Ivanov and colleagues [12]. These 
authors were able to show that reconstitution of germfree mice with the ASF induces the 
production of natural secretory IgA in the gut at levels equivalent to that detected in SPF 
mice; however, the number of IgA+ plasmablasts in the small intestinal lamina propria were 
reduced compared to SPF mice [12, 42, 53]. Another study investigated the dynamics of 
microbiota-specific secretory IgA and used ASF colonized mice to demonstrate that IgA-
specificity is determined by the immunodominant antigens of the resident microbiota. 
Moreover, the loss of transient microorganisms correlates with the attrition of the respective 
antigen-specific IgA secreting plasma cells in the lamina propria [42]. Cong and colleagues 
utilized ASF mice to demonstrate that IgA-mediated immune exclusion of bacterial flagellin 
was antigen-specific and was not polyspecific [53]. While several of the ASF express 
flagella, ASF-colonized mice were useful in these studies because they possess a limited 
bacterial antigen load due to the small size of this bacterial community and, thus, lack 
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preexisting antibody to antigen(s) not present (i.e., anti-CBir1 flagellin antibody) [53]. 
Because the ASF promotes the development of mucosal immunity, the limited complexity of 
the ASF community allows colonization with new microorganisms (e.g., Proteobacteria) 
unrelated to the existing community and can thus be used to evaluate antigen-specific 
mucosal IgA to the newly introduced organism within the context of a resident microbial 
community [53].  
There are greater than 170 genes now identified as susceptibility markers for 
inflammatory bowel diseases (IBD) and polymorphisms or deficiencies in Nod1 and Nod2 
have been directly linked to IBD susceptibility [54]. In this regard, SPF and ASF-colonized 
Nod1-/-; Nod2-/- mice were used to evaluate the impact of the microbial complexity on 
intestinal barrier function and susceptibility to DSS-induced colitis [55]. In comparison to an 
SPF microbiota, Natividad and colleagues demonstrated that colonization of Nod1-/-; Nod2-/- 
mice with the ASF attenuated the severity of DSS-induced colitis. While the ASF-colonized 
Nod1-/-; Nod2-/- mice presented with increased epithelial permeability, there was no evidence 
of spontaneous colitis. In addition, ASF-colonization was sufficient to normalize RegIII-γ 
expression when compared to Nod1;Nod2 sufficient mice [55]. The same authors 
subsequently demonstrated that ASF colonized mice expressed RegIII-γ at lower levels when 
compared to mice with a complex SPF microbiota [56]. Collectively, these studies indicate 
that ASF-colonized mice can be used to interrogate the role of the microbiota in the onset of 
IBD and that the ASF is a microbial community lacking “colitogenic” bacteria that initiate 
spontaneous IBD as seen in other genetic models of IBD. Due to the reduced microbial 
complexity, ASF-colonized mice can also be used to evaluate the benefits of probiotic 
bacterial species to attenuate disease in genetically susceptible colitic mice [56]. 
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ASF and Colitis Research 
IL-10-/- mice maintained under traditional housing conditions develop severe 
enterocolitis, while SPF IL-10-/- mice (i.e., likely colonized by Helicobacter species) develop 
localized colitis [57]. As the ASF was designed to be free of any members of the 
Proteobacteria (e.g., Helicobacter, Campylobacter, Escherichia,), ASF-colonized mice can 
be used to evaluate the impact of specific members of the Proteobacteria on the development 
of colitis in genetically susceptible mice. Unlike conventionally-reared IL-10-/- mice, ASF-
colonized IL-10-/- mice fail to develop colitis or exhibit very mild disease, emphasizing the 
impact of the microbiota in this colitis model [28].  The ASF community has proven useful 
as a microbial GI community to evaluate the underlying mechanisms by which introduction 
of microbial provocateurs directly contribute to the onset of colitis. For example, it has been 
demonstrated that SPF IL-10-/-  mice colonized with Helicobacter trogontum developed 
typhlocolitis shortly after infection; in addition, the relative abundance of some of the ASF 
members decreased during the H. trogontum-induced inflammatory response consistent with 
the observed dysbiosis in IBD patients [58]. Using ASF-colonized SCID mice, Cahill and 
colleagues demonstrated that Helicobacter hepaticus alone was insufficient to trigger IBD-
like colitis in the absence of CD45RBHigh CD4+ T cells [59]. Because of their defined nature, 
ASF-colonized mice have been used to demonstrate that there are decided interactions 
between the host immune system, inflammatory triggers provided by individual bacterial 
provocateurs, and onset of colitis in genetically susceptible mice. 
A mouse model of typhlocolitis using gnotobiotic ASF mice colonized with either H. 
bilis or Brachyspira hyodysenteriae demonstrated increased ASF-specific antibody, variable 
severity of colitis in the B. hyodysenteriae infected ASF mice versus H. bilis-colonized ASF 
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mice [60]. As the previous studies focused on the host response to the provocateur [58, 59], 
more recent studies have focused on the host response to the ASF [29]. Because each of the 
ASF is cultivable using brain heart infusion medium or Schaedler’s medium supplemented 
with bovine serum, host immune responses to the “entire” microbiota can be evaluated. In 
another study, gnotobiotic ASF mice colonized with H. bilis demonstrated increased ASF-
specific serum antibody and CD4+ T cell responses [29]. A subsequent study using a similar 
study design used microarray analysis to demonstrate differential mucosal gene expression 
associated with fatty acid metabolism and detoxification in a time course following H. bilis 
colonization [61]. The addition of low dose DSS-treatment to induce colitis demonstrated 
that H. bilis increases the host’s sensitivity to a mild colitic insult by initiating inflammation 
and disrupting mucosal homeostasis [62].    
 
Limitations of the ASF Model 
 With a limited, defined microbiota, ASF mice lack the functional redundancy and 
metabolic capacity of a conventional microbiota [63]. It could be argued that one limitation 
of ASF community is that it may be considered dysbiotic (i.e., limited diversity); regardless, 
it is evident that ASF-colonized mice are immunologically, reproductively, and metabolically 
similar to conventional mice. The limited nature of the ASF should allow investigators to 
evaluate the in vivo effect of other bacterial species (e.g., segmented filamentous bacteria) on 
the community dynamics as well as mucosal homeostasis (i.e., development of Th17 cells). 
In contrast, additional iterations of the ASF community, to further limit the diversity and 
metabolic capabilities of this consortium of microorganisms would also be informative. 
Recently, this has been successfully addressed by colonizing mice with three ASF members, 
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ASF356 Clostridium species, ASF361 Lactobacillus murinus and ASF519 Parabacteroides 
goldsteinii, to study colonization dynamics in a mouse model of H. pylori-induced gastric 
cancer [46]. While it can be informative to further reduce the GI microbiota, it would be 
extremely laborious to construct “altered” ASF communities that lack one or more of the 
ASF microorganisms to evaluate the factorial interactions of this model community. Lastly, 
even though all members of the ASF community can be cultivated in vitro (e.g., BHI plus 
serum or Schaedler’s medium plus serum), there have been no published works describing 
the replication of these eight organisms on defined medium. Therefore, there is a need to 
develop better in vitro culture techniques to fully realize the potential that this model 
community can provide with respect to bacterial-bacterial interactions and bacterial-host 
interactions.  
 
Conclusions 
The usefulness of the ASF model is multidimensional. The ASF bacteria form a 
stable community that colonizes long term each mouse within a colony (e.g., 14 years at 
ISU).  In addition, as all microorganisms can be cultured in vitro, bacterial antigen can be 
prepared to test immune responses to individual organisms by evaluating for antigen-specific 
antibody or ex vivo cell stimulation [29, 60]. With the availability of ASF genome sequences, 
every microorganism within the community can be detected and quantified by qPCR and 
interrogated by amplicon sequencing, and expression of individual genes of interest 
monitored. Because the ASF community possesses eight bacterial species, this can be viewed 
as both an advantage and a limitation of this model community. From the perspective of an 
advantage, the ASF offer a stable consortium of bacterial species that can be used to build a 
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road map that describes and potentially predicts community dynamics following a variety of 
perturbations including diet, introduction of other bacteria, fungi, or viruses, and/or induction 
of inflammation. On the other hand, the limitations of the ASF should be realized in as much 
that this consortium is less complex than the microbiota of conventional animals and may be 
limited in its ability to fully predict the impact of a microbial community on the health of the 
host. Though the original Schaedler flora is celebrating its 50th anniversary, with the 
development of new techniques and technologies, use of unique defined microbiota models 
offer opportunities to study host-microbiota interactions well beyond what may have been 
envisioned by Schaedler in 1965. 
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CHAPTER 3: INFLUENCE OF MATERNAL GASTROINTESTINAL 
INFLAMMATION ON VERTICAL TRANSMISSION OF MICROBIOTA OVER 
MUTLIPLE GENERATIONS  
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Abstract 
The gastrointestinal microbiota has been intimately linked to human health and 
disease. In this regard, microbial dysbiosis has been associated with inflammatory bowel 
disease, but few studies have been performed to evaluate the transmissibility of a dysbiotic 
microbiota from mother to offspring. Gnotobiotic mice harboring the altered Schaedler flora 
(ASF) were used as a model to evaluate the heritability/transmissibility of a dysbiotic 
microbiota over multiple generations. It was hypothesized that repeated inflammatory insults 
would result in a shift in the microbiota to a dysbiotic state that is transmissible through 
generations, and that after multiple generations the microbiota would be significantly altered 
from it’s original composition. ASF mice were colonized with an adherent invasive 
Escherichia coli (LF82), and bred over multiple generations, with one group also receiving a 
regimen of 2% dextran sodium sulfate (DSS) in each generation to trigger inflammation. 
Fecal samples were collected at multiple time points within each generation, and sequencing 
of the 16S rRNA gene was performed to assess microbial abundance. Results demonstrate 
small changes in abundance in different organisms within each generation regardless of DSS 
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treatment, following the colonization of LF82 E. coli. Intergenerationally, there were 
multiple significant differences in relative abundance (p < 0.05) in various organisms 
between the early and later generations, with a general shift in microbial composition 
visualized by principal coordinates analysis (PCoA) through the generations independent of 
DSS-treatment. This suggests that the ASF is a resilient microbial community, and capable of 
enduring provocation to restructure and reestablish itself. Collectively, the data suggests that 
each member of the ASF is functionally important to the maintenance of the community as 
evidenced by the observation that all eight ASF members are maintained, regardless of the 
perturbation, for at least 6 generations. 
 
Introduction 
The human gastrointestinal (GI) tract is home to a diverse and dynamic population of 
bacteria, and may include organisms that normally are symbionts but cause disease in certain 
circumstances (i.e., a pathobiont) [1-5]. The complex GI microbiota is incredibly diverse 
between individuals with no single core microbiome identified. However, alterations in the 
diversity, composition and/or functionality of the microbiota, widely defined as a dysbiosis, 
have been linked to inflammatory bowel disease (IBD) and other intestinal disorders, as well 
as a wide a range of developmental processes and diseases [1, 6-8]. Inflammatory bowel 
diseases, including Crohn’s disease and ulcerative colitis, are a group of chronic intestinal 
disorders with a multifactorial etiology consisting of complex interactions between the GI 
microbiota, genetics, environment, and the immune system [9]. The incidence of pediatric 
IBD is increasing, and the GI microbiota of pediatric patients has been demonstrated to be 
dysbiotic similar to that described for adult IBD patients [10-12]. A dysbiotic microbiota in 
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children is also associated with conditions such as necrotizing enterocolits, obesity, atopy, 
asthma, and autism-spectrum disorders [13]. 
Gastrointestinal pathogens have been suggested to contribute to the etiology of IBD, 
notably the pathobiont adherent and invasive Escherichia coli (AIEC) [14-18]. AIEC have 
been recovered from 30 to 40 % of patients with ileal Crohn’s disease, although AIEC have 
also been isolated from a small portion of normal, non-diseased individuals [15, 16].  LF82 is 
an AIEC strain isolated from damaged ileal mucosa of a Crohn’s disease patient that has 
previously been utilized in murine colitis models, including dextran sodium sulfate (DSS)-
induced gastrointestinal inflammation [14, 19-21].  
The initial acquisition of the GI microbiota occurs during the neonatal period from 
the mother, and microbiota continues to be shaped through early life, eventually stabilizing in 
early adolescence [22, 23]. Women with IBD-associated dysbiosis may pass their dysbiotic 
microbiota to their babies. Additionally, these women are less likely to remain on their 
medications during pregnancy, potentially increasing the likelihood of developing GI 
inflammation and further influencing their microbiota during pregnancy [24]. The 
ramifications of a newborn acquiring a dysbiotic microbiota in early life have not been well 
studied, though a few murine studies have demonstrated vertical or horizontal transmission 
of a disease-associated dysbiotic microbiota for a single generation [25-28].  
The microbiota has a profound influence on the immunological development of the 
neonate, thus, it’s been proposed, and in some cases demonstrated, that alterations in 
acquisition may affect systemic immune function, such as increased susceptibility to 
development of allergies, asthma, diabetes, IBD, obesity, colon cancer, and increased 
susceptibility to infections [13, 29]. Human studies demonstrate that the induction of 
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alterations to the mother’s microbiota can alter the composition of the neonatal microbiota, 
and, in some cases, may have long-lived consequences as evidenced by the well-studied 
impact on childhood atopic diseases [30].  
In humans and conventional animal models, the microbiota is difficult to study, with 
hundreds of species and large diversity between individuals [31]. To better understand host-
microbiota and microbiota-microbiota relationships, simplification of this daunting 
complexity by utilizing a less complex (e.g., gnotobiotic) model system could be used to 
identify fundamental principles in host-microbiota relationships that are translatable to a 
complex (i.e., conventional) microbial community. We have utilized well-characterized, 
gnotobiotic mice harboring the eight bacterial species of the altered Schaedler flora (ASF) as 
a simplified model of a complex GI community [32-34]. Each member of the ASF can be 
cultivated in vitro, has been sequenced, and its presence/abundance can be individually 
evaluated; furthermore, organism-specific immune responses can be characterized [33, 35]. 
While ASF consortium contains no proteobacteria, we have shown that multiple 
proteobacteria (e.g., Helicobacter bilis, Campylobacter jejuni) including E. coli LF82 stably 
colonize ASF mice [21, 32, 33]. Others have shown that LF82 does not colonize 
conventionally-reared mice harboring a complex microbiota [36]. The aim of this study was 
to evaluate the impact of repeated, multigenerational inflammatory insults on microbial 
changes across multiple generations. The ASF community has been described as inherently 
dysbiotic compared to a conventionally-reared murine microbial community, but in this 
manuscript we use the term “dysbiotic” to describe alterations in diversity and/or function 
within the ASF from the normal steady-state community [37]. We hypothesized that repeated 
inflammatory insults would result in a shift in the microbiota to a dysbiotic state that is 
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transmissible through generations, and that after multiple generations the microbiota would 
be significantly altered from it’s original composition both numerically and/or functionally. 
We demonstrate small changes in abundance in different organisms within each generation 
regardless of DSS treatment or not, following the colonization of LF82 E. coli. 
Intergenerationally, there were multiple significant differences in relative abundance (p < 
0.05) in various organisms between the early and later generations, with a general shift in 
microbial composition visualized by principal coordinates analysis (PCoA) through the 
generations independent of DSS-treatment. 
 
Materials and Methods 
Animals 
Gnotobiotic C3H/HeN:TAC mice colonized with the altered Schaedler flora (ASF) 
were bred and maintained in flexible film isolators under gnotobiotic conditions. The ASF 
consists of eight bacterial species, ASF 356 Clostridium species, ASF 360 Lactobacillus 
intestinalis, ASF 361 Lactobacillus murinus, ASF 457 Mucispirillum schaedleri, ASF 492 
Eubacterium plexicaudatum, ASF 500 Pseudoflavinofractor species, ASF 502 Clostridium 
species, and ASF 519 Parabacteroides goldsteinii [38]. Mice were fed irradiated chow 
(Teklad 2919, Envigo, Huntingdon, Cambridgeshire UK) and autoclaved water for the 
duration of the experiment. 
 
Experimental Design for Breeding Project 
All mice were infected with E. coli LF82 and divided into two groups and maintained 
gnotobiotically in two separate experimental/breeding lines for the duration of the 
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experiment, with or without DSS treatment (Figure 1A). Six to eight pairs of male and 
female mice were paired for breeding in each group. After 2.5 weeks, the male was removed 
to prevent the females becoming pregnant again after delivery of her first litter. Fecal 
samples were collected from all breeding females in generation 1 (G1) through generation 5 
(G5) at five separate time points (Figure 1B): weaning (4 week), pre-DSS (8 week), post-
DSS/pre-breeding (11 week), prior to parturition (14 week), and necropsy (18 week) (Figure 
1). Serum and cecal contents were collected for CFU assessment from extra offspring not 
used for breeding at 10 weeks of age, as well as adult ASF mice colonized with LF82 at 6 
weeks of age, to be equivalent to G0 mice. 
 
Infection with E. coli LF82 
At six weeks of age, all mice of the G0 generation were colonized with E. coli LF82 
via oral gavage of 0.2 ml containing approximately 5 x 108 CFU. It was previously 
demonstrated that E. coli LF82 is stably maintained in these gnotobiotic ASF mice [21]. E. 
coli LF82, obtained from Dr. Kenny Simpson (Cornell, Ithaca, NY), was aerobically grown 
on TSA plates at 37 °C. Cells were harvested from plates, suspended in sterile PBS, and 
quantified with McFarland standards and confirmed by serial dilution. Colonization was 
confirmed by culture of fecal samples on TSA plates, as the only members of the ASF that 
replicate aerobically are easily differentiated from E. coli.  
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Figure 1: All founder mice for these experiments were infected with E. coli LF82 as adults, and 
divided into two breeding groups that were maintained separately for six generations, with one group 
exposed to DSS in their drinking water prior to breeding (A). Throughout the generations, fecal 
samples were collected at multiple time points for 16s rRNA sequencing to assessment microbial 
abundance (B). Fecal samples from generation 1 (G1) through G4 were collected at multiple time 
points. The first sample was collected after weaning, at 4 weeks of age. At 8 weeks of age the second 
sample was collected, immediately prior to initiation of DSS treatment in the group that received 
treatment. The 2 % DSS regimen consisted of 5 days of DSS administration in the drinking water, 
followed by 6 days of standard water, and then another 6 days of DSS treatment. On the last day of 
DSS treatment, mice were paired for breeding (11 weeks of age). After 2.5 weeks, the male mice were 
removed from the cages to prevent rebreeding of the female. 20 days after pairing for breeding another 
fecal sample was collected, prior to parturition (14 weeks). Pups were weaned at 3.5 weeks of age and 
dams were culled (18 weeks). The sequence was repeated for each subsequent generation of mice.  
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Induction of DSS (dextran sulfate sodium) colitis in breeding mice 
2% DSS (MP Biomedicals, LLC, Santa Ana CA) was prepared in sterile water and 
filter sterilized (0.2 um). Mice were allowed to drink DSS ad libitum for 5 days, followed by 
6 days of water, and then 5 more days of DSS exposure before being paired for breeding 
(Figure 1B).  
 
Fecal Collections 
In generations 1 through 4, fecal samples were collected at the indicated time points 
within the gnotobiotic isolators, and stored frozen (-20 °C) in 100 µl nuclease-free water 
(Ambion, ThermoFisher, Waltham MA) until DNA extraction was performed. In generation 
0, samples were collected prior to breeding and at necropsy, and in generation 5 samples 
were collected at weaning (four weeks of age) and at necropsy (eight weeks of age). 
 
Genomic DNA isolation and analysis 
Microbial genomic DNA was isolated from fecal samples with the PowerSoil-htp 
DNA Isolation Kit (MoBio, Vancouver BC). The manufacturer’s protocol was followed with 
the exception that the initial vortex step was extended to 20 minutes to thoroughly 
homogenize the samples. The purified genomic DNA extracts were quantified using a Qubit 
3.0 Fluorometer (Life Technologies, Carlsbad CA), and stored at -20°C in 10mM TRIS 
buffer. PCR amplification of the V4 variable region of the 16S rRNA gene using V4 region 
specific primers (515F-816R) and amplicon sequencing were performed by Institute for 
Genomics & Systems Biology at the Argonne National Laboratory (Argonne, IL) on the 
Illumina MiSeq Platform. The sequences were analyzed using QIIME (Quantitative Insights 
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into Microbial Ecology) [39]. Reads were first demultiplexed and quality filtered, then 
sequences with homopolymer runs or ambiguous bases greater than 6, nonmatching 
barcodes, barcode errors, or quality scores less than 25 were removed. Operational 
taxonomic units (OTUs) were called using uclust and the closed reference OTU picking 
strategy in QIIME using 97% similarity and aligned to a custom database that includes only 
the 16S rRNA sequences of the ASF organisms as well as common challenge organisms or 
contaminants at 97% similarity [40]. Weighted UniFrac PCoA plots were generated in 
QIIME and visualized in EMPeror (Biocore) [41]. 
 
LF82 Cecal Bacterial Load 
Cecal contents from mice necropsied at 12 weeks of age were serially diluted in PBS 
and then inoculated onto MacConkey agar in triplicate 10 µL spots to measure colony 
forming unity (CFU). Plates were incubated at 37 °C overnight before colonies were counted. 
 
Preparation of bacterial antigens 
Bacterial antigen was prepared as previously described [21]. Briefly, bacteria were 
cultivated on aerobically (LF82) or anaerobically (ASF), harvested and washed in PBS, 
frozen, lyophilized and stored at -20 °C until used. Bacterial cells were re-suspended in 
sterile PBS at 2 mg/ml, freeze-thawed four times, sonicated, UV irradiated, and sterility 
confirmed by culture. Aliquots were stored at -20 °C.  
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Serum ELISA 
Serum was collected at necropsy from offspring mice at 12 weeks of age and frozen 
at -20C until use. After thawing, serum was spun for 10 min at 10,000 x g. Whole bacterial 
antigen (10 µg/ml) was coated on high binding plates (Costar High Binding Plates, Corning, 
Corning NY) and incubated overnight at 4 °C. Plates were washed three times in phosphate 
buffered saline with 0.05% Tween 20 (PBST) and blocked with 2% gelatin with 2% goat 
serum in PBST and incubated at room temperature for 2 hours. Plates were washed three 
times with PBST and serum (1:200 in PBST with 2% goat serum) was added. Plates were 
incubated overnight at 4C. Plates were with washed PBST four times and 1:2000 alkaline 
phosphatase conjugated goat anti-mouse IgG (H+L) (Jackson ImmunoResearch, Bar Harbor 
ME) with 2% goat serum was added. Plates were incubated at room temperature for 2 hours, 
and then washed in PBST four times. p-Nitrophenyl phosphate (ThermoFisher, Waltham 
MA) was diluted in substrate buffer as recommended by the company and added to develop 
the plates. Plates were incubated 60 min and then read at 405 nm on a spectrophometer 
(SpectraMAX 190, Molecular Devices, Sunnyvale CA). 
 
Western Blots and SDS-PAGE 
Ten µl of 2 mg/ml LF82 and ASF whole bacterial antigens were boiled for 10 min in 
Laemmli loading buffer at 90 °C then run on a 12 % SDS-PAGE gel (Mini-PROTEAN TGX, 
Bio-Rad, Hercules CA) in TRIS/tricine/SDS buffer (Bio-Rad, Hercules CA) at 100 volts until 
the loading buffer reached the bottom of the gel, approximately 1 hour [42]. The gel was 
transferred to a PVDF membrane at 100 volts for 1 hour in TRIS/glycine buffer with 20% 
methanol. After transfer, the membrane was blocked with 2.5 % skim milk powder in TRIS 
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buffered saline with 0.05 % Tween 20 (TBST). The blots were incubated with pooled serum 
diluted 1:250 in 1.25 % milk buffer in TBST at 4C rocking overnight. The blots were rinsed 
with TBST and incubated with 1:1000 alkaline phosphatase conjugated goat anti-mouse IgG 
(Jackson ImmunoResearch, Bar Harbor ME) in TBST for three hours rocking. After rinsing 
with TBST and then water, blots were developed with Sigma Fast Red (Sigma-Aldrich, St. 
Louis MO) for 10 min then rinsed in water before drying. Alternatively, after running the 
SDS-PAGE gel it was stained with Coomassie Protein Assay Reagent (Thermo Fisher, 
Waltham MA) for two hours at room temperature, rinsed with water, then destained 
overnight in destain solution (55% water, 40% methanol, 5% acetic acid) before imaging 
with a Canon Rebel T2i camera attached to a Multiimage Light Cabinet (Alpha Innotech 
Corporation, Santa Clara CA) with EOS Utility software (Canon, Melville NY). 
 
Statistics 
Prism 6 software was used for statistical analysis (GraphPad, La Jolla CA). For 
microbial statistics, counts were converted to percentages (relative abundance). The 
intergenerational necropsy samples were analyzed with a Kruskal-Wallis test with Dunn’s 
multiple comparisons test, and the intergenerational time points were measured with a 
Friedman’s test with Dunn’s multiple comparisons test. As the samples collected in G0 were 
limited in number, the single necropsy sample was combined with pre-breeding samples for 
this group only in the intergenerational statistical calculations. CFU data and antibody data 
was analyzed with a one-way ANOVA with Tukey’s multiple comparisons test. 
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Ethical Considerations 
All mouse experiments were performed according to the requirements of the Iowa 
State University Institutional Animal Care and Use Committee (IACUC). 
 
Results 
Minimal intragenerational microbial changes  
Intragenerational microbial changes were evaluated between the different time points 
in generations 1-3 to assess the effects of DSS-induced inflammation within a given 
generation. Through the time points assessed in G1 through G3, multiple significant 
abundance changes in various organisms are present, with no discernible impact of DSS-
induced inflammation on microbial abundance (Figure 2). In G1, the only significant changes 
were in LF82 in comparing weaning to later time points. In the G1 + DSS treatment group, 
the significant changes in abundance were detected for 519, 500, 361, and LF82 at different 
time points but these changes were not maintained. In the G2 treatment group, significant 
changes in abundance were noted for 457 and 356, while in G2 + DSS treatment group, there 
were significant changes in the abundance of 457, 500, and 492. No changes were significant 
in the G3 or G3 + DSS, likely due to the limited sample size. Time point samples from 
generations 4 and 5 have not yet been sequenced. 
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Figure 2 continued 
  
  
Figure 2: Minimal intragenerational microbial changes. Throughout the generations, fecal samples 
were collected at multiple time points for 16s rRNA sequencing to assess microbial abundance. Fecal 
samples from generation 1 (G1) through G4 were collected at multiple time points. The first sample was 
collected after weaning, at 4 weeks of age. At 8 weeks of age the second sample was collected, 
immediately prior to initiation of DSS treatment in the group that received treatment. The 2% DSS 
regimen consisted of 5 days of DSS administration in the drinking water, followed by 6 days of 
standard water, and then another 6 days of DSS treatment. On the last day of DSS treatment, mice 
were paired for breeding (11 weeks). After 2.5 weeks, the male was removed to prevent rebreeding of 
the female. 20 days after pairing for breeding another fecal sample was collected, prior to parturition 
(14 weeks). Pups were weaned at 3.5 weeks of age and dams were culled (18 weeks). Relative 
abundance was analyzed as repeating measures with Freidman’s Test with Dunn’s multiple 
comparisons test across LF82 only and LF82 + DSS separately: G1 n=6, G1 + DSS n=5, G2 n=5, G2 + 
DSS n=5, G3 n=5, G3 + DSS n=2 
 
Intergenerational changes in microbial abundance was independent of inflammation 
Changes in microbial abundance were present through the generations, in both the 
DSS-treated and LF82 only groups. In the LF82 only group, the most changes in abundance 
that were statistically significant were observed when comparing G0 to G5 and G2 to G5; 
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while in the LF82 + DSS treatment group, the most significant changes in ASF organisms 
were seen in comparing G2 to G4 (Figure 3A). PCoA plots of relative abundance of these 
samples demonstrated a mild shift in the microbiota in the later generations compared to the 
early generations, that was present in both groups regardless of DSS-induced inflammation 
(Figure 3B-D). In a direct comparison of the G0 to G5 in both LF82 only and LF82 + DSS, 6 
of the 9 organisms significantly changed in the LF82 only group (ASF 519, 457, 500, 360, 
361, and 492) while only 3 of the 9 organisms significantly changed in abundance in the 
LF82 + DSS group (ASF 457, 360, and 492). In comparing the LF82 treatment group to 
LF82 + DSS treated mice directly between each generation, ASF 519, ASF 356, and LF82 
were significant in G0, 360 and LF82 in G3, and 519 in G4.  
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Figure 3 continued 
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Figure 3 continued 
 
Figure 3: Intergenerational changes in microbial abundance occurred following colonization 
with E. coli LF82 and was independent of inflammation. Throughout the generations, fecal samples 
were collected at multiple time points for 16s rRNA sequencing to assessment microbial abundance. 
Here fecal samples taken at necropsy are compared across multiple generations, and a non-colonized 
control group is also included (A). The DSS group received a 2% DSS regimen of 5 days of DSS 
administration in the drinking water, followed by 6 days of standard water, and then another 6 days of 
DSS treatment immediately prior to breeding. Relative abundance was analyzed with the Kruskal-
Wallis test with Dunn’s multiple comparisons test across LF82 only and LF82 + DSS separately. 
Additionally a Mann-Whitney test was done to compare the G0 to G5 within each group, and to 
compare LF82-only to LF82 + DSS within each generation. Additionally PCoA plots were generated 
for all necropsy samples (B), LF82 only (C), and LF82 + DSS (D). n = 3 to 9 animals per group.  
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Assessment of CFU of E. coli LF82 over five generations  
By culture of E. coli from cecal contents, in the non-DSS group there was an increase 
in LF82 in G3 in comparison to the earlier generations. However, in G4 and G5 generations, 
LF82 CFU were not elevated compared to G0 (Figure 4). 
 
 
Figure 4: Mild increase in LF82 load through generations. Cecal contents collected at 12 weeks of 
age from mice for each generation were serially diluted in PBS and plated on MacConkey agar to 
quantitate colony forming units per gram of contents. n= 4 to 28. 
 
 
Increase in serum LF82-specific IgG though generations  
As a measure of the host response to the presence of E. coli LF82, serum antibody to 
LF82 was measured. The results depicted in Figure 5A indicate that there was an increase in 
anti-LF82 antibodies through generations. Early generations have a low, background level 
antibody response similar to control ASF mice (no E. coli), while serum samples from mice 
in generations G2, G3, and G5 demonstrate a higher serum antibody level. Western blot 
analysis of antigen-specific IgG to LF82 and the 8 members of the ASF demonstrated an 
increased response to LF82 in generation 1 and 5 compared to generation 0, while the 
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response to antigens derived from the 8 ASF was unchanged (Figure 5B). Across all five 
generations, the highest serum reactivity (i.e., number of antigenic bands detected) was to 
ASF 492 and 519, which is consistent with the highest OD values in serum antibody 
assessment by ELISA in these mice (data not shown, see chapter 4). 
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Figure 5 continued 
 
 
Figure 5: Increase in serum LF82-specific IgG through generations. Serum antibody to LF82 
through generations, measured by ELISA from serum collected at 12 weeks of age (A). Western blots 
of serum antibody antigen specificity to LF82 and the other members of the autochthonous microbiota  
(B). Also included is an SDS-PAGE gel stained with Coomassie for reference (C). n= 4 to 28 for the 
ELISA, 4-12 pooled for the western blot serum. 
 
 
 
Discussion 
IBD has a prevalence of over 400 cases per 100,000 in American adults [43, 44]. 
Child-bearing age corresponds to peak age of IBD activity, and pregnant women with active 
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IBD have an increased risk of adverse event during pregnancy, and may be more likely to 
stop their medication due to perceived risk to the fetus [24, 45, 46]. IBD is associated with a 
dysbiotic microbiota, but few studies have evaluated the heritability/transmission of a 
dysbiotic microbiota from one generation to the next [6, 7]. A handful of murine studies 
demonstrate vertical or horizontal transmission of a disease-associated dysbiotic microbiota, 
and human studies have demonstrated altered microbiota in neonates to mothers treated with 
antibiotics [25-28, 47-49]. A few studies have evaluated the stability of the microbiota over 
multiple generations, though minimal studies have examined the impact of dysbiosis being 
passed to subsequent generations [50-55]. In this study, we attempted to model the 
transmission of a dysbiotic microbiota (i.e. altered relative abundance) over multiple 
generations in a defined microbiota mouse model, the altered Schaedler flora. We 
hypothesized that repeated inflammatory insults would result in a shift in the microbiota to a 
dysbiotic state that is transmissible through generations, and that after multiple generations 
the microbiota would be significantly altered from it’s original state. 
With this model, we attempted to induce an inflammation-associated change in 
abundance following the administration of DSS. A previous study evaluating the impact of 
DSS-induced colitis in conventionally-reared mice demonstrated repeated rounds of DSS 
resulted in a progressively altered microbial structure [56]. In our study, multiple microbial 
changes are present across different time points and for different members of the ASF, with 
no definitive or unique pattern associated with of induction of inflammation. The significant 
changes are integrated across all time points assessed, in both DSS and non-DSS treated 
groups. As this study is underpowered, that was likely a huge limitation to finding any 
pattern of microbial change, as even with a limited microbiota, these animals exhibit a fair 
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amount of microbial variation between individuals for which a larger sample size would be 
needed. 
Pregnancy also impacts the microbiota, as multiple studies have described a 
pregnancy-related change in the microbiota in humans that has been associated with changes 
in hormones, immune responses, and metabolic changes associated with fetal growth and 
development [57]. Generally, pregnancy-associated microbial changes have been described 
as changes in the community composition with an increase in diversity, though some studies 
show no difference [58-60]. Additionally, an increase in proteobacteria has been 
demonstrated in pregnancy, similar to changes in abundance associated with gastrointestinal 
inflammation [28, 58, 61, 62]. A murine microbiota-transfer study demonstrated increased 
pregnancy-associated physiological changes associated with transferring the microbiota from 
the in the third trimester of pregnancy, rather than the first trimester microbiota [58]. 
Furthermore, a recent study has demonstrated an impact of the dam’s microbial exposure 
during pregnancy impacts the immunological development of the fetus by enhancing barrier 
function and cellular activity of the innate immune system [63]. The maternal diet affects the 
gut microbiota prior to and during pregnancy, and antimicrobial treatment and/or probiotics 
during pregnancy can alter the neonate microbiota and immune parameters [64-66]. Though 
the diet did not change in the mice in our study, they likely consume more feed to 
accommodate the caloric demands of gestation and fetal development. Thus, in addition to 
DSS-induced colitis, pregnancy is likely influencing the microbial changes demonstrated in 
this study via physiological parameters.  
In addition to intragenerational changes, intergenerational changes were also 
evaluated over the course of six generations (G0 à G5). To our knowledge, this is the first 
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study to examine multiple generations of an inflammation-induced dysbiotic microbiota. In 
one macaque study evaluating a dietary-induced dysbiosis, it was reported that with 
successive generations of exposure to a low-microbiota-accessible carbohydrate (MAC) diet, 
there was a permanent loss of taxa that were not recoverable in later generations with 
reintroduction of MAC to the diet [67]. A transmissible dysbiosis has been demonstrated in 
several models of murine gastrointestinal inflammation, including NOD2 deficiency, 
increased TNF, and increased TLR4 expression models, though these were only evaluated for 
one generation of transmission [25-27]. In the TRUC (T-bet-/- x Rag2-/- ulcerative colitis) 
mouse model, Klebsiella and Proteus drive a microbial-associated colitis that can be 
maternally transmitted to offspring [28]. We aimed to examine the impact of E. coli LF82 in 
combination with the environmental DSS trigger to create a transmissible alteration in the 
ASF microbiota over multiple generations. 
In evaluating for intergenerational microbial changes in abundance, most of the ASF 
members in the defined microbiota model fluctuated in abundance over time between the 
earlier and later generations, with more significant changes in the non-DSS treated group. 
This may be due to the episodic microbial perturbance of DSS not causing uniform changes 
in the animals treated with DSS, and thus increasing variability between animals and 
decreasing the likelihood of finding significant microbial changes. Even in comparing the 
LF82 only treatment group to LF82 + DSS groups within each generation, changes in 
microbial abundance are only seen in the initial generation, G0, and then in G3 and G4. The 
abundance (i.e., CFU) of E. coli LF82 is only significantly different between G0 and G3, in 
the LF82-only group, and in G2 to G3 in both the DSS and LF82-only groups, corresponding 
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to an increase seen by bacteriological culture methods. A significant increase in E. coli LF82 
CFU was seen in G3 compared to the earlier generations by culture of cecal contents.  
The significant changes in microbial abundance even in the absence of DSS-treatment 
may indicate the intergenerational changes/modulations of the ASF in this model originates 
from the colonization of these mice with E. coli LF82, not gastrointestinal inflammation. 
Indeed, when visualized by PCoA plots, a generational progression and shift in abundance 
can be appreciated through generations that was independent of DSS-induced inflammation. 
The microbial community may continue to be shaped over multiple generations solely by the 
addition of the new proteobacteria, unrelated to any of the other organisms in the community. 
Rather than a catastrophic collapse, the community just subtly shifts to allow colonization 
with the new organism, essentially just making room for a new neighbor.  
Additionally, this data demonstrates that the “minimal” ASF microbial community 
still behaves like a “core” complex community, that is resilient to inflammation and change, 
as we did not observe a community collapse but rather a slow adaptation to changes. Based 
on this data and that these organisms are stable within our mouse model over 17 years of 
breeding, this suggests there is minimal redundancy between organisms, or we would expect 
to loose organisms in the community through time.  
One potentially interesting finding from this study is the increased abundance of ASF 
360 (Lactobacillus intestinalis) in the later generations. ASF 360 has been previously 
described as primarily colonizing the upper gastrointestinal tract at low numbers, and by past 
16s RNA sequencing, it is rarely detected in fecal samples [35, 38]. Here, ASF 360 was 
increasingly detected in the later generations, though still at very low numbers. It’s also 
important to note that these samples were sequenced in two sets. For the first set, there was 
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no 360 detected and the second set having a very small number of 360 reads in some samples 
(up to 20), and thus this may be an artifact of different sets of sequencing runs. 
Due to the gnotobiotic nature of these animals, limited facilities, and logistical 
resources for a gnotobiotic study of this magnitude, this study is underpowered. Based on a 
paper evaluating 16s data, calculations of statistical power in this model indicate an n of 
around 18 necessary for adequate statistical power due to the small effect size [68]. 
Nevertheless, significant changes in microbial abundance were seen in this limited study. 
With increased power, potentially a more definitive pattern of microbial changes would 
emerge that would be reflected at specific time points.  
In an examination of serum antibody, there was an increase in E. coli LF82-specific 
IgG with increased generations, demonstrating a slow increase in IgG with increased 
exposure to E. coli in the lineage. In evaluating the antigen-specificity of this serum IgG by 
western blot, the IgG is specific to many different LF82 proteins, and the blots also 
demonstrate the increase in LF82-specific IgG in G5 compared to G0. The antigen-specific 
IgG to the rest of the microbial community was equivalent between G0 and G5. In both of 
these two generations, the highest serum reactivity was to antigens derived from ASF 492 
and 519, which is consistent with the highest OD values in serum antibody assessment by 
ELISA in these mice (data not shown). 
Not analyzed within the confines/scope of this study are genetic changes in LF82 
itself, and the impact of putting a human isolate into a murine microbial environment. As a 
human pathobiont, this organism is not adapted to mice and likely goes through an adaptation 
to the mouse intestine. This analysis has been performed by Alexandra Proctor and will be 
part of her dissertation, and incorporated with the work presented in this Chapter for a 
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combined publication. Additionally, examination of genetic changes in the ASF or 
functional/metabolomic changes in the ASF or LF82 have not been evaluated thus far, but 
may be impacting the disease in this model. 
Based on our relative abundance data, we demonstrate limited microbial changes 
within generations triggered by DSS-induced inflammation, but not a clear pattern for DSS-
induced inflammation triggering the observed changes in abundance. Similarly, we didn’t 
demonstrate a transmissible dysbiosis (i.e., loss of microbial diversity) that would be 
expected to continue to be shaped through multiple generations by DSS-induced 
inflammation, but rather a slow change in the microbial community through time, a result 
associated with E. coli LF82 colonization and not repeated gastrointestinal inflammation in 
each generation. These studies were limited in evaluation of the microbial community based 
on relative abundance, but other changes in the community may be revealed by assessment of 
spatial redistribution. In human and murine models, dysbiosis can be pointed to as a cause or 
an effect of gastrointestinal inflammation, and though in experimental models dysbiosis itself 
may be enough to trigger disease (i.e. obesity, metabolic disease, colitis), these specific 
factors are difficult to evaluate in humans [8, 69-71]. Though the mere presence of a 
dysbiotic microbiota may predispose to a disease state, likely other contributions are 
necessary to elicit disease, including genetic/epigenetic effects, environmental triggers, and 
inappropriate activation of the immune system. Dysbiotic or not, the “heritability” of a 
microbiota across multiple generations is a topic that has been little studied. Faith and 
colleagues have developed a transmission algorithm to describe the probability of 
colonization with a particular microbe, and propose that studying microbial inheritance of 
specific organisms could be beneficial in determining the microbial contribution to complex 
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diseases [72]. Additionally, a recent review discusses how little is understood about 
transmission of the autochthonous microbiota between individuals, suggesting this is a topic 
that will be increasingly studied in the future [72, 73].  
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Abstract 
The gastrointestinal microbiota is initially acquired during birth and evolves over 
time, eventually establishing an adult-like state in early adolescence. Few studies have 
evaluated the impact of neonatal colonization by a pathobiont on the subsequent sensitivity to 
colitic insults. LF82 is an adherent invasive E. coli (AIEC) strain that has been associated 
with ileal Crohn’s disease. The aim of this study was to evaluate the sensitivity to dextran 
sodium sulfate (DSS)-induced colitis following E. coli LF82 colonization of gnotobiotic 
C3H/HeN:TAC mice harboring the altered Schaedler flora (ASF). While LF82 stably 
colonizes ASF mice, LF82 is neither adherent nor invasive in this model. We have previously 
demonstrated colonization of ASF mice with LF82 as an adult increases the susceptibility to 
DSS-induced colitis. We hypothesized that ASF mice colonized with LF82 as a neonate 
would be less susceptible to DSS-induced inflammation compared to ASF mice colonized 
with LF82 as young adults. Adult ASF mice were colonized with LF82 by oral gavage 
(Generation 0, G0) and bred to produce offspring (G1) ASF mice colonized with LF82 from 
birth. To trigger colitis, LF82 colonized G1 and G0 mice were given 2.0 % DSS in drinking 
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water for seven days. At necropsy, colonic tissues, serum, and mesenteric lymph nodes 
(MLN) were harvested to evaluate the severity of intestinal inflammation and magnitude of 
immunologic responses. More severe macroscopic and histologic inflammation was present 
in the G1 LF82  + DSS mice when compared to G0 LF82 + DSS mice, characterized by 
marked ulceration, inflammatory cell infiltrate, glandular hyperplasia, and stromal collapse, 
and was diffuse and transmural in most of the G1 LF82 + DSS mice. Colitis was 
accompanied by elevated levels of proinflammatory cytokines (IFNγ, IL-17) secreted from 
colonic explants and transcript levels visualized with RNAscope. Additionally, differential 
immunoreactivity to microbial antigens by serum IgG and ex vivo CD4+ T cell proliferation, 
and differential gene expression of immunity and inflammation associated genes evaluated 
by RNA sequencing were observed. Analysis of the microbial community revealed no 
significant changes in relative community abundance in the lumen by 16S rRNA sequencing, 
and minimal changes in spatial redistribution by fluorescent in situ hybridization. Pathway 
analysis of differential gene expression revealed activation of pathways relevant to 
inflammatory bowel disease (IBD), including apoptosis signaling, inflammation mediated by 
chemokine and cytokine signaling, JAK/STAT signaling, T cell activation, and Toll receptor 
signaling pathways, and the IBD KEGG pathway was significantly represented by the gene 
list. Analysis of differential gene expression between G0 LF82 and G1 LF82 suggest that 
neonatal colonization with LF82 induces subclinical inflammation, most likely chronically, 
that may predispose to more severe inflammation after exposure to a colitic insult (e.g., 
DSS). These data suggest that the age at which an individual is colonized by a pathobiont 
differentially affected the host’s mucosal immune profile and impacted the host's 
susceptibility to subsequent inflammatory insults. 
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Introduction 
The human intestine is home to a diverse population of bacteria that reaches 1011 
cells/gram contents in the colon, providing benefits to the host including vitamin production, 
immune system development, and competitive exclusion of pathogens [1-4]. The 
gastrointestinal (GI) microbiota is initially acquired in the neonatal period and evolves 
throughout the postnatal period and is influenced by diet, antibiotics, and other 
environmental exposures, to shape a microbial community that reaches maturity as a young 
adult [5, 6]. 
It has long been thought that in normal circumstances, mammals are born sterile, and 
the birth process provides the first exposure to microbes, though recent controversial studies 
challenge that dogma, demonstrating microbial exposure during gestation [7-12]. Regardless 
of when microbes are first introduced in the GI environment, these early microbial exposures 
are fundamental to the developing microbial community, GI physiology, and developing 
immune system. It has long been recognized the microbiota impacts the development of the 
immune system, with early studies in germfree mice depicting an underdeveloped mucosal 
immune system, as well anatomical, histological, and physiological differences compared to 
conventionally reared mice [13-17]. More recent studies have identified distinct host tissue 
transcriptional profiles of immune-related genes between mice colonized with a microbiota 
as neonates compared to being colonized as adults [18, 19]. 
Multiple studies have demonstrated how early microbial exposures can have lasting 
influence on the host. In the 1960s, Dubos, Savage, and Schaedler introduced the concept of 
“Biological Freudianism,” stating that early environmental factors or influences impact 
health later in life, and demonstrating differences in weight gain of young mice that was 
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entirely dependent on their microbiota [20, 21]. The development of atopy has been 
particularly well studied in relation to the gut microbiota in early life, and multiple studies 
have identified variations in the microbiota in early life correlating with the development of 
allergic disease later in life [22-28]. Other studies have demonstrated altering the microbiota 
during early life with antibiotics has a lasting metabolic impact, and may influence the 
development of chronic inflammatory conditions like inflammatory bowel disease (IBD) and 
asthma [29-31].  
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, are a 
group of chronic intestinal disorders with a multifactorial etiology consisting of complex 
interactions between the GI microbiota, genetics, environment, and the immune system [32]. 
Gastrointestinal pathogens have been implicated as an etiological component of IBD, notably 
adherent and invasive Escherichia coli (AIEC) in Crohn’s disease [33-35]. Though usually 
diagnosed in young adults, pediatric IBD cases are increasing, as more children are 
presenting with severe colitis at younger ages [36, 37]. 
A challenge to studying AIEC in colitis models is the lack of chronic, stable 
colonization in immunocompetent, microbiota-harboring, murine models. In humans, AIEC 
attach and invade via the CEACAM6 receptor, and studies employing CEACAM6 transgenic 
mice indicated that AIEC strains can be persistently colonized and induce inflammation in 
conventionally reared mice [38, 39]. In immunosufficient, conventional microbiota mice, 
LF82 does not readily colonize, though antibiotic treatment has been shown to facilitate 
colonization in multiple models [40, 41]. Even in a NOD2 knockout mouse model pretreated 
with antibiotics, AIEC was not able to persistently colonize mice [40]. In another study with 
multiple strains of streptomycin-treated mice, infection with AIEC NRG857c induced a Th17 
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response, increased proinflammatory cytokines, and led to transmural inflammation and 
fibrosis [41]. TLR5 knockout mice do exhibit inflammation after colonization with AIEC 
strain LF82, suggesting a dependence on flagellin-mediated signaling for development of 
colitis in that model [42-44]. 
LF82 is an AIEC isolate recovered from an ileal Crohn’s disease patient [34]. We 
have previously demonstrated LF82 chronically colonizes immunocompetent gnotobiotic 
microbiota mice harboring the altered Schaedler flora (ASF) and increases the susceptibility 
to dextran sodium sulfate (DSS)-induced colitis [45, 46]. The aim of this study was to 
evaluate changes in the microbiota and in the sensitivity to DSS-induced colitis following 
colonization with LF82 as an adult or neonate by vertical acquisition or gavage in gnotobiotic 
mice harboring the ASF. We hypothesized that ASF mice colonized with LF82 as a neonate 
would be less susceptible to DSS-induced inflammation compared to ASF mice colonized 
with LF82 as young adults. Contrary to our hypothesis, we demonstrate increased 
susceptibility to DSS-induced colitis in mice colonized as a neonate compared to mice 
colonized as an adult, with increased proinflammatory cytokine production and secretion, 
and differential microbiota-specific immune responses within the context of a stable 
microbial community. Additionally, pathway analysis of differential gene expression 
revealed pathways relevant to IBD in colitic mice, and suggest subclinical chronic 
inflammation in mice colonized as a neonate that may predispose to more severe 
inflammation after exposure to DSS. 
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Materials and Methods  
Animals 
Adult gnotobiotic C3H/HeN:TAC mice harboring the altered Schaedler flora (ASF) 
were maintained in Trexler plastic isolators [46, 47]. ASF members include: ASF356, 
Clostridium sp.; ASF360, Lactobacillus intestinalis; ASF361, Lactobacillus murinus; 
ASF457, Mucispirillum schaedleri; ASF492, Eubacterium plexicaudatum; ASF500, 
Pseudoflavonifactor sp.; ASF502, Clostridium sp.; and ASF519, Parabacteroides goldsteinii. 
[46, 47]. Mice were maintained on an irradiated diet (Teklad 2919, Envigo, Huntingdon, 
Cambridgeshire UK) and autoclaved water for the duration of the experiment. All animal 
experiments were approved by Iowa State University’s Institutional Animal Care and Use 
Committee. 
 
 
Figure 1: Experimental Protocol. Adult gnotobiotic C3H/HeN:TAC mice harboring the Altered 
Schaedler Flora were orally gavaged with E. coli LF82. After three weeks, LF82-infected and ASF-
only control mice were paired for breeding. Pups born to LF82-infected dams were colonized by 
vertical transmission during the process of microbial succession and were designated as generation 1 
(G1) LF82. G1 LF82 and ASF-only pups were weaned after 3 weeks of age. At 6 weeks of age, a subset 
of ASF-only mice were colonized with LF82 by oral gavage and designated as generation 0 (G0) LF82 
mice. At 9 weeks of age, mice were treated with filter sterilized 2% dextran sodium sulfate in their 
drinking water for seven days prior to necropsy. 
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Microbial colonization  
LF82 Escherichia coli was provided by Kenny Simpson (Cornell, Ithaca, NY). 
Bacteria were streaked onto TSA plates and grown aerobically at 37 °C. On the day of 
infection, bacteria were washed from plates and suspended in sterile PBS. The suspension 
was aseptically entered into the isolators and mice were infected with one dose (0.2 ml) of 
5x108 CFUs by oral gavage. Confirmation of colonization was performed by culture from 
fecal samples. 
 
 
Experimental design 
Mice were orally infected with LF82 by oral gavage three weeks prior to pairing for 
breeding. Males were removed after 2.5 weeks to prevent rebreeding and prevent any 
microbial impact of coprophagy from the pups. Pups born to LF82-infected dams were 
colonized by vertical transmission during the process of microbial succession and were 
designated as generation 1 (G1) LF82 (Figure 1). Pups were weaned after 3 weeks of age and 
dams removed from the isolators. At 6 weeks of age, a subset of ASF only mice were 
colonized with LF82 by oral gavage and designated as generation 0 (G0) LF82 mice. At 9 
weeks of age, mice were treated with filter sterilized 2% dextran sodium sulfate (MP 
Biomedicals, LLC, Santa Ana CA) in their drinking water for seven days prior to necropsy 
following CO2 asphyxiation. At necropsy, colonic tissues, serum, and mesenteric lymph 
nodes (MLN) were harvested to evaluate the severity of intestinal inflammation and 
magnitude of immunologic responses.  
For generation 0 neonate mice (G0Neo) LF82 mice, on day 0 (less than 24 hours of 
age) and again on day 2, pups were exposed to a suspension of 5 x 108 CFU/ml of E. coli 
LF82 by smearing the suspension on their face, body, and the dam’s abdomen. A subset of 
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mice also had colonization extended an extra 6 weeks, where adults infected with LF82 were 
infected for 10 weeks total (10 wk G0 LF82) and neonates were infected for 16 weeks total 
(16 wk G1 LF82) before being treated with DSS. Additionally, G1 LF82 mice were generated 
whose dam and sire had additionally been treated with 2% DSS for five days on, six days off, 
then 5 days on prior to breeding (designated as + DSS in parentheses). Additionally, second 
through fifth generation mice (G2 LF82-G5 LF82) were treated with 2% DSS for seven days 
prior to necropsy to compare to G0 LF82 + DSS mice. 
 
Preparation of bacterial antigens 
Bacterial antigen was prepared as previously described [45]. Briefly, bacteria were 
cultivated aerobically or anaerobically, harvested by centrifugation and washed in PBS, 
frozen, lyophilized, and stored at -20 °C until used. The bacterial cells were weighed and 
resuspended in sterile PBS at 2 mg/mL, subjected to a freeze-thaw cycle, sonicated, and 
sterilized. Sterility of the antigen preparations was confirmed by bacterial culture. Aliquots 
were stored at -20 °C.  
 
Macroscopic Inflammatory Scores 
Excised cecum and colon were scored on a previously published scale [45]. Briefly, 
tissue was evaluated for inflammatory changes of the cecum and colon, including changes in 
contents and tissue changes. Additionally, the length of the colon was measured. 
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Histopathological Analysis 
Intestinal tissue was fixed in 10% neutral buffered formalin, paraffin embedded, 
sectioned, and stained with H&E. Tissue sections were evaluated by a blinded board certified 
veterinary pathologist (JH) as previously described [45]. Briefly, tissue was examined for 
epithelial damage, cellular infiltrate and proliferation of epithelium/glands. 
Photomicrographs were taken on an Olympus Bx53 camera microscope with CellSense 
software. 
 
Ex Vivo T cell proliferation 
At necropsy, mesenteric lymph nodes (MLNs) were excised and single cell 
suspensions were created. MLN cells were labeled with 2.5 µM carboxyfluorescein diacetate, 
succinimidyl ester (CFSE, Molecular Probes, Eugene OR), washed in fetal bovine serum, and 
cultured (2 x 105 cells/well) in a 96 well plate with whole bacterial antigen (100 µg/mL) or 
anti-mouse CD3ε (4 µg/mL, eBioscience, San Diego CA) and anti-mouse CD28 (1 µg/mL, 
eBioscience, San Diego CA) and incubated. For wells stimulated with pooled ASF antigens, 
the total concentration of antigen was still 100 µg/ml (dry weight) with each organism’s 
antigen as an equivalent proportion of the pool. After three days of incubation, MLN cells 
were labeled with anti-mouse CD4 PerCP-Cy5.5 (eBioscience, San Diego CA) and anti-
mouse Thy1.2 PE-Cy7 (eBioscience, San Diego CA) and evaluated using a FACS CANTO 
(BD, Franklin Lakes NJ) at the Iowa State University Flow Cytometry Facility. Results were 
analyzed with FlowJo software (version 10.1, Ashland OR). 
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Cytokine Analysis 
Supernatants from incubated colon tissue explants were harvested and prepared as 
previously described [45]. Supernatants were assayed for the presence of IL-17, IFNγ, TNFα, 
IL-6, and IL-1β on the Bio-Plex 200 system (Bio-Rad, Hercules CA) using a multiplex bead-
based assay. 2500 beads (Bio-Rad, Hercules CA) coupled to cytokine-specific monoclonal 
antibodies (eBioscience, San Diego CA) were added to each well along with 50 µL of culture 
supernatant. Cytokine standards (eBioscience, San Diego CA) were used to generate a 
standard curve covering cytokine concentrations from 500,000 to 3.2 pg/ml. The biotinylated 
detection antibodies (eBioscience, San Diego CA) were used at a final concentration of 2 or 4 
µg/mL, and PE streptavidin (eBioscience, San Diego CA) was added for detection at 10 
µg/mL. 
 
ELISA 
Serum was collected at necropsy and stored frozen until use. After thawing, serum 
was centrifuged for 10 min at 10,000 x g to remove residual cellular debris. High binding 
microtiterplates (Costar High Binding Plates, Corning, Corning NY) were coated with whole 
bacterial antigen (10 µg/mL) and incubated overnight at 4 °C. Plates were washed three times 
using phosphate buffered saline (0.05 M, pH 7.2) containing 0.05 % Tween 20 (PBST) and 
blocked with 2 % gelatin with 2% goat serum in PBST and incubated at room temperature 
for 2 hours. Plates were washed three times with PBST and serum (1:200 in PBST with 2 % 
goat serum) was added. Plates were incubated overnight at 4 °C. Plates were then washed 
with PBST four times and alkaline phosphatase conjugated goat anti-mouse IgG (H+L) 
(Jackson ImmunoResearch, Bar Harbor ME) diluted 1:2000 in PBST containing 2 % goat 
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serum was added. Plates were incubated at room temperature for 2 hours, and then washed in 
PBST four times. p-Nitrophenyl phosphate (ThermoFisher Scientific, Waltham MA) was 
diluted in substrate buffer as recommended by the manufacturer and added to each well. 
Plates were incubated 60 min and the OD at 405 nm was measured using a spectrophometer 
(SpectraMAX 190, Molecular Devices, Sunnyvale CA). 
 
E. coli Quantification 
Cecal contents at necropsy were collected and serially diluted to -7 in sterile PBS and 
spot plated in triplicate on McConkey agar. After overnight incubation at 37 °C, CFUs were 
counted in each spot.  
 
16s Microbial Sequencing 
Fecal samples were collected the day prior to necropsy and stored at -20°C until DNA 
isolation. Genomic DNA isolations from fecal samples were performed with the PowerSoil-
htp DNA Isolation Kit (MoBio, Vancouver BC) as recommended by the manufacturer. DNA 
was quantified with a Qubit 3.0 Fluorometer (Life Technologies, Carlsbad CA) and stored at 
-20°C in 10mM TRIS buffer. DNA was sent to Argonne National Laboratory’s Institute for 
Genomics & Systems Biology for PCR amplification of the V4 variable region of the 16S 
rRNA gene using V4 region specific primers (515F-816R) and amplicon sequencing on the 
Illumina MiSeq Platform. QIIME (Quantitative Insights into Microbial Ecology) was used to 
analyze sequences [48]. Briefly, reads were demultiplexed and quality filtered to remove 
sequences with homopolymer runs or ambiguous bases greater than 6, nonmatching 
barcodes, barcode errors, or quality scores less than 25. A custom designed database, 
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including only the 16S rRNA sequences of the ASF organisms, challenge organisms, and 
likely contaminants, was used to call operational taxonomic units (OTUs) at 97% similarity 
with uclust and the closed reference OTUs in QIIME [49]. Weighted UniFrac PCoA plots 
were generated in QIIME and visualized in EMPeror (Biocore) [50]. Kruskal-Wallis tests 
were coupled with Wilcoxon Rank Sum tests and performed on taxonomic summaries, 
obtained from the QIIME pipeline, using a custom R script (R Project) developed by the 
Institute for Genome Sciences at the University of Maryland School of Medicine [51].  
 
Table 1: FISH probe targets 
 
 
Fluorescent in Situ Hybridization 
Tissues were processed, hybridized with FISH probes (Table 1), stained with 4,6-
diamidino-2-phenylindole (DAPI), imaged, and counted as previously described [52]. 
Briefly, sections of proximal colon with intact contents were fixed overnight in formalin 
before moving to 70% ethanol and paraffin embedded. 3-µM thick sections were 
deparaffinized, labeled with probes overnight, and stained with DAPI. Tissues were imaged 
with x60 Plan Apo oil objective in conjunction with an optional x1.5 multiplier lens on an 
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Eclipse TE2000-E fluorescence microscope (Nikon Instruments Inc., Minato, Tokyo Japan). 
A CoolSnap EZ camera (Photometrics, Tuscon AZ) with MetaMorph software (Nashville, 
TN) was used to photograph images. Counting was performed as previously described with 
8-10 sections of each tissue in the lumenal, attached, and invasion compartments [52]. 
Eub338, Erec 482, Lab158, and ASF 457 probes have previously been described [52]. 
BacPrev1080 probe sequence was 5’-GCACTTAAGCCGACACCT-3’ and E. coli probe 
sequence was 5’-GCAAAGGTATTAACTTTACTCCC-3’. 
 
Antigen-specific ex vivo T cell proliferation 
Mesenteric lymph nodes were collected and a single cell suspension was created. 
Cells were stained with 2.5 µM carboxyfluorescein diacetate, succinimidyl ester (CFSE, 
Molecular Probes), washed in fetal bovine serum, and cultured with whole bacterial antigen 
(100 µg/ml) or anti-mouse CD3 (4 µg/ml, eBioscience) and anti-mouse CD28 (1 µg/ml, 
eBioscience) and incubated. For wells stimulated with pooled bacterial antigen from multiple 
organisms, the total concentration of antigen was still 100 µg/ml with each organism’s 
antigen as an equivalent proportion of the pool. After four days cells were stained with anti-
mouse CD4 PE-Cy7 and Thy1.2 APC (eBioscience) and run on a FACS CANTO (BD) at the 
Iowa State University Flow Cytometry Facility. Results were analyzed with FlowJo software. 
 
RNAscope 
Proximal colon tissue was fixed and embedded as described above for histopathology. 
RNAscope was performed as recommended by the manufacturer with the RNAscope 2.5HD 
Duplex assay with probes specific for CD4 (C2, channel #2) and IFNγ or IL-17 (C1, channel 
#1) (Advanced Cell Diagnostics, Newark CA). Briefly, 5 µM sections of paraffin embedded 
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tissue were deparaffinized, treated with hydrogen peroxide, steamed for target retrieval, and 
treated with protease to prepare the samples. Next the tissues were hybridized at 40 °C and 
repeatedly washed and hybridized for amplification sequentially for each probe before being 
stained with hematoxylin, dried, and mounted. RNAscope images were taken on an Olympus 
Bx53 camera microscope with CellSense software (Olympus, Shinjuku, Tokyo Japan). Halo 
image analysis software (Advanced Cell Diagnostics, Newark CA) was used to evaluate 
RNA-labeling by examining the lamina propria and epithelial compartments separately. Five 
images captured at 60x from three tissues each were examined for RNA-labeling, and the 
five replicates were averaged for each tissue. 
 
RNA sequencing 
RNA sequencing was performed on three samples from each group. At necropsy, a 1 
cm section of colon, approximately 3 cm from the proximal end, was saved in RNAlater 
solution (Ambion, ThermoFisher, Waltham MA) and frozen at -20 °C until extraction. A 15-
20 mg piece of tissue was used for mRNA extraction with the PowerLyzer UltraClean Tissue 
& Cells RNA Isolation Kit (MoBio, Vancouver BC). mRNA extraction was performed as 
recommended by the manufacturer with homogenization performed on a Minibeadbeater 
(Biospec Products, Bartlesville OK), with the addition of the On-Spin Column DNase I Kit 
(MoBio, Vancouver BC) as suggested by the manufacturer. mRNA was analyzed on an 
Agilent 2100 Bioanalyzer (Santa Clara, CA) at the Iowa State University DNA Facility. The 
RNA integrity number (RIN) for all samples was at least 8.5, with most samples between 9.5 
and 10. mRNA was stored at -80 °C until use. 
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 mRNA was sent to Qiagen (Germantown, MD) for the QIAseq Mouse Inflammation 
and Immunity Transcriptome Targeted RNA Panel. After sequencing, Qiagen utilized their 
own GeneGlobe Data Analysis Center to generate gene counts and lists of genes with 
differential expression between different groups by utilizing Gene Globe to calculate nominal 
p-values using a parametric unpaired two-sample equal variance two-tailed distribution, and 
the data was normalized to housekeeping genes listed in decreasing rank order: Map3k2, 
Fbrsl1, Zfp446, Zbtb22, 2700049A03Rik, Ppie, Ppil2, Thap3, and Rfx1. Gene lists were 
generated with a cutoff of < 0.05 p value, with no cut off for fold change. Venn Diagrams 
were generated with Galaxy Web Portal to examine overlap between lists generated by each 
group compared to control [53]. The G1 LF82 + DSS list first had a multiple test correction 
and log fold cut off of 2 or greater to reduce the size of the list (219 to 157).  
Differential gene expression lists were analyzed with the (w)HOL(e)ISTIC GO 
enrichment as previously described [54]. GO::TermFinder, PANTHER Pathways, DAVID 
6.8, g:Profiler (gGost Tool), and STITCH were utilized for gene ontology and pathway 
analysis [55-59]. For analysis of gene ontology term overrepresentation in G1 LF82 + DSS 
compared to control, GO::TermFinder and g:profiler were given a false discovery rate (FDR) 
of 0.1 for inclusion. Overlapping terms from these programs were confirmed with DAVID 
and PANTHER. For STITCH analysis, gene lists first had a FDR of 0.05 applied, and KEGG 
pathway analysis was performed in STITCH. 
 
Quantitative polymerase chain reaction (qPCR) 
cDNA was generated from mRNA with the RT2 First Strand Kit (Qiagen, Hilden 
Germany) as recommended by the manufacturer in a myCycler Thermal Cycler (Bio-Rad, 
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Hercules CA). cDNA quality was evaluated on a NanoDrop ND-1000 spectrophotometer 
(NanoDrop, Wilmington DE) and stored at -20C until use. Primers for 18S rRNA were used 
as previously described, and primers for Fasl, Nos2, Cxcl9, Tnfrsf9, and Egf were obtained 
from Mouse Primer Depot (Table 2) [60, 61]. qPCR amplification was performed on a 
CFX96 Real-Time PCR machine (BioRad, Hercules CA) with the Luna Universal qPCR 
Master Mix (New England Biolabs, Ipswich MA) as recommended by the manufacturer with 
50 ng of cDNA as template and primers at a final concentration of 0.25 µM. A series of 
dilutions of pooled cDNA was performed to test primer efficiency and the melt curve was 
examined for specificity of amplification. All qPCR was performed in duplicate. Relative 
mRNA quantities were normalized against 18S rRNA and control samples.  
 
Table 2: qPCR Primers  
 
 
 
Statistics 
Prism 6 software was used for initial statistical analysis (GraphPad, La Jolla CA). A 
one way ANOVA with Tukey’s multiple comparisons test or a Kruskal-Wallis is Dunn’s 
multiple comparisons test were first used for parametric and nonparametric data, 
respectively. For the disease assessment indices, if the initial test demonstrated no statistical 
difference between G0 LF82 + DSS and G1 LF82 + DSS (or other groups in question), an 
unpaired t test or Mann-Whitney to directly compare the groups in question was performed. 
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In addition, a simple linear regression model with an interaction term was created to 
analyze colon lengths as well as IL-17, IFNγ, and IL-1β production by explants. This model 
is described as yijk = αi + βj + γij + eijk where i = 1,2 for DSS treatment, i = 1 is no DSS 
treatment, i = 2 is DSS treatment; j = 1, 2, 3 for groups, j = 1 is G0 LF82, j = 2 is G1 LF82, 
and j = 3 is control (no LF82); k = 1,2,...,nij are the individual observations in each group and 
treatment; n11= 21, n12 = 24, n13 = 17; n21 = 28, n22 = 32 and n23 = 21; eijk are independent and 
identically distributed random variables following a normal distribution with mean 0 and 
unknown variance σ2. Data was analyzed in SAS software 9.4 (Cary NC). Colon lengths 
were initially analyzed with all groups, and then analyzed with only the DSS groups in the 
model. 
Statistical analysis for the RNAseq and 16S rRNA sequencing data are explained 
above. Additionally, direct comparisons tests were performed in Prism by converting counts 
to percentages (relative abundance) and performing Mann-Whitney tests to directly compare 
two groups. 
 
Results 
G1 LF82 mice develop severe, transmural colitis following DSS-induced inflammation  
Gnotobiotic mice harboring the ASF were colonized with LF82 by oral gavage as an 
adult (G0 LF82) or by vertical acquisition as a neonate (G1 LF82) to evaluate differences in 
the sensitivity to DSS-induced colitis influenced by age of colonization with LF82. Contrary 
to our hypothesis, G1 LF82 + DSS mice developed more severe macroscopic (Figures 2A & 
2B) and histologic inflammation (Figure 2C) when compared to G0 LF82 + DSS mice. Using 
a linear regression statistical model with an interaction term (see methods), colon length was 
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not significantly different with p = 0.4325 when all six groups were considered in the 
statistical model; however, DSS significantly shortened colons of the G0 LF82 group by 
1.5214 cm (p < 0.0001) and that of the G1 LF82 mice by 1.7750 cm (p < 0.0001) when 
compared to non-treated control mice, and when utilizing the linear regression model to just 
analyze across the DSS treated groups, colon length was significantly different between G1 
LF82 + DSS and G0 LF82 + DSS (p = 0.0028).  
The lesions in the G1 LF82 + DSS mice were characterized by marked multifocal 
ulceration and stromal collapse with a prominent inflammatory cell infiltrate that extended 
through the tunica muscularis (transmurally), and in areas of intact epithelium there was 
hyperplasia of the glands (Figure 2D). The mice in the G1 LF82 (+ DSS) + DSS treatment 
group, mice whose dam and sire were also treated with a regimen of DSS prior to breeding, 
were not as severely inflamed, and were equivalent to G0 LF82 + DSS mice (Supplemental 
Figure 1A-C). G1 LF82 (+ DSS) mice, mice whose dam and sire were treated with a regimen 
of DSS but they themselves were not treated in this generation, had lesion scores equivalent 
to other non-DSS treated animals (Supplemental Figure 1A-C). Mice in subsequent 
generations (G2 - G5) of LF82-colonization, regardless of DSS treatment of the dam and sire, 
did not develop the more severe colitis characterized by the transmural lesions observed in 
the G1 LF82 + DSS mice (Supplemental Figure 2A-I). The possible exception were mice in 
the G4 LF82 + DSS treatment group, though DSS treatment alone induced more severe 
disease in this experiment than the other generational studies and may account for the 
increased macroscopic score and decreased colon length in the G4 LF82 + DSS mice 
(Supplemental Figure 2F-G). Because of the unremarkable appearance of macroscopic 
lesions, histologic scores were not evaluated beyond generation 2. 
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Figure 2: G1 LF82 mice have severe, transmural colitis following DSS-induced inflammation. 
Mice were scored at the time of necropsy for macroscopic parameters of disease including colon length 
(A) and macroscopic colitis score (B). Additionally, proximal colon was fixed and scored by a 
pathologist for histopathologic parameters of inflammation (C). Representative histopathological 
sections imaged at 40X (D). Most G1 LF82 + DSS mice have severe, transmural inflammation. Shared 
letters between different groups indicate no statistical significance with an ANOVA or Kruskal-Wallis 
with multiple group comparisons test. Asterisk indicate statistical significance based on a direct 
comparison with a Mann-Whitney test, *p ≤ 0.05, **p ≤ 0.01. p for colon length data indicates 
significance based on a linear regression model for 1all groups and 2DSS-only groups. 
 
As the G1 LF82 mice at the time of necropsy have been infected with LF82 for 10 
weeks while the G0 LF82 have only been infected for four weeks, necropsy and DSS 
exposure was delayed in a group of G0 LF82 mice an additional six weeks, such that the G0 
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LF82 mice were colonized for a total of 10 weeks (10 wk G0 LF82), in order to mimic the 
length of time E. coli LF82 colonizes the G1 LF82 treatment group. Extending the length of 
time the adult mice (G0) were colonized with LF82 did not increase their susceptibility to 
DSS-induced colitis, as the disease scores of the 10 wk G0 LF82 + DSS mice were 
unremarkable as characterized by insignificant changes in colon length and macroscopic 
scores compared the 10 wk G0 LF82 mice not treated with DSS (Supplemental Figure 3A,B). 
Extending the length of time of LF82 colonization was also assessed in G1 LF82, in that they 
were not exposed to DSS until 16 weeks of age (16 wk G1 LF82). The 16 wk G1 LF82 + DSS 
mice presented with more variability in colon length as well as in macroscopic score, with 
three mice developing severe inflammation (scores 8/10) and three mice with mild disease 
(0-2/10) (Supplemental Figure 3A,B).  
 
 
FIGURE 3: G0Neo LF82 mice have intermediate colitis scores to G1 LF82 and G0 LF82 following 
DSS-induced inflammation. Mice were scored at the time of necropsy for macroscopic parameters of 
disease including colon length (A) and macroscopic colitis score (B). Shared letters between different 
groups indicate no statistical significance with an ANOVA or Kruskal-Wallis with multiple group 
comparisons test; ns indicates no statistical significance based on a direct comparison with a t or 
Mann-Whitney test.  
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Infecting mice horizontally at 24 hours of age rather than vertically from the dam was 
also assessed. G0Neo LF82 mice treated with DSS had colon lengths and gross scores 
intermediate between G0 LF82 + DSS and G1 LF82 + DSS (Figure 3A,B) suggesting that 
there was a partial maternal influence on disease susceptibility. 
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Figure 4 continued 
 
Figure 4: No statistical changes in the luminal microbial community following LF82 colonization 
and/or DSS-induced inflammation. At necropsy cecal LF82 load was assessed by culture (A), and 
16s rRNA gene sequencing was performed to assess changes in microbial abundance in the cecum (B). 
A weighted UniFrac PCoA plot was generated to assess microbial OTU diversity between samples 
(C). Shared letters between different groups indicate no statistical significance with an ANOVA with 
multiple group comparisons test. 
 
 
Minimal changes in the microbial community following LF82 colonization and/or DSS-
induced inflammation 
By culture of cecal contents at necropsy, LF82 consistently and persistently colonized 
G0 and G1 mouse ceca, and DSS-induced inflammation increased LF82 bacterial load (Figure 
4A). Based on 16s rRNA taxonomic profiling, LF82 colonization and/or DSS treatment 
minimally altered the composition of the microbial community, as no statistical differences 
were seen in any organism’s relative abundance between any groups in a multi-group 
statistical comparison (Figure 4B). Direct comparison of G0 LF82 + DSS to G1 LF82 + DSS 
and G0Neo LF82 + DSS to G1 LF82 + DSS also revealed no statistically significant 
differences. Visualization of the community structures by PCoA plot revealed most of the 
groups cluster closely together, while G0 LF82 + DSS demonstrated increased variability and 
a very slight shift in microbial abundance, and both the G1 LF82 + DSS and G0Neo LF82 + 
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DSS (yellow and pink) demonstrated a mild shift away from the rest of the groups including 
the non-treated controsl (red) (Figure 4C). 
Tissue sections of proximal colons with intact contents of control, G0 LF82 + DSS, 
and G1 LF82 + DSS mice were assessed for microbial spatial changes by fluorescent in situ 
hybridization (FISH, Figure 5).  Inflammation often induces discontinuous biofilms in G1 
LF82 + DSS mice. (Figure 5A-D). Following the onset of inflammation, Lactobacillus (Lab 
158 probe) demonstrates a trend for more close association with the mucosa (interfaced 
region) in G0 LF82 + DSS and G1 LF82 + DSS mice (Figure 5C,D,G-I). Additionally with 
inflammation, G1 LF82 + DSS mice demonstrate significantly increased numbers of ASF 457 
bacteria associated with the mucosa and migrating into the colonic glands (Figure 5E,F,H,I). 
Consistent with bacteriological evaluation, FISH also demonstrated an increase in LF82 
numbers in the lumen in G1 LF82 + DSS mice and, with inflammation there was a trend for 
movement of LF82 towards the mucosa and into the glands in small numbers (Figure 5G-I). 
Three color FISH demonstrated LF82 moves towards the mucosa in the context of the 
biofilm of the entire microbial community (Figure 6). Thus it may become associated with 
the mucosal surface as the mucous layer is disturbed in G1 LF82 + DSS mice, but is not itself 
adherent or invasive in the absence of DSS-induced inflammation.  
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Figure 5 continued 
 
Figure 5: Minimal microbial changes in spatial redistribution with LF82 colonization and DSS-
induced inflammation by FISH. Proximal colons with intact contents were assessed for microbial 
spatial changes by fluorescent in situ hybridization. All images are labeled with DAPI (blue), EUB 
(FITC, green), and an Alexa Fluor 555 (orange) specific to individual bacterial groups (see Table 1). 
Control (A) and G1 LF82 + DSS (B) with BacPrev1080, control (C) and G1 LF82 + DSS (D) with 
Lab158, and control (E) and G1 LF82 + DSS (F) with 457. Inset magnifies 457 in the glandular space. 
Changes in spatial distribution of organisms evaluated by group-specific FISH probes in the lumen 
(G), adherent/attaching (H), and invading (I) compartments. Asterisk indicate statistical significance 
based on a direct comparison with a Mann-Whitney test, *p ≤ 0.05, **p ≤ 0.01. 
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Figure 6: LF82 is not adherent or invasive in ASF mice. Proximal colons with intact contents were 
assessed for microbial spatial changes by fluorescent in situ hybridization by labeling with DAPI 
(blue), EUB (FITC, green), and E. coli (Cy-3, orange).  
 
Minimal production of microbial-specific serum IgG following LF82 colonization 
Examination of antigen-specific antibody demonstrated minimal production of E. coli 
LF82-specific serum IgG, with a mild increase in G1 LF82 mice over other groups (Figure 
7A). With time, G1 mice colonized for 16 weeks (16 wk G1 LF82)  with LF82 demonstrated a 
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trend for increased E. coli LF82-specific serum IgG (Supplemental Figure 4). Evaluation of 
serum ASF-specific IgG revealed no increase in antibody to any member of the ASF 
associated with LF82 colonization; in fact the serum IgG specific to some ASF members 
decreased with LF82 colonization ± DSS treatment (Figure 7B-I). 
 
 
Figure 7: Minimal production of microbial-specific serum IgG following LF82 colonization. 
Antigen specific serum IgG to each member of the microbiota was assessed by ELISA, including LF82 
(A), ASF 356 (B), ASF 360 (C), ASF 361 (D), ASF 457 (E), ASF 492 (F), ASF 500 (G), ASF 502 
(H), and ASF 519 (I). Shared letters between different groups indicate no statistical significance with 
an ANOVA with multiple group comparisons test. 
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Inflammation induces differential antigen-specific CD4+ T cell proliferation 
Ex vivo stimulation of MLN-derived CD4+ T cells revealed differential ASF antigen-
specific proliferation (Figure 8). Stimulation with all 8 ASF resulted in equivalent 
proliferation between G0 LF82 + DSS and G1 LF82 + DSS, with a trend for increase over 
DSS alone and non-treated groups. Antigen-specific proliferation to E. coli LF82 was 
similar, with a significant difference between G1 LF82 and G1 LF82 + DSS. Antigen-specific 
proliferation to the clostridial-type antigens (ASF 356/492/500/502) demonstrated a trend for 
increase in G1 LF82 + DSS over the other two DSS groups, and a significant increase over 
G1 LF82. G0 LF82 + DSS had a significant increase in antigen-specific proliferation to the 
lactobacilli (ASF 360/361) over G1 LF82 + DSS, and proliferation to the antigens derived 
from the two gram-negative organisms (ASF 457/519) had a trend for an increase in G1 LF82 
+ DSS group over all other groups. 
 
 
Figure 8: Inflammation induces differential antigen-specific CD4+ T cell proliferation. Ex vivo 
antigen-specific T cell proliferation to groups of microbial antigens was assessed by CFSE dilution 
measured by flow cytometry. Indicated are % CFSE low cells of Thy1.2+CD4+. Bars indicate statistical 
significance in a one-way ANOVA with multiple group correction. 
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Figure 9: Inflammation induces differential production of proinflammatory cytokines by colonic 
explants. Analysis of IL-17A (A), IFNγ (B), IL-1β (C), and IL-6 (D) release by ex vivo incubated 
colonic explants by a bead-based multianalyte assay. Shared letters between different groups indicate 
no statistical significance with an ANOVA with multiple group comparisons test. p indicates 
significance based on a linear regression statistical model. 
 
Inflammation induces differential production of proinflammatory cytokines 
In the severely diseased G1 LF82 + DSS mice, colitis was accompanied by elevated 
levels IL-17 secreted from colonic explants compared to G0 LF82 + DSS mice (Figure 9A). 
Increasing the length of LF82 colonization increased the levels of secreted IL-17, as colonic 
explants from 10 wk G0 LF82 + DSS mice tended to release more IL-17 compared to all 
other groups (Supplemental Figure 5A). However, 16 wk G1 LF82 + DSS mice did not 
present with elevated IL-17 levels. G0Neo LF82 + DSS mice had equivalent IL-17 production 
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to G1 LF82 + DSS mice (Supplemental Figure 5A). IFNγ secretion was elevated in both G1 
LF82 + DSS and G0 LF82 + DSS mice over DSS alone (Figure 9B). Colonic explants from 
G0Neo LF82 + DSS mice had the highest levels of IFNγ production, though not significantly 
elevated over the other LF82 + DSS groups. Like IL-17, increasing length of colonization did 
not elevate IFNγ production in 16 wk G1 LF82 + DSS mice (Supplemental Figure 5B). 
Additionally there was a trend for an increase in IL-1β in G1 LF82 + DSS mice, and IL-6 was 
equivalently elevated in all DSS treated groups (Figures 9C & 9D).  
 
 
Figure 10: Inflammation induces differential production of IL-17, IFNγ and CD4 mRNA 
transcripts in the colon. IL-17, IFNγ, and CD4 mRNA was labeled with a duplex RNAscope assay. 
Photomicrographs demonstrate dual labeling of CD4 and cytokine mRNA in multiple experimental 
groups. 
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Examination of IFNγ and IL-17 by RNAscope demonstrated messenger RNA for 
both cytokines in the epithelium and lamina propria of multiple experimental groups, as well 
co-localized expression of CD4-specific mRNA (Figure 10). To quantify mRNA labeling, 
Halo software was utilized to count positive cells in the epithelial and lamina propria 
compartments in G0 LF82 + DSS and G1 LF82 + DSS mice. Both the epithelium and the 
lamina propria of G1 LF82 + DSS mice demonstrated an increase in CD4+ and IFNγ + cells 
over G0 LF82 + DSS mice, as well as an increase in all categories of dual-labeled cells (Table 
3). Dual expression of CD4 by IL-17+ cells in the colonic tissues was increased in the lamina 
propria but not the epithelium, and total cells expressing IL-17-specific mRNA tended to be 
decreased in G1 LF82 + DSS mice. 
 
Table 3: RNAscope analysis with HALO 
 
Data is percent of total cells in that comparment ± standard error of the mean 
aPercent of CD4+ cells also IFNγ+ 
bPercent of IFNγ+ cells also CD4+ 
cPercent of CD4+ cells also IL-17+ 
dPercent of IL-17+ cells also CD4+ 
 
Differential gene expression of immunity and inflammation associated genes 
Venn diagrams of differentially regulated genes in each group compared to control 
were created to examine overlap between differentially regulated genes in each group 
compared back to control (Figure 11). Multiple genes overlap between each group, as well as 
a large number of genes unique to each group in the comparisons.  
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Out of 485 genes in the immunity and inflammation RNAseq panel, 219 were 
significantly different between G1 LF82 + DSS and control, based on p of ≤ 0.05 with no cut 
off for fold change (Table 4). Almost all genes identified as differentially expressed were up-
regulated in G1 LF82 + DSS, and most had a fold change of greater than 2. qPCR of selected 
genes confirmed differential expression between control and G1 LF82 + DSS mice 
(Supplemental Figure 7).  
 
 
Figure 11: Venn diagrams demonstrate the number of unique and overlapping differentially 
expressed genes between different treatment groups compared to non-treated control ASF mice. 
Lists of differentially expressed genes in each group compared to control were analyzed with Galaxy 
Web Portal to compare overlapping and unique genes between different groups. 
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Table 4: Differentially expressed genes in G1 LF82 + DSS compared to control 
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Performing pathway analysis using (w)HOL(e)ISTIC GO enrichment demonstrated 
multiple differentially regulated pathways in the G1 LF82 + DSS over control [54]. Analysis 
of gene ontology (GO) terms from g:Profiler and GO::TermFinder revealed several 
statistically significant overlapping terms between these programs (Table 5). These included 
the GO terms for tumor necrosis factor receptor superfamily binding, tumor necrosis factor 
receptor binding, the human phenotypes increased IgG level, hypochromic anemia, iron 
deficiency anemia, protracted diarrhea, recurrent protozoan infections, and the kegg 
pathways proteasome and nicotinate and nicotinamide metabolism.  
 
Table 5: Significant overlapping Gene Ontology terms from g:Profiler and GO::TermFinder
 
aDatabase: MF, molecular function; hp, human phenotype; keg, KEGG pathway 
bKey differentially expressed genes that are represented by each GO Term 
 
Analysis by the PANTHER revealed that the most overrepresented gene families 
included apoptosis signaling, B cell activation, EGF receptor signaling, inflammation 
mediated by chemokine and cytokine signaling, integrin signaling, interleukin signaling, 
JAK/STAT signaling, PDGF signaling, T cell activation, and Toll receptor signaling 
pathways (Figure 12). Finally, the list of differentially expressed genes was analyzed with 
STITCH, and the hairball generated demonstrates many levels of interaction between the 
differentially expressed genes (Figure 13A). Additionally, STITCH identified one 
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significantly represented KEGG pathway, Inflammatory Bowel Disease (Figure 13B). 
Eighteen genes in the IBD KEGG pathway were over represented in the G1 LF82 + DSS over 
control gene list. The interactions between these genes (Rorc, Tgfb2, Foxp3, Tnf, Tbx21, 
Stat3, Nfkb1, Stat6, Stat1, Il12b, Tlr4, Stat4, Il12rb2, Il4, Il4ra, and Maf) are visualized in 
Figure 13B. Additionally it should be noted that multiple other genes associated with human 
IBD, especially cytokines, were highly up-regulated in G1 LF82 + DSS, but were not 
significant; this is discussed further in the discussion below. 
 
 
Figure 12: PANTHER Pathway analysis demonstrates differential expression of multiple gene 
families associated with inflammation in G1 LF82 + DSS mice compared to control. Each slice of 
the wedge represents a gene family, with the size of the wedge indicating the amount of genes from the 
list represented in that family. The PANTHER pathways program recognized 217 of the 219 genes 
from the list, and 213 matched to at least one gene family in the database. 
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Figure 13 continued 
 
Figure 13: STITCH analysis demonstrates multiple interactions between differentially expressed 
genes in G1 LF82 + DSS and significant representation of the IBD KEGG pathway. A STITCH 
hairball representing all significantly differentially expressed genes with interactions with other genes 
(A) and highlighting of genes in red from the IBD KEGG pathway (B). 
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Other direct comparisons between groups were also performed, including DSS alone 
to G1 LF82 + DSS and G0 LF82 + DSS to G1 LF82 + DSS to determine what genes were 
differentially expressed in G1 LF82 + DSS compared to the other DSS treated groups (Table 
6). These lists were not large enough to perform pathway analysis, but examining the lists for 
overlap revealed three genes that are shared in both lists. IL22ra2, Gata3, and Lrp1 are 
differentially expressed in G1 LF82 + DSS over the other DSS treated groups, with Gata3 
and Lrp1 up-regulated and IL22ra2 down-regulated in comparison to the other DSS treated 
groups. 
 
Table 6: Differentially expressed genes in G1 LF82 + DSS compared to DSS and G0 LF82 + DSS 
 
aDifferential expression in G1 LF82 + DSS compared to DSS as baseline 
bDifferential expression in G1 LF82 + DSS compared to G0 LF82 + DSS as baseline 
Gray boxes demonstrate shared genes between the two comparisons 
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Table 7: Differentially expressed genes in G1 LF82 compared to G0 LF82 
 
 
Table 8: Significant KEGG pathways identified by STITCH in differentially expressed genes in 
genes in G1 LF82 compared to G0 LF82 
 
 
A direct comparison was also performed between G0 LF82 and G1 LF82, to evaluate 
changes in gene expression solely due to the impact of age of colonization in the absence of 
DSS-induced inflammation (Table 7). This list was analyzed using STITCH, and again 
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demonstrated multiple interactions between genes. STITCH identified multiple KEGG 
pathways from the gene list, including Salmonella infection and again Inflammatory Bowel 
Disease (Figure 13, Table 8). 
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Figure 14 continued 
 
 
Figure 14: STITCH analysis demonstrates multiple interactions between differentially expressed 
genes in G1 LF82 compared to G0 LF82. A STITCH hairball representing all significantly 
differentially expressed genes (A) and highlighting of genes in red from the Salmonella infection (B) 
and IBD (C) KEGG pathways. 
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Discussion 
Inflammatory bowel disease develops in young adults, and has long been thought to 
be due at least in part to an increased immunoreactivity to the autochthonous microbiota after 
perturbation from a bacterial provocateur, which has been well demonstrated in experimental 
colitis models in our lab and others [32, 41, 42, 44, 45, 62-66]. Bacterial pathobionts, such as 
AIEC, have been implicated in the pathogenesis IBD in that these organisms act as a 
provocateur by disrupting mucosal homeostasis [34]. In this study, we hypothesized that the 
mice colonized with E. coli LF82 as a neonate would be less susceptible to DSS-induced 
colitis than mice colonized as an adult. Provocateurs and pathobionts aren’t overt pathogens, 
and our rationale was that colonization with an organism normally considered a provocateur 
as a neonate would induce host tolerance, and the organism would be normally assimilated 
into the autochthonous microbiota, protecting from the increased susceptibility to DSS-
induced colitis previously seen with adult colonization of a provocateur [45, 64-66]. Contrary 
to our hypothesis, we demonstrated increased severity of adult DSS-induced colitis in mice 
that were colonized with LF82 as a neonate (G1 LF82) compared to being colonized as a 
young adult (G0 LF82), demonstrating in this model neonatal colonization of a provocateur is 
not protective from the effects on mucosal homeostasis triggered by a provocateur. 
The colitis in the G1 LF82 + DSS mice was manifested as decreased colon lengths 
and increased histologic and macroscopic scores compared to G0 LF82 + DSS mice. 
Histopathologically, many of the G1 LF82 + DSS mice had transmural lesions that resemble 
the lesions seen in Crohn’s disease [67, 68]. DSS-induced colitis severity was not influenced 
by mucosal inflammation in the dam and sire, as DSS treatment of the dam and sire resulted 
in equivalent levels of colitis scoring in their offspring. It appears that further generations of 
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LF82 colonization (G2- G5) did not enhance disease, suggesting this was influenced by the 
dam’s immunological naivety to LF82 prior to colonization, rather than an effect of simply 
acquiring LF82 as a neonate, though mice infected horizontally as a neonate to naïve dams 
exhibited intermediate macroscopic parameters of disease when comparing lesion severity 
between G0 and G1 following DSS-induced inflammation, together suggesting a complicated 
model. Additionally, extending the length of colonization in the G0 LF82 mice did not 
account for the increased severity of colitis. 
It has previously been demonstrated that E. coli LF82 cannot colonize or cause 
disease in immunocompetent, conventionally-reared mice, unless transgenic for the human 
CEACAM 6 receptor, immunodeficient, or pretreated with antibiotics [38-44]. One study 
with antibiotic pretreatment of mice followed by infection with a different human AIEC 
isolate, NRG857c, demonstrated development of transmural inflammation and fibrosis in the 
GI tract of these mice [41, 69]. LF82 was also evaluated in this model, and when dual 
colonized with NRG857c, NRG857c outcompeted LF82, and mono-colonization with LF82 
had lower levels of colonization than monocolonized NRG857c [41]. TLR5 knockout mice 
exhibited inflammation after colonization with LF82, and the LF82 mediated increases in the 
severity of DSS-induced colitis was shown to be dependent on flagellin expression [42-44].  
Not analyzed within the confines of this study are genetic changes LF82. As a human 
pathobiont, this organism is not adapted to mice and likely goes through an adaptation to the 
mouse intestine. This has been evaluated by Alexandra Proctor but is not a part of this 
dissertation; however, under the short time span through a G1 mouse to necropsy, no 
significant SNPS within LF82 have been identified that would account for increased 
virulence in a G1 mouse over a G0 mouse. Examination of genetic changes in the ASF or 
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functional/metabolomic changes in the ASF due to the presence of LF82 have not been 
evaluated thus far, but may be impacting the disease in this model. 
Though the G1 mice are more susceptible to DSS-induced colitis, an increased 
antigen-specific immune response to LF82 does not seem to be the mechanism for the 
increased disease, as T cell responses from the mesenteric lymph node to LF82 are 
equivalent in both G0 LF82 + DSS and G1 LF82 + DSS. There is a mild increase in serum 
LF82-specific IgG in G1 mice with and without DSS treatment, but it is hardly above 
baseline and control levels, though mice colonized for longer time periods appear to 
gradually develop an increased IgG response to LF82. Again, FISH demonstrates LF82 is not 
adherent or invasive in this model, with only a small number of organisms becoming 
associated with the mucosa and/or breaching into the tissue even with DSS-induced 
inflammation, though this mild increase in access to the mucosa may account for the mild 
increase in E. coli specific T cell responses seen in the DSS-treated animals. 
Antigen-specific IgG responses to the ASF also do not demonstrate an increase in 
IgG to any members of the microbiota, if anything there is a decrease with LF82 colonization 
in several organisms including 361, 457, 492, and 502. Antigen specific T cell responses 
demonstrate a few trends, including an increased responsiveness to the clostridial group 
(ASF 356/492/500/502) antigens and the gram negatives (ASF 457/519) in G1 LF82 + DSS, 
and an increase in G0 LF82 + DSS to the lactobacilli antigens (ASF 360/361) compared to G1 
LF82 + DSS. The trend for increased response to antigens from ASF 457 and 519 could be 
due to the trend for increased adherence and invasion of ASF 457 seen by FISH in the G1 
LF82 + DSS mice, potentially leading to increased immune system accessibility of microbial 
antigen for sampling by dendritic cell dendrites extending into the gut lumen, as well as DCs 
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and macrophages within the tissue for organisms that invade or breach the disrupted barrier 
epithelium. However, there is a trend for a similar increase is seen in the lactobacilli for 
FISH, but this is opposite the T-cell responses seen in the mesenteric lymph nodes, which 
demonstrates a decrease in T-cell response to the lactobacilli. 
Another factor that could be contributing to increased disease in the G1 mice is 
influence from the LF82-colonized dam. In G1 LF82 mice, the dam has been recently 
infected with LF82 (3 weeks prior to breeding), and may be having an immunological 
contribution to the neonate, by transfer of microbial components, antibody, or cells during 
gestation or lactation. Though by evaluating antigen-specific IgG and T cell responses in G0 
LF82 mice (i.e. the phenotypic equivalent of the G1 LF82 dam) there is minimal evidence of 
an increased immune response to either LF82 or the ASF, though the length of infection is 
two weeks longer in the dams of the G1 LF82 at parturition than the G0 LF82 mice at the time 
of necropsy, potentially allowing a longer time period for immunologic responses to occur. 
Additionally the G0 LF82 mice do not have the metabolic stress of pregnancy potentially 
affecting their immune response during LF82 infection, so G0 LF82 mice may not be an 
immunologic equivalent to the dams of the G1 LF82 mice. To evaluate the impact of the 
dam’s contribution, neonatal mice were horizontally infected at less than 24 hours of age, and 
these mice had an intermediate phenotype to G0 and G1 mice treated with DSS, suggesting 
the increased susceptibility to DSS-induced colitis is at least due in part to colonization 
timeline as a neonate, though a contribution from the dam cannot be eliminated. Indeed, a 
recent study using reversible colonization in pregnant mice, demonstrated the dam’s 
microbial status does impact the developing neonatal immune system [70]. Pups born to 
dams experiencing transient E. coli colonization resulted in increased group 3 innate 
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lymphoid cells (ILC3) and F4/80+ CD11+ mononuclear cells, altered the intestinal gene 
expression in offspring, and were more protected from bacterial translocation when infected 
as a pup [70]. Additionally, these effects were at least in part postnatally acquired through 
ingestion of milk produced by previously colonized dams, demonstrated by cross fostering 
experiments [70]. Thus, further evaluation of an in utero and/or via lactation maternal 
influence to the increased susceptibility to DSS-induced colitis in G1 LF82 mice would be 
warranted.  
Cytokines are important in inflammation in both perpetuating and controlling the 
inflammatory response. Increases in many proinflammatory cytokines are associated with 
IBD, and multiple cytokine blocking therapeutics are currently in use or clinical trials for 
treatment of IBD and other chronic inflammatory conditions [71]. Colitis in the dual treated 
mice was accompanied by elevated proinflammatory cytokines in the colon, including IL-17, 
IFNγ, IL-1β, and IL-6, with G1 LF82 + DSS mice having increased IL-17 and a trend for IL-
1β over G0 LF82 + DSS. When colonization was extended to 10 weeks in the G0 LF82 mice 
and then treated with DSS to induce inflammation, IL-17 production was even higher than 
the G1 LF82 mice treated with DSS. However, IFNγ was quite low in the 10 week G0 LF82 + 
DSS, while IFNγ was much higher in the G0Neo LF82 + DSS compared to the other dual 
treated groups and timepoints. The previously discussed study with E. coli NRG857c 
demonstrated increased proinflammatory cytokines with NRG857c colonization alone that 
was greatly dependent on the mouse background, with C3H demonstrating a large increase in 
IL-17 but not IFNγ [41]. CEACAM6 transgenic mice also demonstrate increased 
proinflammatory cytokine production with LF82 colonization, including IL-1β, IL-17, and 
IL-6, as well as decreased IL-10 [39]. A study that exacerbated DSS-induced colitis by 
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afterwards colonizing with LF82 demonstrated increased IL-6 and IL-1β, and TLR5-/- 
infected with LF82 also demonstrate increased IL-6 [42, 44]. These cytokines are all relevant 
in IBD [42]. 
RNAscope was utilized to evaluate cytokine production in situ in the colon, with a 
limited objective assessment performed by computer software to determine location and 
quantify cytokine labeling, along with CD4+ mRNA in cytokine-transcribing cells. An 
increase in IFNγ was demonstrated in the G1 LF82 + DSS treatment group compared to the 
G0 LF82 + DSS treated mice. In contrast to the colonic explants, there was no difference 
detected in the number of cell expressing IL-17-specific mRNA.  A majority of the cells 
producing IFNγ in G1 LF82 + DSS mice also label with CD4+ (~60%), though a smaller 
number of IL-17+ cells also label with CD4+ (~42%), indicating the majority of IL-17+ cells 
are not CD4+ (~58%). Collectively, this data suggests that other cell types are producing 
these cytokines. IFNγ is also produced by NK and NKT cells and other innate lymphoid 
cells, as well as activated CD8+ T cells; IL-17 is also produced by type 3 innate lymphoid 
cells [42]. 
RNAseq analysis was performed using an immunity and inflammation-associated 
panel containing 485 genes to attempt to elucidate specific inflammatory pathways 
contributing to the increased colitis severity in mice colonized as a neonate (G1) versus an 
adult (G0). Not surprisingly, a large number (219) of genes in the panel were differentially 
expressed (p ≤ 0.05) in G1 LF82 + DSS compared to control ASF mice. Gene ontology 
analysis was performed in multiple software programs, but this analysis was limited by the 
complication of the high number of genes differentially regulated compared to the 
background list. The pathway analysis in PANTHER was revealing in that significant 
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changes in the G1 LF82 + DSS mice identified pathways relevant to the pathogenesis of 
inflammatory bowel disease, gastrointestinal inflammation, and maintenance of homeostasis 
including apoptosis signaling, inflammation mediated by chemokine and cytokine signaling, 
T cell activation, and Toll receptor signaling pathways [71-74]. Apoptosis is an especially 
important process critical for returning damage tissue to homeostatic conditions after 
inflammation by controlling inflammatory cells and signaling; it is well recognized that 
dysregulation of apoptosis pathways contributes to IBD and other chronic inflammatory 
conditions [72]. T cells are integral in maintenance of homeostasis in the intestine and 
responding to disease, but multiple subsets of T cells have been implicated in contributing to 
IBD [73]. Toll-like receptors are necessary in maintaining intestinal homeostasis, with 
signals from the autochthonous microbiota promoting epithelial barrier function, as well as 
recognizing components of pathogens leading to initiation of an immune response, and 
dysregulation again leads to inflammatory processes [74]. Cytokines and chemokines are 
necessary for cellular communication and mediate all aspects of the inflammatory response, 
coordinating an intricate network of complex cellular processes and orchestrating cellular 
trafficking throughout the host that when improperly balanced can lead to pathological 
consequences such as IBD [71]. Additionally, analysis in STITCH revealed multiple levels of 
interaction between significantly differentially expressed genes, and pathway analysis 
revealed the KEGG pathway of IBD. Together with the histological assessment of transmural 
inflammation, this RNAseq data strengthens the argument that these lesions and this colitis 
model are histologically and mechanistically similar to human IBD. 
To address the question regarding why neonatal colonization with E. coli LF82 
affected the disease severity in the G1 LF82 + DSS treatment group, direct comparisons of 
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gene expression in the three DSS treated groups were performed. Specifically, G1 LF82 + 
DSS gene expression was compared to the other two DSS treated groups. These comparisons 
generated smaller lists of genes, especially G0 LF82 + DSS compared to G1 LF82 + DSS, 
which was too small to perform pathway analysis. The DSS only and G0 LF82 + DSS 
compared to G1 LF82 + DSS lists were examined for overlap to identify genes that were 
differentially expressed in G1 LF82 + DSS compared to both of the other DSS treated groups. 
Three genes were identified from these comparisons, Gata3 and Lrp1 with an increased fold 
change and Il22ra2 with decreased fold change in G1 LF82 + DSS compared to the other 
groups. GATA3 and IL-22ra2 have been linked to IBD, and although Lrp1 has not, it is 
involved in inflammatory pathways [75-77]. 
GATA-3 is the transcription factor well known for driving Th2 CD4+ T cell 
differentiation and more recently the development of the related type 2 innate lymphoid cells 
(ILCs), but it has functions well beyond the regulation of type 2 immunity with involvement 
in a variety of other lymphocyte functions including early T cell development other processes 
in a variety of lymphocyte subtypes, as well as development of multiple tissue types during 
embryonic development [78-80]. GATA-3 has also been demonstrated to be produced by 
ILC3 cells in the GI mucosa, and is required for development and maintenance of RORγt+ 
ILCs, as well as the production of IL-22 by these cells [81, 82]. Lrp1 is the low-density 
lipoprotein receptor-related protein that recognizes a variety of ligands and, thus, has a wide 
variety of physiological effects including involvement in endocytic pathways, signaling, 
regulation of response to growth factors, cell migration, and maintenance of the blood brain 
barrier [83]. Additionally, Lrp1 has immunological-related functions including functions as a 
receptor for transforming growth factor-β (TGF-β), interacts with integrins during cell 
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migration, is involved in phagocytosis, and MHC II antigen presentation by dendritic cells; 
however, the role of Lrp1 in these processes are not well elucidated [83]. One paper has 
demonstrated that LPS and IFNγ induce shedding of Lrp1 from macrophages, which then 
induced production of TNF-α, MCP-1/CCL2, and IL-10 regulatory cytokines, and another 
study demonstrated ligand-dependent Lrp1 regulation of NFκB and microRNA-155 in 
macrophages, demonstrating a role in inflammation regulation in macrophages [84]. IL-
22ra2, also known as IL-22 binding protein (IL-22BP), is a soluble secreted receptor for IL-
22, and is discussed further below. 
Other genes that are differentially down-regulated in G1 LF82 + DSS over G0 LF82 + 
DSS include Irf4 and Kitl; genes that are slightly up-regulated included Xrc1 and Eomes; and 
Sigirr was moderately up regulated. Interferon regulatory factor 4 (Irf4) is a transcription 
factor that can act as both an activator and repressor in lymphocytes and macrophages, and 
KIT-ligand (Kitl), also known as stem cell factor, is a growth factor that promotes 
proliferation, migration, and differentiation of hematopoietic cells released by fibroblasts and 
endothelial cells [85-87]. Xrc1 is a chemokine receptor expressed on dendritic cells involved 
in antigen cross-presentation, and additionally has been identified to have a specific function 
in the gut on dendritic cell support for T cell survival and function, and eomesodermin 
(Eomes) is a transcription factor linked to CD8+ activation and differentiation [88-90]. 
Additionally SIGIRR (single Ig IL-1-related receptor, also known as TIR8) functions to 
modulate the immune response and maintain colonic epithelial homeostasis by inhibiting IL-
1 receptor signaling and decreasing TLR-mediated activation [91-93]. Together, this 
collection of differentially expressed genes suggests that the tissue/host has up-regulated 
cellular processes to control inflammation and maintain homeostasis in the G1 LF82 + DSS 
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mice which is not unexpected at this timepoint considering the severity of disease. However, 
this gene expression profile identified at day seven of DSS exposure does not necessarily 
identify genes or pathways that predisposed the ASF mice for the development of the more 
severe colitis following neonatal colonization with LF82. 
The overlap of the gene lists from the DSS treated groups as well as other genes 
differentially expressed in G1 LF82 + DSS compared to G0 LF82 + DSS should to reveal 
clues as to why the G1 LF82 + DSS have more severe inflammation following DSS-induced 
inflammation, yet with such short lists of differential gene expression this evaluation is 
limited. There are some limitations to consider in the RNAseq data array, including the 
number of samples submitted for sequencing (3 from each group), variation in disease 
scoring between animals contributing to variation in gene expression within each group, and 
the well known that DSS-induced inflammation induces patchy colitis lesions interspersed 
with normal tissue [94, 95]. Indeed in evaluating the gene lists there are genes that have a 
high differential gene expression but are not significant, likely indicating large variability 
between samples within the group. Another limitation is the timing of when samples are 
taken. All the data from DSS-induced inflammation is after seven days of DSS exposure. 
Though the disease indices indicate maximum disease (i.e., lesion) severity in the G1 LF82 + 
DSS mice at this time, likely by this time the host is trying to regulate the inflammation, and 
gene expression data will likely demonstrate both pro- and anti-inflammatory processes as 
the host tries to control the inflammation. Thus, examination of differential gene expression 7 
days after DSS-treatment may not be informative with respect to determining the underlying 
mechanisms contributing to the increased disease severity in the G1 LF82 + DSS mice. For 
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these reasons, earlier timepoints (i.e., days 2 to 4) following the initial exposure to DSS will 
need to be evaluated to answer that question. 
However, what can be discerned from this data is the difference between G1 mice and 
G0 mice prior to the induction of DSS-induced inflammation.  Thirty-eight genes were found 
to be differentially expressed between G0 and G1, including several with quite substantial 
fold changes greater than 2. Using KEGG pathway analysis, this gene list again identified 
Inflammatory Bowel Disease as well as other inflammation processes relating to cytokines, 
chemokines, and signaling, and some infections that induce acute and chronic inflammation. 
 IL-22 and IL-22 receptor subunit alpha-2 (IL-22ra2) were identified as differentially 
regulated genes in multiple analyses generated from this data set.  IL-22 has been 
demonstrated to be upregulated in IBD and is produced by multiple cell types including Th17 
and Th22 T cells, as well as innate lymphocytes such as natural killer T cells, γδ T cells, 
ILC3s, dendritic cells (DCs), and neutrophils [96-101]. IL-22 is often associated with 
expression of IL-17, and similarly works to enhances barrier function of epithelial cells, 
stimulate secretion of antimicrobial peptides, and promote would healing and tissue repair; 
however, uncontrolled production of IL-22 contributes to intestinal disease [98, 99, 102-108]. 
Multiple studies have demonstrated IL-22 has dual functional roles as it related to protection 
from and contribution to inflammation. IL-22 has been demonstrated to increase following 
onset of DSS-induced colitis, while other studies have demonstrated recombinant IL-22 
protected from DSS and TNBS induced colitis [100, 103, 104, 109, 110]. A study utilizing 
the CD4+ CD45RBhi (i.e., naïve) T cell transfer model of colitis demonstrated that IL-22 is 
protective, but in CD4+ CD45RBlo (i.e., memory/effector) T cell transfer model where Tregs 
are absent, IL-22 was necessary for development of inflammation [105].  
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Other cytokines and receptors associated with IL-22 are also differentially expressed 
in G1 LF82 compared to G0 LF82. IL-17 receptor B was slightly significantly up-regulated in 
G1 LF82, and IL-17b (1.9 FC) and IL-17f (2.3 FC) were had slightly increased expression, 
but neither were significant. IL-23 is one of the cytokines that drives production of IL-22 and 
was not differentially expressed [98, 102, 111]. IL-1β was also significantly but mildly 
increased in expression, and has been demonstrated to induce production of IL-22 [111]. IL-
22ra2 is a negative regulator of IL-22, and in G1 LF82 mice was down-regulated compared to 
G0 LF82, suggesting a deficit in the regulation of IL-22 production. 
IL-22ra2, also known as IL-22 binding protein (IL-22BP), is a soluble secreted 
receptor for IL-22, though in vivo activity and regulation has not yet been well described, but 
is thought to be produced by mononuclear and epithelial cells, as well as DCs (especially 
CD103+CD11b+DC) and eosinophils, and has a much higher binding affinity for IL-22 than 
membrane bound IL-22R1 [97, 112-115]. It has been demonstrated to be down-regulated by 
the activation of NLRP3 and NLRP6 inflammasomes [116]. Nlrp3 was up-regulated but with 
nonsignificant p values in both G0 LF82 + DSS (4.18, p 0.149) and G1 LF82 + DSS (2.846, p 
0.361) compared to DSS alone, but was not up-regulated in G1 LF82 (1.25, p 0.317) 
compared to G0 LF82. A recent paper in Science identified increased IL-22BP production by 
CD4+ T cells from IBD patients, and the induction of colitis by the transfer of naive 
CD45RBhigh T cells required IL-22BP production from T cells to induce inflammation [75]. 
IL-22BP has previously been demonstrated to decrease with significant increases in IL-22 
during inflammation, similar to the pattern observed for the G1 LF82 mice [97]. 
IL-22 binding to receptor complex induces phosphorylation of JAK1, which activates 
STAT3 and MAPKs pathway [109, 117, 118]. IL-6 has a similar signaling pathway, and is 
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demonstrated by the Stitch pathway analysis of G0 LF82 to G1 LF82 with differentially 
regulated genes in the JAK/STAT pathway, however JAK1, JAK2, and MAPK expression is 
only slightly increased in G1 LF82, even though the p value is significant. IL-6 is elevated in 
G1 LF82 by RNAseq analysis, though examination of explant supernatants demonstrated a 
trend for a decrease in G1 LF82 compared to explants from G0 LF82. IL-6 is a 
proinflammatory cytokine produced by activated lamina propria DCs, macrophages, CD4+ T 
cells, and many other cell types, and has been associated with inflammatory bowel disease 
and other inflammatory conditions [119-122]. IL-6 is important for development of Th17 
cells, prevents apoptosis of mucosal T cells in inflammation, and has been demonstrated to 
enhance production of IL-22, IL-17A, and IFNγ from ILCs [121-123]. IL-6 has also been 
associated with a protective role during epithelial injury and repair associated with a short 
burst of production from intraepithelial lymphocytes [122, 124]. Another proinflammatory 
cytokine, IL-1β, was also mildly increased in gene expression [125]. Production of IL-1β is 
primarily by monocytes and macrophages, and is also associated with IBD [125, 126]. 
 The most highly expressed gene in G1 LF82 over G0 LF82 is CXCL2, also called 
macrophage inflammatory protein-2 (MIP-2), is secreted by monocytes, macrophages, and 
epithelial cells to induce chemotaxis of neutrophils, though has also been demonstrated to be 
chemotactic for lymphocytes [127]. For gastritis involving Helicobacter pylori, IL-22 
promoted STAT-3 dependent CXCL2 production by gastric epithelial cells, which recruited 
myeloid-derived suppressor cells [108]. Other genes up-regulated in G1 LF82 over G0 LF82 
with a fold change greater than 2 are Cxcl5, Inha, Ccr3, and Ccl4. CXCL5, also increased in 
expression in G1 LF82, is another chemokine associated with neutrophil chemotaxis and 
homeostasis [128]. Inhibin α (Inha), a member of the TGF-β superfamily, was first described 
 154 
for its function in the reproductive system, but more recently has been demonstrated to 
negatively regulate maturation of DCs [129-131]. Ccr3 is a high-affinity eotaxin-1 receptor 
on eosinophils, though is found on other cells including colonic epithelial cells and can be 
activated by other chemokines [132, 133]. Additionally, Ccr3 has been reported to be highly 
expressed in colonic biopsies from ulcerative colitis patients, as well as peripheral T cells 
[133]. Ccl4 is also known as macrophage inflammatory protein-1β (MIP-1β) and is produced 
by antigen presenting cells as a chemotactic factor for a variety of cells including NK cells, 
monocytes, and regulatory T cells [134]. Besides IL-22ra2, other down-regulated genes in G1 
LF82 compared to G0 LF82 include CXCL13 a B cell chemoattractant, eomesodermin 
(Eomes) a transcription factor linked to CD8+ T cell activation and differentiation, and IL-5, 
a Th2 cytokine that promotes B cell and eosinophil activity, and there is a trend for decreased 
expression of IL-10 and lysozyme 1 [88, 134].  
 Together, the differential expression of these genes suggests colonization with 
LF82 as a neonate is inducing subclinical mucosal inflammation not discernable by 
histopathology, with increased expression of genes regulating chemotaxis of neutrophils and 
other cells, as well as dual-functional IL-22. Though this is a bit of an assorted collection of 
genes, all together this suggests an increase in innate immune mechanisms with neonatal 
infection with LF82 in this model compared to adult infection. Additionally, G1 LF82 mice 
may have underlying subclinical inflammation driven by innate immune mechanisms, such 
that when inflammation is initiated by DSS, these animals respond more severely to 
inflammation. In evaluation of the disease parameters, G1 LF82 mice do have a very slight 
trend for decreased colon length and increased histopathologic scores compared to G0 LF82, 
though the mean of the histopathology scores in G1 LF82 is increased by only a few animals 
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that have higher scores, with the median still equivalent to G0 LF82. Granted, the G1 LF82 
mice have been colonized with LF82 for a longer time, though the increased susceptibility to 
DSS-induced colitis does not appear to be an effect of the length of infection, as mice 
colonized as adults for a longer period of time prior to initiation of DSS-induced colitis do 
not have severe colitis. Thus length of infection does not account for the increased 
susceptibility to DSS-induced colitis, but appears to be associated with E. coli LF82 
colonization as a neonate rather than an adult. Interestingly, when mice colonized as a 
neonate have an extended length of infection time prior to initiation of DSS-induced colitis 
(16 weeks), the disease phenotypes appears bimodal (Supplementary Figure 3), with some 
animals having very severe colitis and some being much less severe than the standard G1 
LF82 + DSS colonization timeline. However, the “n” was limited in that analysis, and more 
work would need to be performed to determine if that is still an effect. 
 Once the G1 LF82 + DSS treated mice have developed severe inflammation, a 
plethora of inflammatory genes and pathways are activated including some of the genes with 
differential expression in G1 LF82. IL-22ra2 is significantly down-regulated compared to 
control ASF mice (-2.79 FC), and, though IL-22 has a huge fold change (103.66), it is not 
significant. IL-23 is increased in G1 LF82 + DSS mice (5.8356 FC) but just barely misses the 
significance cutoff with a p of 0.051. In the same comparison, IL-6 and IL-1β are similar, 
with large fold changes but not significant p values (IL-6 114.6 FC, p = 0.131; IL-1β 89.9 
FC, p = 0.129) again demonstrating the interindividual variability demonstrated with DSS-
induced inflammation. And IL-17 is similar, with a small but significant increase in IL-17B 
(2.55 FC), while IL-17A and IL-17F with larger but non-significant fold changes (IL-17A 
35.95 p 0.162, IL-17F 4.67 p 0.138). Additionally, in comparing G1 LF82 + DSS to the other 
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DSS groups, compared back to DSS only, again IL-17b and IL-22ra2 are significantly up-
regulated and down-regulated, respectively, and others are non-significantly upregulated, 
(IL-17A 5.22 FC, p = 0.237; IL-23A 2.66 FC, p = 0.121; IL-6 4.38 FC, p = 0.24; IL-1β 4.42 
FC, p = 0.22) though there’s no difference in IL-22. In comparing G1 LF82 + DSS to G0 
LF82 + DSS, of these cytokines only IL-22ra2 down-regulation is significant, and these other 
cytokines are also mostly non-significantly greatly decreased compared to G0 LF82 + DSS 
(IL-17A 1.1416 FC, p 0.8; IL-22 -9.6 FC, p 0.36; IL-23A -20.4 FC, p 0.37; IL-6 -6.34 FC, p 
0.37; IL-1β -1.58 FC, p 0.55). It must again be reemphasized that at this time point 7 days 
post-induction of DSS-induced inflammation, the host is trying to control the inflammation 
and gene signatures will encompass a mix of pro- and anti-inflammatory processes thereby 
complicating mechanistic analysis. 
 Taken all together, this RNAseq data suggests potential new targets to evaluate the 
mechanism for the increased susceptibility to colitis in the G1 LF82 mice. Independent of 
DSS exposure, the observed increase IL-22 accompanied by a decrease in IL-22ra2 gene 
expression in G1 LF82 treatment group is intriguing, and would be a logical next target for 
evaluation. With a wide variety of cell types capable of producing IL-22, the source of IL-22 
would need to be determined first. Based on the RNAscope data demonstrating IL-17 
production from non-CD4+ cells, increased in IL-17 from explants and trend in RNAseq, and 
a potential role for GATA-3, perhaps ILC3s should be evaluated, though other possibilities 
for IL-22 production would include dendritic cells, neutrophils, Th17, and Th22 cells. 
Innate lymphoid cells lack a rearranged antigen-specific cell receptor and are 
CD4/CD8 negative, but function as innate counterpoints to the T cell subsets, relying on the 
same transcription factors and producing the same cytokines, together representing a diverse 
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array of phenotypes and functions [135]. ILC3s are the innate counterpoint to Th17 cells, 
driven by the transcription factors RORγt and Ahr, and are themselves a diverse population 
of cells functioning to maintain mucosal homeostasis, as well as assist in resistance to 
infection and healing after mucosal damage by secreting IL-17A, IL-22, TNF, and GM-CSF 
[135]. ILC22, innate counterpoints to Th22 cells, have also been identified with overlapping 
functionality with ILC3, and producing large amounts of IL-22 in the absence of IL-17 [136]. 
Corresponding with the high expression of Cxcl2 and Cxcl5, neutrophils may also be 
producing the IL-22, as they have been demonstrated to produce high levels in colitis, 
contributing to the attempt to restore homeostasis [100]. If this mechanism is occurring in our 
model, it might be expected to then see more neutrophils in the tissue sections, and that was 
only noted in a few of the G1 LF82 tissues examined, similar to G0 LF82 tissues. 
Additionally, Th17 and Th22 cells may be producing IL-22, as T cell derived IL-22 is the 
main source that has been evaluated in IBD, though in the G1 LF82 mice the RNAseq data 
revealed a minimal increase in genes that would suggest increased T cell activity [96, 97].  
The mechanism for why these genes are differentially expressed is also still a 
mystery, though an evaluation of epigenetic changes may be worth future evaluation. 
Epigenetics describes heritable modifications to chromatin that regulate gene transcription, 
and include histone modifications and DNA methylation, though the mechanism for 
heritability is not well understood [137-140]. Epigenetics have been linked to a variety of 
complex diseases, and have been suggested to be a factor in IBD, especially DNA-
methylation [141, 142]. Additionally, multiple animal models of GI inflammation and 
evaluations of human IBD patients have identified environmental factors during 
embryogenesis and/or early life impacting epigenetic modifications to the genome with 
 158 
lasting effects. A mouse model of intergenerational developmental programming has 
demonstrated that in utero nutritional manipulation impacts the germline gene methylation 
and can be associated with metabolic alterations in the offspring [143]. Additionally, the 
maternal diet, specifically presence or absence of dietary retinoids, has been demonstrated to 
shape development of ILC3 in the offspring [144]. Exposure to farm environments in 
pregnancy and early childhood have demonstrated epigenetic changes in genes related to 
asthma and allergy [145, 146]. In a murine model of asthma, pregnant mice exposure to 
farm-derived Acintobacter lwoffii F78 resulted in epigenetic changes in the Ifng and Il4 
promoters that associated with IFN-γ and IL-4 expression in offspring [147]. A recent study 
in a murine DSS-induced colitis model revealed altered DNA-methylation and associated 
gene expression changes in offspring of males with colitis, and increased susceptibility to 
colitis in offspring [148]. These authors specifically focused on males to eliminate any in 
utero effects and evaluate solely epigenetic influences on susceptibility to colitis in this 
model.  
A recent concept promoted by Netea and colleagues is “innate immune memory” or 
“trained immunity,” which describes long term functional alterations in innate immune cells 
such as macrophages, NK cells, and ILCs [149]. Trained immunity is independent of antigen-
specific processes that trigger gene rearrangement in classical immunological memory of the 
adaptive immune system, and is proposed to be due to epigenetic reprogramming [149]. 
Epigenetic modifications of DNA alter transcription and may alter cellular metabolism, 
allowing quicker and more efficient response [149]. Evidence for innate immune memory 
have been described in plants, invertebrates, and mouse models involving vaccines and cross 
protection from infection, as well as some human responses particularly with the BCG 
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vaccine [149-156]. Multiple studies have even linked trained immunity to signals from the 
microbiota, including microbial signals to monocytes required for NK cell priming to protect 
from viral infection, enhanced immunity via trained immunity in monocytes following 
Sacchromyces cereviae exposure, and that DCs from mice colonized with segmented 
filamentous bacteria protects from Entameoba histolytica via production of IL-17A [153, 
155, 156]. As with adaptive immunity, trained immunity can be detrimental when improperly 
activated and contribute to disease processes, as evidenced in models of atherosclerosis and 
hyperglycemia [149, 157, 158].  
In conclusion, we demonstrated that neonatal colonization of ASF mice with LF82 
resulted in the development of more severe DSS-induced colitis as compared to adult mice 
colonized with LF82. LF82 minimally impacted the microbial community as measured by 
abundance or spatial redistribution, but triggered altered immune responses characterized by 
increased proinflammatory cytokines, mild CD4+ T cell differential immunoreactivity to ASF 
antigens, and differential expression of immunity and inflammation associated genes, 
including activation of pathways relevant to IBD. Analysis of differential gene expression 
between neonatal and adult mice colonized with LF82 in the absence of DSS-induced colitis 
suggest that neonatal colonization with LF82 induces a low-level subclinical (i.e., molecular) 
inflammation that may predispose to more severe inflammation. These data suggest that the 
age at which an individual is colonized by a pathobiont or provocateur may differentially 
affect the host’s mucosal immune profile and impact the host's susceptibility to subsequent 
inflammatory insults.  
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Supplementary Figure 1: DSS treatment of G1 dam and sire does not increase the severity of 
colitis. Mice were scored at the time of necropsy for macroscopic parameters of disease including 
colon length (A) and macroscopic colitis score (B). Additionally, proximal colon was fixed and scored 
by a pathologist for histopathologic parameters of inflammation (C). Shared letters between different 
groups indicate no statistical significance with an ANOVA or Kruskal-Wallis with multiple group 
comparisons test; ns indicates no statistical significance based on a direct comparison with a t or 
Mann-Whitney test. 
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Supplementary Figure 2: Subsequent generations of LF82-infected mice do not increase in 
disease severity. Mice were scored at the time of necropsy for macroscopic parameters of disease 
including colon length (A) and macroscopic colitis score (B). Additionally, proximal colon was fixed 
and scored by a pathologist for histopathologic parameters of inflammation (C). Any shared letters 
between different groups indicate no statistical significance with an ANOVA or Kruskal-Wallis with 
multiple group comparisons test; ns indicates no statistical significance based on a direct comparison 
with a t or Mann-Whitney test. 
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Supplementary Figure 3: Extending the length of LF82 infection in G0 LF82 mice does not 
increase disease severity. Mice were scored at the time of necropsy for macroscopic parameters of 
disease including colon length (A) and macroscopic colitis score (B). Any shared letters between 
different groups indicate no statistical significance with an ANOVA or Kruskal-Wallis with multiple 
group comparisons test. Asterisk indicate statistical significance based on a direct comparison with a 
Mann-Whitney test, ****p ≤ 0.0001, ***p ≤ 0.001, ns indicates no statistical significance. 
 
 
 
Supplementary Figure 4: Serum LF82-specific IgG increases with infection time. Antigen specific 
serum IgG to LF82 was assessed by ELISA. Shared letters between different groups indicate no 
statistical significance with an ANOVA with multiple group comparisons test. 
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Supplementary Figure 5: IL-17A and IFNγ production by explants are differentially affected by 
increased infection time. Analysis of IL-17A (A) and IFNγ (B) release by ex vivo incubated colonic 
explants by a bead-based multianalyte assay. Shared letters between different groups indicate no 
statistical significance with an ANOVA with multiple group comparisons test.  
 
 
 
Supplementary Figure 6: qPCR confirms differential expression of genes in G1 LF82 + DSS mice 
identified by RNAseq. qPCR was performed on colon mRNA with primers for selected genes. 
Relative mRNA quantities from qPCR were normalized against 18S rRNA and control samples. 
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Abstract 
 
Probiotics are gaining in popularity as a therapeutic or prophylactic option for 
modification or regulation of gastrointestinal inflammation, the immune system, or 
microbiota. Escherichia coli Nissle 1917 (EcN) is a gram-negative probiotic sold as 
Mutaflor® in Europe but not often used in the United States. We utilized the 
multigenerational colitis model described in chapter 4 of this dissertation to evaluate the 
impact of EcN on this multiple hit model of colitis. The results indicated that co-colonization 
with EcN does not prevent DSS-induced colitis with or without colonization of E. coli LF82. 
However, EcN modulated the host’s immune response as evidenced by a decrease in the 
induction of proinflammatory cytokines from diseased tissue and decreased antigen-specific 
T cell responses. 
 
Introduction 
The human intestine is home to a diverse population of bacteria that reaches 1011 
cells/gram contents in the colon, providing benefits to the host including vitamin production, 
immune system development, and competitive exclusion of pathogens [1-4]. The microbiota 
begins to colonize the gastrointestinal (GI) tract at birth and continues to be shaped through 
early life, eventually reaching a mature microbial community in early adolescence [5, 6]. The 
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concepts that the composition of the microbiota 1) reflects a state of health or disease and 2) 
that manipulation and/or modification of the microbiota can/will influence GI health or 
disease is an emerging field of study [7, 8]. 
The FAO/WHO defines a probiotic as “live bacteria which when administered in 
adequate amounts confer a health benefit to the host” [9]. Probiotics have become a more 
attractive option as therapeutics for a wide range of conditions, and provide a benefit by 
enhancing the competitive exclusion of pathogenic microbial organisms and/or modulation of 
the immune system [8, 10]. Probiotics have been administered to neonates with the intent to 
decrease colonization of pathogenic bacteria and decrease the impact of chronic disease, and 
pre-and probiotics are often a component of infant formula [11, 12]. Escherichia coli Nissle 
1917 (EcN) is marketed as Mutaflor® in Europe and is a non-pathogenic, O6:K5:H1 E. coli 
with no pathogenic adhesion factors, enterotoxins, or cytotoxins, is non-invasive, and rapidly 
killed by innate immune components of normal serum [13, 14]. One of the only gram-
negative probiotics available, Mutaflor® is used for the treatment of chronic constipation, 
infectious diarrhea, chronic colitis, and related conditions in Europe [15, 16]. EcN’s exact 
mechanism of action is unknown, though is likely multifactorial as it has been demonstrated 
to have a wide variety of effects, well reviewed in multiple publications [13, 17, 18]. 
Generally, EcN has been demonstrated to produce immunomodulatory molecules and 
decrease inflammatory immune responses in the gut, especially TNFα via TLR2 signaling 
[19-23]. Additionally it has been demonstrated to promote gastrointestinal barrier function, 
including inducing defensin production and up-regulating tight junction proteins [24-26]. 
EcN has multiple mechanisms to competitively exclude pathogens, including production of  
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microcins and siderophores for iron acquisition as well as competition for other nutrients, and 
directly preventing pathogen adhesion [27-33].  
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, 
are a group of chronic intestinal disorders with a multifactorial etiology consisting of 
complex interactions between the GI microbiota, genetics, environment, and the immune 
system [34]. Pediatric IBD cases are increasing, as more children present with severe colitis 
at younger ages [35]. GI pathogens have been suggested to contribute to the etiology of IBD, 
notably adherent and invasive Escherichia coli (AIEC) in Crohn’s disease, and are also 
isolated from a small portion of normal, non-diseased individuals, thus, AIEC strains have 
been classified as pathobionts [36-38]. LF82 is an AIEC isolate isolated from an ileal 
Crohn’s disease patient that has been well characterized [36, 37].  
EcN has been used as therapy in IBD patients, mostly in ulcerative colitis (UC), and 
multiple studies have demonstrated beneficial effects in preventing relapses in UC patients 
equivalent to mesalazine, a standard therapy for IBD [39-42]. In cell culture, EcN has been 
shown to inhibit adhesion to and invasion of intestinal epithelial cells by multiple AIEC 
strains including LF82, as well as suppress the induction of proinflammatory cytokines, 
though it did not prevent invasion to ileal mucosa biopsies [43-45]. Additionally, EcN use in 
infants has been demonstrated to have a lasting impact on the immune system, by reducing 
the incidence of allergies in children up to 10 years after therapy [46]. As described in 
chapter 4 of this dissertation, neonatal colonization with LF82 increases the sensitivity of 
gnotobiotic mice to DSS-induced colitis as an adult. In this chapter, we aimed to evaluate the 
impact of EcN on host sensitivity to DSS-induced colitis in a colitis model. We hypothesized 
that EcN would lessen severity of DSS-induced colitis in mice colonized with LF82 as a 
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neonate. We demonstrate a reduction in secretion of IL-17 and IFNγ in DSS-induced colitis 
in mice colonized with EcN, but no reduction in disease severity. 
 
Materials and Methods  
Animals 
Adult gnotobiotic C3H/HeN:TAC mice harboring the altered Schaedler flora (ASF) 
were bred and maintained in Trexler plastic isolators [47, 48]. ASF members include: 
ASF356, Clostridium sp.; ASF360, Lactobacillus intestinalis; ASF361, Lactobacillus 
murinus; ASF457, Mucispirillum schaedleri; ASF492, Eubacterium plexicaudatum; ASF500, 
Pseudoflavinofactor sp.; ASF502, Clostridium sp.; ASF519, Parabacteroides goldsteinii [47, 
48]. Mice were maintained on an irradiated diet (2919 Teklad, Envigo) and autoclaved water 
for the duration of the experiment. All animal experiments were approved by Iowa State 
University’s Institutional Animal Care and Use Committee. 
 
Preparation of E. coli cultures  
Escherichia coli Nissle 1917 was provided by Milton Allison at Iowa State 
University, and Escherichia coli LF82 was provided by Kenny Simpson at Cornell 
University. LF82 isolates previously isolated from pregnant dams (LF82PD) and mouse-naïve 
EcN were streaked onto TSA plates (Fisher Scientific, Waltham MA), and grown aerobically 
at 37 °C. Bacteria were passaged once to a lawn on plates. Multiple plates of LF82PD 
(hereafter referred to as LF82) were produced prior to parturition and refrigerated until 
needed. On the day of infection with E. coli LF82, bacteria were washed from plates and 
suspended in sterile PBS.  
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Experimental design 
The suspension of EcN was aseptically entered to the gnotobiotic isolators and mice 
were orally infected with one dose (0.2 ml) of 5 x 108 CFUs. Confirmation of colonization 
was done by culture from fecal samples. Mice were paired for breeding and males were 
removed after 2.5 weeks to prevent rebreeding and any microbial impact of coprophagy from 
the pups. Starting at 21 days post-pairing for breeding, mice were checked daily for pups. On 
day 0 (less than 24 hours of age) and again on day 2, pups were exposed to a suspension of 5 
x 108 CFU/ml of E. coli LF82 by smearing the suspension on their face, body, and the dam’s 
teats (Figure 1). Pups were weaned after 3 weeks of age and dams removed from the 
isolators. Confirmation of E. coli colonization was performed by culture of fecal samples 
after weaning; however, culture alone could not differentiate between EcN and LF82 in the 
dual colonized pups. At 9 weeks of age, mice were treated with filter sterilized 2% dextran 
sodium sulfate (DSS, MP Biomedical, Santa Ana CA) in their drinking water for seven days 
prior to necropsy following CO2 asphyxiation. At necropsy, colonic tissues, serum, and 
mesenteric lymph nodes (MLN) were harvested to evaluate the severity of intestinal 
inflammation and magnitude of immunologic responses. Intestinal tissues were collected and 
fixed in 10 % neutral buffered formalin at necropsy, sectioned and stained with hematoxylin 
and eosin.  
 
Macroscopic Inflammatory Scores 
Excised cecum and colon were scored on a previously published scale [49]. Briefly, 
tissue was evaluated for inflammatory changes of the cecum and colon, including changes in 
contents and tissue changes. Additionally, the length of the colon was measured. Intestinal 
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tissue was fixed in 10 % neutral buffered formalin, paraffin embedded, sectioned, stained 
with H&E, and evaluated by microscopy. 
 
 
Figure 1: Experimental Design. ASF-colonized C3H/HeN mice were infected with E. coli Nissle as 
adults by oral gavage (generation 0, G0), paired for breeding, and males were removed after 2.5 weeks. 
Pups were vertically colonized with EcN from their dam (generation 1, G1) during the process of 
neonatal microbial succession. On day 0 (less than 24 hours of age), and again on day 2, pups were 
exposed to a suspension of 5 x 108 CFU/ml of E. coli LF82 by smearing the suspension on their face, 
body, and dam’s teats (generation 0 colonization as a neonate, G0 Neo). At 3 weeks of age, pups were 
weaned. At 9 weeks of age, mice were treated with sterile 2% dextran sodium sulfate (DSS) in their 
drinking water for seven days and then necropsied.  
 
Preparation of bacterial antigens 
Bacterial antigen was prepared as previously described [49]. Briefly, bacteria were 
cultivated aerobically or anaerobically, harvested by centrifugation and washed in PBS, 
frozen, lyophilized, and stored at -20 °C until used. The bacterial cells were weighed and 
resuspended in sterile PBS at 2 mg/mL, subjected to a freeze-thaw cycle, and sonicated. 
Sterility of the antigen preparations was confirmed by bacterial culture. Aliquots were stored 
at -20 °C.  
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Ex Vivo T cell proliferation 
At necropsy, mesenteric lymph nodes (MLNs) were excised and single cell 
suspensions were created. MLN cells were labeled with 2.5 µM carboxyfluorescein diacetate, 
succinimidyl ester (CFSE, Molecular Probes, Eugene OR), washed in fetal bovine serum, and 
cultured (2 x 105 cells/well) in a 96 well plate with whole bacterial antigen (100 µg/mL) or 
anti-mouse CD3ε (4 µg/mL, eBioscience, San Diego CA) and anti-mouse CD28 (1 µg/mL, 
eBioscience, San Diego CA) and incubated. For wells stimulated with pooled ASF antigens, 
the total concentration of antigen was still 100 µg/ml (dry weight) with each organism’s 
antigen as an equivalent proportion of the pool. After four days, MLN cells were labeled with 
anti-mouse CD4 PerCP-Cy5.5 (eBioscience, San Diego CA) and anti-mouse Thy1.2 PE-Cy7 
(eBioscience, San Diego CA) and evaluated using a FACS CANTO (BD, Franklin Lakes NJ) 
at the Iowa State University Flow Cytometry Facility. Results were analyzed with FlowJo 
software (version 10.1, Ashland OR). 
 
Cytokine Analysis 
Supernatants from incubated colon tissue explants were harvested and prepared as 
previously described [49]. Supernatants were assayed for the presence of IL-17, IFNγ, TNFα, 
IL-6, and IL-1β on the Bio-Plex 200 system (Bio-Rad, Hercules CA) using a multiplex bead-
based assay. 2500 beads (Bio-Rad, Hercules CA) coupled to cytokine-specific monoclonal 
antibodies (eBioscience, San Diego CA) were added to each well along with 50 µL of culture 
supernatant. Cytokine standards (eBioscience, San Diego CA) were used to generate a 
standard curve covering cytokine concentrations from 500,000 to 3.2 pg/ml. The biotinylated 
detection antibodies (eBioscience, San Diego CA) were used at a final concentration of 2 or 4 
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µg/mL, and PE streptavidin (eBioscience, San Diego CA) was added for detection at 10 
µg/mL.  
 
ELISA 
Serum was collected at necropsy and stored frozen until use. After thawing, serum 
was centrifuged for 10 min at 10,000 x g to remove residual cellular debris. High binding 
microtiterplates (Costar High Binding Plates, Corning, Corning NY) were coated with whole 
bacterial antigen (10 µg/mL) and incubated overnight at 4 °C. Plates were washed three times 
using phosphate buffered saline (0.05 M, pH 7.2) containing 0.05 % Tween 20 (PBST) and 
blocked with 2 % gelatin with 2% goat serum in PBST and incubated at room temperature 
for 2 hours. Plates were washed three times with PBST and serum (1:200 in PBST with 2 % 
goat serum) was added. Plates were incubated overnight at 4 °C. Plates were then washed 
with PBST four times and alkaline phosphatase conjugated goat anti-mouse IgG (H+L) 
(Jackson ImmunoResearch, Bar Harbor ME) was diluted 1:2000 in PBST containing 2 % 
goat serum was added. Plates were incubated at room temperature for 2 hours, and then 
washed in PBST four times. p-Nitrophenyl phosphate (ThermoFisher Scientific, Waltham 
MA) was diluted in substrate buffer as recommended by the manufacturer and added to each 
well. Plates were incubated 60 min and the OD at 405 nm was measured using a 
spectrophometer (SpectraMAX 190, Molecular Devices, Sunnyvale CA). 
 
Western Blot 
Ten µL of 2 mg/mL E. coli LF82 and ECN whole bacterial antigen were heated for 10 
min in Laemmli loading buffer at 90 °C then separated on a 12 % SDS-PAGE gel (Mini-
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PROTEAN TGX, Bio-Rad, Hercules CA) in TRIS/tricine/SDS buffer (Bio-Rad, Hercules 
CA) at 100 volts until the loading buffer reached the bottom of the gel, approximately 1 hour 
[50]. The bacterial antigens were transferred to a PVDF membrane at 100 volts for 1 hour in 
TRIS/glycine buffer containing 20 % methanol. After transfer, the membrane was blocked 
with 2.5 % skim milk in TRIS buffered saline containing 0.05 % Tween 20 (TBST). The 
PVDF membranes were incubated with pooled serum diluted 1:250 in 50 % milk buffer in 
TBST at 4 °C rocking overnight. The membranes were rinsed with TBST and incubated with 
alkaline phosphatase conjugated goat anti-mouse IgG (Jackson ImmunoResearch, Bar Harbor 
ME) diluted 1:1000 in TBST for three hours while rocking. After rinsing with TBST and 
then water, the PVDF membranes were incubated in a solution containing the colorimetric 
substrate (Sigma Fast Red, Sigma Aldrich, St. Louis MO) for 10 min to develop the antigenic 
bands and then rinsed in water before drying. 
 
Differential culture 
Frozen cecal samples from LF82 and EcN infected mice were streaked for isolation 
on MacConkey and TSA agar. 12 to 30 single colonies were picked from multiple mice and 
used to inoculate XLT agar to differentiate LF82 from EcN. EcN is partially to mostly 
inhibited on Difco XLT agar with supplement (BD, Franklin Lakes NJ) (Figure 3A). On TSA 
plates, it was also noted that some LF82 colonies were larger and slightly more mucoid than 
EcN colonies. 
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PCR 
DNA isolated from frozen cecal samples, E. coli LF82 and EcN pure cultures, and 
total E. coli isolated on MacConkey plates from frozen cecal contents were extracted using 
the UltraClean Fecal DNA Kit (MoBio, Vancouver BC), using a Mini-beadbeater for sample 
homogenization (Biospec Products, Bartlesville OK) and the addition of a Proteinase K 
digestion (MoBio, Vancouver BC) at 55 °C for 1 hour prior to homogenization. The primer 
used for ECN was previously described, and a primer for E. coli LF82 was designed based on 
genomic sequence alignment with Mauve (Darling Lab) based on genomes deposited in 
NCBI in an inverted region (F primer ACCAGCGACTGGTAACAACG, R primer 
ATACATTGACCCCTGAGGTGC), after attempting to use a published primer that did not 
differentiate E. coli LF82 from EcN [51-53]. Extracted DNA was amplified with Taq DNA 
polymerase with Standard Taq Buffer kit (NEB, Ipswich MA) as recommended by the 
manufacturer. Amplification was in a myCycler Thermal Cycler (Bio-Rad, Hercules CA) at 
95 °C for 4 min followed by 30 cycles of 95 °C for 30 sec and 60 °C for 30 sec, then run on a 
1.5% agarose gel at 100 volts, stained with ethidium bromide (Sigma Aldrich, St. Louis 
MO), and imaged with a Canon Rebel T2i camera attached to a Multiimage Light Cabinet 
(Alpha Innotech Corportation, San Leandro CA) with EOS Utility software (Canon, Melville 
NY). 
 
Statistics 
All statistics were performed with Prism 6 (GraphPad, La Jolla CA) with a Kruskal-
Wallis with Dunn’s multiple comparisons test or an ordinary one-way ANOVA with Tukey’s 
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multiple comparisons test. The G1 ECN group was not used for any statistical testing as it has 
only one sample. 
 
 
Figure 2: EcN does not decrease macroscopic colitis scoring with DSS-induced inflammation. At 
necropsy, the cecum and colon was excised and scored for presence or absence of gross anatomic 
changes indicative of inflammatory changes (A) and the colon length was measured (B). 
 
Results 
EcN does not decrease macroscopic DSS-induced colitis 
To evaluate the impact of EcN on the severity of DSS-induced colitis, mice were 
colonized with EcN and LF82 as a neonate, and then treated with DSS as an adult to induce 
colitis. Macroscopic evaluation of DSS-induced colitis was not statistically different between 
any treatment groups in either macroscopic score or colon length (Figure 2A, B). There was a 
trend for the G1 EcN/G0 Neo LF82 mice treated with DSS to have more severe macroscopic 
score and shorter colons, though this is not statistically significant. Additionally, there was no 
protection for EcN colonization to attenuate or prevent DSS-induced colitis, as the 
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macroscopic scores were slightly worse and colon lengths were similar to the DSS only 
group. Based upon a subjective histologic evaluation, tissues appear to be equivalently 
inflamed between G0 Neo LF82 + DSS and G1 ECN/G0 Neo LF82 + DSS, and DSS and G1 
EcN + DSS which is consistent with the macroscopic scores and colon lengths (data not 
shown).  
 
 
Figure 3. EcN outnumbers LF82 in the cecum. Pure culture of LF82 grows well on XLT media, 
while stock EcN is partially inhibited (A, labeled at top). The remaining wedges of the plate 
demonstrate both EcN and LF82 isolated from a dual-infected mouse. Approximately 10% of the E. 
coli colonies isolated from frozen cecal contents from dual colonized mice were determined to be 
LF82 by differentiation on XLT agar (B). 
 
EcN outnumbers LF82 in the cecum 
Based on bacteriological culture techniques, EcN and E. coli LF82 both still 
colonized the ASF mice at necropsy; furthermore, it appeared that EcN out-numbered E. coli 
LF82. Numerically, E. coli LF82 comprised approximately 10% of the total E. coli colonies 
(Figure 3B). 
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Figure 4: EcN may attenuate CD4+ T cells proliferation to antigens derived from the 
autochtonous microbiota during inflammation. At necropsy, mesenteric lymph nodes were 
harvested, labeled with CFSE, stimulated with ASF and E. coli antigens (100 µg/mL), and incubated. 
After four days, MLN cells were harvested and stained for flow cytometry and data was analyzed with 
FlowJo software. n = 1-4 animals per group. 
 
Modulation of antigen-specific CD4+ T cells responses by EcN to the autochtonous 
microbiota during inflammation 
An advantage of utilizing the ASF community is the ability to evaluate antigen-
specific immune responses to each of the resident microbiota [54, 55]. Evaluation of MLN 
CD4+ T cell antigen-specific proliferation showed no statistical differences between the 
treatment groups. However, there was a trend towards differential proliferative responses for 
MLN cells recovered from mice colonized with EcN compared to those colonized with E. 
coli LF82 (Figure 4). Overall, DSS treatment caused an increase in antigen-specific 
immunoreactivity in all treatment groups. The MLN cells recovered from EcN + DSS treated 
mice tended to have decreased immunoreactivity compared to MLN cells recovered from 
LF82 + DSS treated mice, and EcN colonization generally attenuated the proliferative 
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response to pooled 8 ASF antigens in the DSS-treated animals exposed to both E. coli 
compared to LF82 alone. 
 
 
 
Figure 5: EcN colonization induces a more robust antibody response than LF82. Serum collected 
at necropsy was analyzed by ELISA for anti-EcN and anti-LF82 total IgG (A). All samples were 
analyzed against antigen from both E. coli strains. Pooled serum from each non-DSS group was also 
used for western blot analysis against both EcN and LF82 antigens (B). n = 1-10 animals per group. 
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EcN colonization induces a more robust antibody response than LF82 
Examination of anti-E. coli serum IgG also shows no statistically significance 
differences (Figure 5A). There is cross reactivity between LF82 and EcN antigens, as 
expected. LF82 infection doesn’t result in much E. coli specific IgG, while there is a trend 
for an increased E. coli specific IgG with EcN colonization. However, EcN infected mice 
treated with DSS have a decrease compared to nontreated animals. Western blots to evaluate 
antigen specificity correlates to that data (Figure 5B). Both antigens are equivalent in their 
specificity, with perhaps a few differences in the dual infected mice between the antigens that 
may be due to differential antigen production, visualized on the SDS-PAGE gel. G0 Neo 
LF82 have much less reactivity than EcN infected mice, and the Ab response in the dual 
infected mice was similar to that observed for the EcN only infected animals. 
 
EcN colonization tends to decrease proinflammatory cytokines in inflammation 
Examination of cytokine production by explants demonstrated a trend for decreased 
IL-17, IFNγ, IL-1β, and IL-6 in EcN colonized ASF mice treated with DSS compared to DSS 
only or G0Neo LF82 + DSS. The only statistical significance between DSS treated groups 
was a decrease in IL-17 and IFNγ in G1 ECN/G0 Neo LF82 + DSS treatment group compared 
to DSS only. TNFα in general was low across all groups, with a trend for increased 
production in G1 EcN + DSS over other DSS treated groups.  
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Figure 6: EcN tends to decrease proinflamatory cytokines in inflammation. Supernatants were 
harvested after 24 hour of incubation of colonic tissue explants and were assayed for presence of IL-
17, IFNγ, TNFα, IL-6, and IL-1β by multiplex bead-based analysis. n = 1-10 animals per group.  *p < 
0.05 
 
 
Discussion 
Colonization with EcN has previously been demonstrated to impart protective effects 
when utilized in DSS-induced colitis [20, 25, 56-62]. In these models, attenuation of the 
severity of colitis was observed as less severe macroscopic lesions, lower histopathological 
indices, as well as less severe weight loss. In one study, heat killed EcN and EcN DNA alone 
provided protective benefits towards DSS-induced colitis [58]. EcN also has been 
demonstrated to have impact on epithelial barrier function, by up-regulating tight junction 
proteins and protecting from DSS-induced mucosal permeability [25, 63]. In our gnotobiotic 
mouse model, EcN did not attenuate DSS-induced inflammation. However, in this study, we 
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relied solely on EcN colonization of mice, whereas for most colitis studies with DSS, mice 
were orally gavaged daily (or via rectal administration) with a large dose of EcN (i.e. 108 
CFU), likely resulting in a much higher exposure to EcN [20, 57-60, 63]. In other studies that 
examined the impact of EcN on DSS-induced colitis, germfree mice were colonized with 
EcN, but were treated with 3.5-6% DSS, a much higher dose than this study [25, 56, 59]. 
Thus to see an effect on disease severity in our model, we may need to dose daily with EcN 
and/or increase the dose of DSS. 
However, EcN colonization may have had an impact on proinflammatory cytokine 
secretion during DSS-induced colitis, as we demonstrated a trend for a decrease in IL-17, 
IFNγ, IL-1β, and IL-6 in G1 ECN + DSS and G1 ECN/G0 Neo LF82 + DSS treated mice 
compared to ASF mice treated with DSS only. Multiple studies have reported a decrease in 
proinflammatory cytokines with EcN treatment, in both mouse models and cell culture [19-
23, 44, 57, 63]. The production and secretion of TNFα has been reported to decrease when 
the TLR2 signaling pathway is engaged [19-22]. In our colitis model, TNFα production is 
minimal. Several DSS-induced colitis models have demonstrated an effect of EcN treatment 
in decreasing IFNγ [19, 20, 57]. In another study, EcN dosed immediately prior to and 
through 7 days of DSS treatment reduced IFNγ and IL-6 but did not affect the inflammatory 
severity of mucosal lesions [57]. This is consistent with the results of our model, in that there 
was an observed trend for a decrease in IFNγ and IL-6 with no effect on macroscopic 
parameters of inflammation. 
The pathobiont AIEC is associated with Crohn’s disease [36-38]. EcN has been 
studied specifically with the AIEC isolate LF82 in relation to adherence to intestinal 
epithelial cells and human biopies in cell culture. EcN has been demonstrated to dramatically 
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inhibit adhesion to and invasion into intestinal epithelial cells by multiple AIEC isolates 
including LF82 [43]. Another study demonstrated that EcN inhibited the invasion of Caco-2 
cells by LF82 and suppressed the secretion of IL-8, Gro-α, and sICAM1. [44].  A study 
evaluating LF82 adherence to ileal and colonic human biopsies reported EcN did not reduce 
adhesion of LF82 [45]. LF82 is not adherent or invasive in the ASF mouse model used for 
these studies (data not shown) and it’s currently unknown what mechanism(s) may be 
modulating the immunologic/inflammatory responses subsequent to DSS exposure 
(discussed in Chapter 4). Thus, assuming that EcN is having an beneficial effect in this 
model of colitis by decreasing GI inflammation, it is not mediated through decreasing LF82 
adherence or invasion. 
The cellular adaptive immune system in response to EcN administration has not been 
well studied. EcN has been demonstrated to increase number and function of γδ T cells but 
downregulate αβ T cell function [19, 23]. Peripheral blood T cells isolated from mice treated 
with EcN showed reduced TNFα, IFNγ, MCP-1, and IL-10 following stimulation with anti-
CD3 and anti-CD28 [20]. Additionally, in a study with allergic children, EcN decreased the 
incidence of allergy but did not increase Tregs [64]. In premature infants colonized with 
EcN, increased EcN-specific proliferation of blood cells and antibody were increased over 
noncolonized infants [65]. In serum ELISAs and western blots from this study, EcN 
colonization resulted in an increased amount of E. coli specific IgG over LF82 colonization. 
The current study also examined ex vivo antigen-specific T cell proliferation to members of 
the autochtonuous microbiota along with LF82 and EcN. Across all groups, those MLN cells 
recovered from mice treated with DSS had increased ex vivo T cell proliferation to microbial 
antigens. G1 EcN + DSS showed a trend for a decrease in proliferation to a pool of all 8 ASF, 
	 193 
ASF 457/519, and E. coli antigens compared to DSS alone. Similarly, G1 EcN/G0Neo LF82 
+ DSS demonstrated a trend for a decrease in the pool of all 8 ASF. Together with the 
cytokine data, these results suggest that even if EcN did not impact disease severity, it may 
have had an impact on the immune response. 
In this study, neonatal mice were colonized with EcN by vertical transmission from 
the dams during the process of microbial succession as the neonates acquire the gut 
microbiota. Within the first 24 hours of life, the neonates were also exposed to a 5 x 108 
CFU/ml concentration of LF82, and it is assumed the neonates were first colonized with 
EcN. Based on bacteriological methods, the mice were colonized with both EcN and LF82, 
with LF82 comprising approximately 10% of the E. coli load. A lower amount of LF82 in the 
G1 EcN/G0Neo LF82 (10% of the total E. coli load) compared to G0Neo LF82 may account 
for differences in cytokine production following DSS-induced inflammation. Positive 
identification was attempted with differential PCR primers, with success in identifying EcN 
but not definitively identifying LF82 (supplementary figure 1). The primer for EcN was 
previously described, though a published primer for LF82 did not differentiate between the 
two E. coli isolates [51, 52]. A new primer was designed across an inverted sequence in 
LF82, but it still yielded a PCR product when DNA from EcN was used as a template. PCR 
was initially attempted on DNA isolated from cecal samples, but resulted in very low to no 
amplification (despite culturing positive for E. coli), so identification was shifted to cultured 
E. coli isolated from frozen cecal samples. As mentioned above, we are assuming that 
inoculation of XLT agar medium differentiated LF82 from EcN; however, it is possible that 
the LF82-like colonies are actually metabolically distinct EcN isolates after selective 
pressure in the mouse gut.  
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In other studies, EcN has been show to competitively exclude pathogen colonization 
and adherence to the epithelium [28-33]. One study demonstrated that EcN colonization/oral 
gavage eliminated E. coli K-12 and Lactobacillus johnsonii from gnotobiotic mice [30]. EcN 
has also been demonstrated to reduce GI levels of Salmonella and to prevent pathogenic E. 
coli from colonizing conventional microbiota mice [28, 29]. EcN has been reported to more 
effectively generate a biofilm than do pathogenic E. coli strains, and EcN numerically 
outcompetes these strains due to biofilm formation [32]. Thus, it is possible that EcN 
colonization of neonatal mice would prevent colonization of LF82. However, if the more 
severe colitis in the multigenerational colitis model described in chapter 4 is an effect of 
neonatal colonization with LF82, it is possible LF82 may only need to be briefly present 
during a critical window to establish it’s adverse effect (i.e. “imprinting,” potentially via 
epigenetics or another mechanism) in modulating the host’s immune response to a 
subsequent colitic insult, suggesting that potentially LF82 need not be present at the time of 
DSS treatment. 
EcN has been studied in neonatal mice and humans in regards to the impact on the 
neonatal animal. In neonatal mice, EcN stimulation has been demonstrated to induce 
transcription and production of a variety of chemokines and proinflammatory and regulatory 
chemokines, and increase TLR2 and decrease TLR4 expression in the gut mucosa, and 
monocolonization of EcN in germfree mice increase mucin gene transcription in comparison 
to germfree and SPF mice [66, 67]. EcN has been successfully used as prophylaxis in human 
neonates to prevent colonization of pathogenic bacteria for up to six months when 
administered orally for the first 5 days of life, and has also been used in infants for the 
treatment of acute diarrhea, taken up to three times daily until symptoms resolve [15, 68]. In 
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another study, administration of EcN to preterm infants resulted in increased IgA and IgM 
[65]. Additionally, EcN use in infants has been demonstrated to have a lasting impact on the 
immune system as evidenced by a reduction in the risk of developing allergies in children for 
up to 10 years after therapy [46].  
The underlying mechanism(s) responsible for the induction of more severe DSS-
induced colitis in mice colonized with E. coli LF82 as a neonate is currently unclear. 
However, we predict there is an early immunologic effect (i.e, innate and/or adaptive) 
initiated during a critical window of mucosal development that alters the immune system 
such that the response to DSS-induced colitis as an adult is more severe. In the present study, 
we hypothesized that EcN colonization would lessen severity of DSS-induced colitis in mice 
colonized with LF82 as a neonate. While there was no demonstrated reduction of disease 
severity, there was a reduction in the production and secretion of the cytokines IL-17 and 
IFNγ and antigen-specific T cell responses. Use of EcN or other probiotics in this colitis 
model warrant more research to determine if there is an immunologic effect of the probiotic 
in prevention of the immunologic response that induces increased severity of DSS-induced 
colitis. Further work with probiotics in this and other research models may lead to new 
therapies for gastrointestinal disorders like inflammatory bowel diseases. 
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Supplementary Figure 1: DNA from LF82 and EcN pure culture (LF82+, EcN+) and total mixed 
population E. coli isolated on MacConkey plates from frozen cecal contents of two dual-exposed mice 
(Sample 1 & 2) were tested by PCR with primers designed for EcN and LF82 specificity. The EcN 
primer was able to identify EcN, though the LF82 primer cross reacts with EcN. NTC, no template 
control. 
	202 
CHAPTER 6. CAMPYLOBACTER JEJUNI CHRONICALLY COLONIZES A 
GNOTOBIOTIC MOUSE MODEL AND INDUCES MILD COLITIS 
 
 
A manuscript to be submitted as a short communication to Microbes and Infection 
 
 
Meghan Wymore Brand1, Orhan Sahin2, Jesse Hostetter3, Julian Traschel1, Qijing Zhang1, 
and Michael J. Wannemuehler1 
 
 
Departments of 1Veterinary Microbiology and Preventive Medicine, 2Veterinary Diagnostic 
and Production Animal Medicine, and 3Veterinary Pathology, Iowa State University, Ames, 
IA 50011 
 
 
Abstract  
Animal models for Campylobacter jejuni infection, colonization, and disease are 
limited. To address this need, we utilized gnotobiotic C3H/HeN mice colonized with the 
altered Schaedler flora (ASF) to demonstrate that the pathogenesis of C. jejuni is 
differentially influenced by the complexity of the microbiota. Four C. jejuni isolates 
chronically colonized ASF mice for at least 45 days and induced mild mucosal inflammation, 
while C. jejuni did not stably colonize conventionally-reared SPF C3H/HeN mice. We 
conclude mice harboring a less complex microbiota are more permissive to colonization by 
C. jejuni, and that the complexity of the microbiota additionally influences the development 
of gastrointestinal lesions in the murine host. 
 
Introduction  
Campylobacter jejuni is a major cause of human bacterial gastroenteritis worldwide 
with increasing case prevalence in developed countries [1, 2]. Campylobacter-induced 
gastroenteritis is usually self-limiting, but some patients progress to develop Guillain-Barre 
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syndrome, an autoimmune disease mediated by host responses to C. jejuni antigens [1]. 
Inflammatory bowel disease, functional gastrointestinal (GI) disorders such as irritable bowel 
syndrome, periodontitis, and other GI conditions have been associated with GI colonization 
by different species of Campylobacter [1]. C. jejuni naturally colonizes the GI tract of 
poultry, and poultry meat serves as a primary vector for transmission to humans, along with 
contaminated milk, water, and other animal meat products [1, 2]. In addition to its food-borne 
disease significance, C. jejuni has a veterinary impact as it causes abortion in small 
ruminants, and human transmission may occur through contact with infected animals [1, 2].  
Despite the public health significance of C. jejuni, human disease research models are 
limited. C. jejuni irregularly colonizes immunocompetent, conventional microbiota mice 
without intestinal disease, suggesting that the murine microbiota exhibits colonization 
resistance to C. jejuni [3, 4]. Murine models such as humanized microbiota or limited 
microbiota mice, serial C. jejuni in vivo murine passage, antibiotic pre-treatment, and dietary 
fat manipulation have resulted in successful C. jejuni colonization [3-7]. Some 
immunodeficient mouse models, including IL-10-/-, TLR- and NF-κB-deficient signaling, and 
SCID mice have successfully demonstrated chronic C. jejuni colonization, but result in 
variable levels of GI inflammation [3-8]. Because of the unreliability of rodent models, non-
human primates, neonatal swine, and ferrets are the most widely used models for 
Campylobacter disease [2, 6].  
We utilized the altered Schaedler flora (ASF), a well characterized murine defined 
microbiota model, along with conventional microbiota (specific pathogen free, SPF) mice, to 
demonstrate that colonization of C. jejuni is differentially influenced by the complexity of the 
microbiota [9]. The ASF mouse model is a well-described community of eight bacteria [9]. 
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The ASF stably colonize the murine GI tract, and are functionally representative of a full 
microbiota but lack proteobacteria [9, 10]. Previous data with this model demonstrates an 
adherent invasive Escherichia coli (LF82) chronically colonizes these mice, though is not 
maintained in SPF microbiota mice [11, 12]. We have previously demonstrated that 
Helicobacter bilis or Brachyspira hyodysenteriae persistently colonize ASF mice resulting in 
the development of typhlocolitis [13]. Thus, we hypothesized that C. jejuni, a member of the 
epsilonproteobacteria, would colonize ASF mice and induce mucosal inflammation. The 
results of this study indicate that four strains of C. jejuni chronically colonize and induce 
mild histopathological changes in the GI tract of gnotobiotic mice colonized with the ASF. 
This observation supports the concept that mice harboring a less complex microbiota are 
more susceptible to colonization by C. jejuni than those with a more complex microbiota, and 
may provide a useful model to study the pathogenesis and virulence of C. jejuni. 
 
Materials and Methods 
Animals 
Adult gnotobiotic C3H/HeN:TAC mice harboring the Altered Schaedler Flora (ASF) 
were bred, raised, and maintained in Trexler plastic isolators until colonization with C. jejuni 
[9]. Specific pathogen free (SPF) C3H/HeN mice were obtained from Envigo (Huntingdon, 
Cambridgeshire UK). All animals were housed and maintained in the Iowa State University 
Laboratory Animal Resource facility on a filtered air unit (Innovive, San Diego, CA) and 
were maintained on an irradiated diet (2919 Teklad, Envigo, Huntingdon, Cambridgeshire 
UK) and sterile water for the duration of the experiment. All mouse experiments were 
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performed according to the requirements of the Iowa State University Institutional Animal 
Care and Use Committee (IACUC). 
 
C. jejuni colonization 
C. jejuni was cultured on BD Difco Mueller-Hinton agar (Fisher Scientific, Waltham 
MA) in microaerophilic conditions (5 % oxygen, 10 % carbon dioxide, and 85 % nitrogen) at 
42 °C. Four strains of C. jejuni were utilized, two human disease isolates (81-176 and NCTC 
11168) and two arbortifacient ovine isolates (IA 3902 and IA 5908), also human pathogens 
[14-17]. Mice were colonized with one of the four strains (5 x 108 CFUs in 0.2 ml) by oral 
gavage.  
 
Culture from feces and liver 
Colonization persistence was evaluated by measuring fecal CFU shedding by serial 
dilution of feces in Mueller-Hinton (MH) broth and plating on MH agar supplemented with 
Campylobacter selective agents and supplements (SR0232E and SR0117E; Oxoid, 
Basingstoke UK) for C. jejuni. Plates were incubated for 48 hours at 42 °C under 
microaerophilic conditions before counting. At necropsy a piece of liver (about 0.5 g) was 
homogenized in a four-fold volume of MH broth and 100 µl was spread on a MH plate with 
supplements described above.  
 
Histopathological Analysis 
Mice were euthanized after three or seven weeks of colonization. Intestinal tissues 
were collected at necropsy, routinely processed and section in paraffin, and stained with 
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hematoxylin and eosin. They were scored by a pathologist (JH). Tissues were scored as 
previously described, by scoring a scale of 0-5 for the parameters of ulceration, 
inflammation, edema, stromal collapse, and gland hyperplasia, and a sum score of those 
individual parameters [18]. 
 
Statistical Analysis 
Prism 6 software (GraphPad Software, San Diego CA) was used for all statistical 
calculations. All data were evaluated by the Kruskal-Wallis test with Dunn’s multiple 
comparisons test or the Mann-Whitney test. 
 
Results 
Multiple strains of C. jejuni persistently colonize ASF mice 
All four strains of C. jejuni evaluated persistently colonized ASF mice for 7 weeks 
(107
 
-109
 
CFU/g feces) while C. jejuni CFU in fecal samples from SPF mice decreased 
throughout the seven-week study (Figure 1). 11168, IA 5908, and IA 3902 maintained 
consistent colonization levels between 108 - 109
 
CFU/g feces, while strain 81-176 began to 
decrease after day 21. On a repeat colonization experiment with C. jejuni 81-176, 
colonization levels were maintained at 107-108
 
in ASF mice with no evidence of decrease as 
observed in the first study (data shown is grouped from the two individual experiments). In 
SPF mice, C. jejuni 81-176 initially reached over 107 CFU/g feces, but dropped to 105 by the 
end of the 7-week study. One to two colonies of C. jejuni were additionally isolated in a 1:4 
dilution from the liver of one of the IA 3902 and two of the 11168 colonized ASF mice (data 
not shown). 
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Figure 1: Multiple strains of Campylobacter jejuni chronically colonize ASF mice. Gnotobiotic 
C3H/HeN mice harboring the ASF were colonized with one of four strains of C. jejuni and monitored 
for fecal shedding, reported as CFUs/g feces, for seven weeks (A, B). SPF C3H/HeN mice were also 
colonized with C. jejuni 81-176 and monitored for fecal shedding for seven weeks (B). Symbols 
indicate p < 0.05 in comparison to 81-176: ^11168, #IA 3902, *IA 5908 (A). In comparison to 81-176 
in SPF mice: *p <0.05, **p <0.01 (B). 
 
 
Persistent colonization of C. jejuni induces mild colonic inflammation  
Colons of ASF mice colonized with C. jejuni for seven weeks had an increased total 
histopathological scores characterized by increased inflammatory cell infiltrate and stromal 
collapse (Figure 2). In contrast, ASF mice colonized for only three weeks presented with 
histopathological scores intermediate between controls and ASF mice colonized for seven 
weeks. Both SPF control and SPF C. jejuni-colonized were similar to control ASF mice. The 
inflammatory infiltrate in ASF mice colonized for seven weeks was primarily characterized 
by the presence of mononuclear cells and some PMNs. Although not statistically significant, 
these tissues also exhibit moderate glandular hyperplasia in comparison to controls. The 
cecum and distal ileum of the ASF mice did not show evidence of inflammation following 
colonization for seven weeks with any of the four strains of C. jejuni (data not shown). 
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Figure 2: ASF-colonized mice have mild colonic inflammation following persistent C. jejuni 81-
176 colonization. The tissues were evaluated in a blinded fashion by a board certified pathologist. The 
total histopathological score (A) is the summation of multiple parameters (see Materials and Methods) 
including the inflammatory cell infiltrate (B) and stromal collapse (C). Photomicrographs (D) are 
representative of H&E stained sections of proximal colons from C. jejuni 81-176 colonized ASF and 
SPF mice. *p < 0.05 compared to control ASF. 
 
Discussion 
These data suggest that gnotobiotic mice harboring a less complex microbiota are 
more susceptible to persistent colonization by C. jejuni versus those with a more complex 
microbiota (e.g., SPF). Four separate C. jejuni isolates persistently colonized ASF mice (107-
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109 CFU/g feces) for at least seven weeks. The CFU of C. jejuni 81-176 appeared to decrease 
over time in an initial experiment, though on an experimental repeat with increased numbers 
of colonized mice there was no apparent decrease in CFU through time. As C. jejuni 
infections are often self-limiting, it is possible that the four C. jejuni would eventually be 
eliminated from the ASF mice.  
C. jejuni 81-176 colonization in SPF mice demonstrated a gradual decline in bacterial 
load. We hypothesize that 81-176 would eventually be below detectable limits as time 
progresses beyond seven weeks, and would be cleared from the SPF mice. In past studies, 
SPF mice demonstrate irregular colonization with Campylobacter [3, 4]. Pretreatment of SPF 
mice with antibiotics has been demonstrated to enhance C. jejuni colonization, as well as past 
studies in limited microbiota mice; together, these observations suggest that the nature of the 
microbiota impacts colonization resistance for C. jejuni [3, 4, 7]. In a previous study using 
limited microbiota mice, C. jejuni dropped below the limit of detection by 20 weeks post-
colonization [4]. However, the ASF community has been demonstrated to be metabolically 
representative of a full, conventional microbiota, and better representative than other 
randomly selected consortia, thus the ASF microbiota may be more relevant for studies on 
limited microbiota communities than other models [10].  
As is characteristic of C. jejuni, the isolates used in this study were not host adapted 
to mice. Past studies have demonstrated increased pathogenicity by serial passage through 
mice [5]. Short term serial passage (2 week colonization, 5 passages) of C. jejuni 81-176 
through ASF mice did not result in the development of more severe disease in the ASF mice 
receiving passage five C. jejuni 81-176 (data not shown).  
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The C. jejuni isolates IA 3902 and 11168 were isolated from the liver of ASF mice 
indicating that live C. jejuni had entered the portal circulation (data not shown). Bacteremia 
with C. jejuni has previously been demonstrated in murine models and human infections [1, 
2]. As has been observed in sheep, the ability of these C. jejuni isolates to enter the systemic 
circulation may provide an opportunity to develop an abortion model in ASF mice, as IA 
3902 is a C. jejuni isolate from ovine abortion cases [16, 17]. This is notable as isolation 
from the liver was performed seven weeks post-colonization without any other disturbance to 
the epithelial barrier (e.g., use of DSS). Orally administered C. jejuni IA 3092 has previously 
been associated with abortion in pregnant guinea pigs, the standard model for C. jejuni ovine 
abortion [2, 19].  
C. jejuni colonization resulted in the onset of mild colitis characterized by mild 
histopathological lesions in ASF mice. Human campylobacterosis has been reported to affect 
the small intestine through the colon [1, 2, 20]. Previous murine studies demonstrate disease 
in the stomach through the colon, though in our model the cecum and ileum were not 
affected [3, 4, 8]. Some murine models have demonstrated mild colonic inflammation with 
increased lymphocytes and neutrophils [3, 4].  The histopathologic changes in the colon of 
ASF mice were most prevalent after seven weeks of colonization, suggesting a chronicity to 
the pathogenesis of C. jejuni in this mouse model rather than the acute inflammation most 
frequently described in human disease [20]. This is consistent with mild inflammation 
induced by E. coli LF82 in this same ASF mouse model [11]. Though antibiotic 
administration allows colonization with C. jejuni in models using conventionally reared 
mice, no disease is observed unless the mice possess an immunodeficiency such as impaired 
TLR signaling or lack of regulatory T cells [3, 5, 7]. 
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The notable histopathologic changes observed at seven weeks were an increase in 
inflammatory cell infiltrate (primarly lymphocytic with some neutrophils) and stromal 
collapse. Human campylobacterosis is characterized by polymorphonuclear leukocytes and 
blood in the stool, with colonic diffuse inflammatory colitis [1, 20]. As the lesions in ASF 
colonized mice lesions progress with time following colonization, this suggests either host 
mediated immune changes are modulating the disease progression, or C. jejuni is becoming 
more fit as a mouse pathogen.  
This study suggests the pathogenesis of disease caused by C. jejuni is differentially 
influenced by the complexity of the microbiota, and ASF mice offer a model that will be 
useful to evaluate the impact of a chronic, host-provocateur interaction. Additionally, the 
ASF model may offer the unique opportunity to evaluate colonization factors and 
pathogenesis of C. jejuni within the context of a microbial community, particularly in the 
corresponding evaluation of metabolomic, transcriptional and/or genomic changes that could 
be ascribed to members of the resident microbiota [21]. In conclusion, four C. jejuni strains 
were demonstrated to chronically colonize and induce mild histopathological changes in the 
GI tract of gnotobiotic mice colonized with the ASF, supporting the concept that mice 
harboring a less complex microbiota are more susceptible to colonization by C. jejuni than 
those with a more complex microbiota. 
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CHAPTER 7: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
Together, the research in this dissertation evaluates microbial and host responses after 
colonization with proteobacteria (Escherichia coli LF82, E. coli Nissle 1917, and 
Campylobacter jejuni) and during disease (i.e. dextran sodium sulfate, DSS-induced 
inflammation) in otherwise healthy animals. E. coli LF82 is a pathobiont isolated from 
biopsies collected from patients with inflammatory bowel disease (IBD); this adherent 
invasive E. coli (AIEC) contributes to disease in susceptible hosts, but is also found in 
healthy individuals. C. jejuni is a gastrointestinal (GI) pathogen that causes acute colitis, and 
prior campylobacteriosis has been linked to an increased risk of developing IBD. Bacterial 
pathobionts may act as a provocateur by disrupting mucosal homeostasis and/or the resident 
microbial community, thus increasing susceptibility to GI disease following an inflammatory 
trigger or colitic insult. These multifactorial interactions are thought to be part of the 
multifactorial etiology of inflammatory bowel disease (IBD). Probiotics such as E. coli 
Nissle 1917 (EcN) have been utilized therapeutically to ameliorate the clinical signs of IBD, 
as well as to treat or prevent a range of other inflammatory diseases.  
The research described in Chapter 3 evaluated the heritability/transmissibility of a 
dysbiotic microbiota over multiple generations of gnotobiotic mice. We demonstrated small 
changes in microbial abundance within generations and a slow change in the microbial 
community over the length of the study (i.e., G1 to G5). These changes over time occurred 
independent of repeated episodes of GI inflammation, and suggested that the microbial 
changes were associated with the presence of the E. coli provocateur. We concluded that the 
altered Schaedler flora (ASF), a functionally “minimal” microbial community, still behaves 
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like a complex community, as it is resistant to inflammation. Dysbiotic or more diverse, the 
“heritability” of a microbiota is a topic that has been little studied, and is a subject that has 
recently received increased interest, as understanding microbial inheritance from dam to 
offspring of specific organisms and/or the whole community could be beneficial in 
determining microbial contributions to complex diseases and establishing a healthy GI tract. 
ASF mice offer the unique opportunity to study microbial inheritance in a less complex and 
defined community. A limitation of this study was microbial analysis only based on 
abundance; further studies in this multigenerational microbial model are warranted in order 
to evaluate genetic changes or functional/metabolomic changes in individual organisms in 
the community, or changes in spatial redistribution. 
Chapter 4 evaluated the sensitivity to dextran sodium sulfate (DSS)-induced colitis 
following E. coli LF82 colonization of ASF mice as an adult or neonate. Contrary to our 
hypothesis, we demonstrated that neonatal colonization of ASF mice with LF82 resulted in 
the development of more severe DSS-induced colitis as compared to adult mice colonized 
with LF82, with minimal impact on the microbial community. The more severe colitis was 
accompanied by altered immune responses characterized by increased proinflammatory 
cytokines, differential CD4+ T cell immunoreactivity to ASF antigens, and differential gene 
expression of immunity and inflammation associated genes, including pathways relevant to 
inflammatory bowel disease. These data suggest that the age at which an individual is 
colonized by a pathobiont or provocateur may differentially affect the host’s mucosal 
immune profile and impact the host's susceptibility to subsequent inflammatory insults. As 
our only evaluation of colitis and host response was at 7 days post-DSS treatment, to more 
fully understand the immunological pathways contributing to the more severe disease, earlier 
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time points (e.g., days 3 or 4 of DSS exposure) would need to be evaluated, while 
inflammation is still being initiated and before compensatory anti-inflammatory pathways to 
control the inflammation have been initiated. 
Further studies with this model are warranted to understand the mechanism for 
increased susceptibility to DSS-induced colitis in mice colonized with LF82 as a neonate. 
Analysis of differential gene expression between neonatal and adult mice colonized with 
LF82 in the absence of DSS-induced inflammation suggest that neonatal colonization with 
LF82 induces a low-level subclinical (i.e., molecular) inflammation that may predispose to 
more severe inflammation and tissue damage. Further examination of the products of these 
differentially expressed genes, especially the cytokines IL-22, IL-6, and IL-1β, and 
evaluating the cellular origin would be a logical next step to determine what cells are 
differentially functioning in mice colonized as a neonate than mice colonized as an adult. 
Based on the overall gene expression analysis suggesting differential innate immune 
mechanisms, type 3 innate lymphoid cells (ILC3) may be worthy of investigation, especially 
considering the increased ex vivo IL-17 production by intestinal tissue and the observation of 
a large number of CD4- IL-17+ cells in the epithelium and lamina propria following DSS-
induced inflammation in mice colonized with LF82 as a neonate.  
Additionally, it will be crucial to determine the underlying mechanism(s) mediating 
the differential response to DSS in the G1 LF82 + DSS treatment group. The concept of 
“innate immune memory” or “trained immunity,” long-term functional alterations in innate 
immune cells such as macrophages, NK cells, and ILCs, may be occurring in this model. 
This is proposed to be due to epigenetic reprogramming, and as with adaptive immunity, 
trained immunity can be detrimental when improperly activated and contribute to disease 
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processes. Thus far in our model system, we have no evidence of trained immunity or 
epigenetic modifications, but may be a future direction to explore. Perhaps the presence of E. 
coli LF82 in a neonate differentially “program” macrophages, ILC3s, and/or other innate 
cells via epigenetic mechanisms to differentially respond to microbial signals from the 
autochthonous microbiota and LF82, resulting in increased IL-6 and IL-1β, triggering IL-22 
production, such that when perturbed with DSS-induced inflammation instead of maintaining 
mucosal homeostasis, results in more severe colitis. 
Another factor to evaluate is if the effect of increased susceptibility to DSS-induced 
colitis is solely due to colonization as a neonate, or if there is an impact from the dam, by 
transfer of microbial components, antibody, or cells during gestation or lactation. Limited 
studies described in this dissertation suggest there is a partial contribution from the dam, but 
these studies could be expanded with cross-fostering experiments and/or transient E. coli 
colonization (i.e., use of an auxotrophic mutant) that only occurs in the dam or offspring. 
Clinical studies and research models have demonstrated an impact in the neonatal immune 
response by modulation of the dam’s microbiota, including via epigenetic effects and 
impacting ILCs and macrophage function in the neonate. Thus, further evaluation of an in 
utero and lactational maternal influence to the increased susceptibility to DSS-induced colitis 
in mice colonized with LF82 as a neonate would be warranted. 
In Chapter 5, we evaluated the impact of colonization of EcN on the severity of DSS-
induced colitis in mice colonized with LF82 as a neonate. Though there was no demonstrated 
reduction of disease severity, there was a decrease in the secretion of IL-17 and IFNγ, and 
differential antigen-specific T cell responses with EcN colonization, suggesting EcN may 
modulate the immune response with DSS-induced colitis. Perhaps with an increased dose of 
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EcN (i.e. daily gavage) rather than colonization, a greater effect in prevention of DSS-
induced inflammation would be observed. Additionally, further studies would be warranted 
to evaluate the colonization dynamics between EcN and LF82 in ASF mice. Further work 
with probiotics in this and other research models may lead to new therapies for 
gastrointestinal disorders like inflammatory bowel diseases. 
Finally, Chapter 6 evaluated the impact of colonization of another suggested IBD 
provocateur, C. jejuni. This chapter demonstrated that the pathogenesis of C. jejuni is 
differentially influenced by the complexity of the microbiota, with four strains of C. jejuni 
persistently colonizing ASF mice for at least seven weeks and inducing mild colonic 
inflammation in the absence of DSS. We conclude that the ASF mice provide a model to 
evaluate the impact of a chronic, host-provocateur interaction, and may offer the unique 
opportunity to evaluate colonization factors and pathogenesis of C. jejuni within the context 
of a microbial community. Further work would be warranted to determine if C. jejuni is 
eventually expelled from ASF mice or if it remains a stable member of the microbiota. 
Together, the research in this dissertation evaluates microbial and host responses after 
colonization of proteobacteria in health and during disease. The ultimate goal of this research 
is to understand the effects on mucosal homeostasis after disturbance of the resident 
microbiota by a bacterial provocateur, more specifically a member of the proteobacteria. By 
investigating basic mechanisms associated with the host-microbial relationship and effects on 
mucosal homeostasis in the gut, we can achieve a greater understanding of the mechanisms 
of inflammatory bowel disease, as well as what constitutes a ‘healthy’ state in the 
relationship with our microbiota. 
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APPENDIX: OTHER PUBLICATIONS 
 
 
 
Henderson A, Wymore Brand M, Darling R, Maas K, Detzel C, Hostetter J, Wannemuehler, 
M, Weaver E. Attenuation of colitis by serum-derived bovine immunoglobulin/protein isolate 
in a defined microbiota mouse model. Dig Dis Sci, 2015. 60(11): p. 3293-303.  
 
 
Background The pathogenesis of inflammatory bowel disease (IBD) is complex and 
multifaceted including genetic predisposition, environmental components, microbial 
dysbiosis, and inappropriate immune activation to microbial components. Pathogenic 
bacterial provocateurs like adherent and invasive E. coli have been reported to increase 
susceptibility to Crohn’s disease. Serum-derived bovine immunoglobulin/protein isolate 
(SBI) is comprised primarily of immunoglobulins (Igs) that bind to conserved microbial 
components and neutralize exotoxins.  
Aim To demonstrate that oral administration of SBI may modulate mucosal 
inflammation following colonization with E. coli, LF82, and exposure to dextran sodium 
sulfate (DSS).  
Methods Defined microbiota mice harboring the altered Schaedler flora (ASF) were 
administered SBI or hydrolyzed collagen twice daily starting 7 days prior to challenge with 
E. coli LF82 and continuing for the remainder of the experiment. Mice were treated with 
DSS for 7 days and then evaluated for evidence of local and peripheral inflammation.  
Results Igs within SBI bound multiple antigens from all eight members of the ASF 
and E. coli LF82 by western blot analysis. Multiple parameters of LF82/DSS-induced colitis 
were reduced following administration of SBI, including histological lesion scores, secretion 
of cytokines and chemokines from cecal biopsies, intestinal fatty acid binding protein (I-
FABP) and serum amyloid A from plasma.  
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Conclusions Oral administration of SBI attenuated clinical signs of LF82/DSS-
induced colitis in mice. The data are consistent with the hypothesis that SBI immunoglobulin 
binding of bacterial antigens in the intestinal lumen may inhibit the inflammatory cascades 
that contribute to IBD, thus attenuating DSS-induced colitis.  
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